GlaxoSmithKline_NN
159_CD
Index_NN
page_NN
page_NN
page_NN
A_DT
Corporate_JJ
Executive_NN
Team_NN
25,33,34,36,40,42_CD
,_,
Forward-looking_VBG
statements_NOMZ
2,64,65_CD
Access_NN
to_PIN
healthcare_NN
27_CD
44,46,50,121_CD
G_NN
Accountability_NOMZ
,_,
audit_NN
and_CC
internal_JJ
control_NN
35_CD
Corporate_JJ
governance_NN
4,34-38_CD
,74_CD
Gearing_GER
52_CD
Accounting_GER
policies_NN
59,83-85_CD
Corporate_JJ
Social_NN
Responsibility_NOMZ
Committee_NN
34_CD
Global_JJ
community_NOMZ
partnerships_NN
4,27-29_CD
Accounting_GER
standards_NN
65,72,82-85_CD
,124_CD
Critical_JJ
accounting_GER
policies_NN
59_CD
Global_JJ
Supply_NN
Network_NN
14_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
78,79,108,124_CD
Cross_NN
reference_NN
to_PIN
Form_NN
20-F_JJ
157_CD
Glossary_NN
of_PIN
terms_NN
158_CD
ADR_NN
program_NN
administrator_NN
153_CD
,_,
D_NN
Going_VBG [WZPRES]
concern_NN
basis_NN
37,74_CD
inside_PLACE
back_RB
cover_VB
Derivative_JJ
financial_JJ
instruments_NOMZ
62,63,85,111-113_CD
,_,
Goodwill_NN
,_,
American_NN
Depositary_NN
Shares_NN
5,152,153,155_CD
123,124,126-129_CD
Animals_NN
and_PHC
research_NN
22_CD
Dermatologicals_NN
9_CD
Governmental_NN
investigations_NOMZ
65,103,106,107_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
34,35,40,153_CD
Description_NOMZ
of_PIN
business_NOMZ
6-29_CD
,82_CD
Group_NN
companies_NN
139-141_CD
Antitrust_NN
37,106_CD
Dialogue_NN
with_PIN
shareholders_NN
34_CD
Anti-bacterials_NN
7,8_CD
,_,
Direct-to-consumer_JJ
advertising_GER
13_CD
H_NN
Anti-virals_NN
7,8_CD
,_,
Directors_NN
and_CC
senior_JJ
management_NOMZ
32-33_CD
,45,48_CD
,_,
Healthcare_NN
Services_NN
58,88,148_CD
Associates_NN
50,119,120_CD
Hedging_GER
Audit_NN
Committee_NN
34-38_CD
,74_CD
Directors_NN
History_NN
and_PHC
development_NOMZ
of_PIN
the_DT
company_NN
6_CD
Auditors_NN
,_,
independent_JJ
4,34-38_CD
,75_CD
interests_NN
47,49,50_CD
HIV_NN
and_PHC
AIDS_NN
3,4_CD
,_,
7,8_CD
,_,
,_,
interests_NN
in_PIN
contracts_NN
50_CD
54-56_CD
,66_CD
-69,144_CD
-147_CD
B_NN
remuneration_NOMZ
39-50_CD
Balance_NN
sheet_NN
,_,
I_FPP1
report_VPRT [PUBV]
2-72_CD
123,125,129_CD
Impairment_NOMZ
of_PIN
assets_NN
,_,
responsibility_NOMZ
74_CD
Block_NN
Drug_NN
126,128-130_CD
,132_CD
share_NN
options_NOMZ
41,42,48,155_CD
109,122_CD
Independent_NN
Auditors_NN
4,34-38_CD
,75_CD
share_NN
ownership_NN
guidelines_NN
42_CD
Board_NN
and_PHC
Executive_NN
34_CD
Information_NOMZ
technology_NN
24,37,65_CD
terms_NN
and_PHC
conditions_NOMZ
43-45_CD
Board_NN
committees_NN
32,34_CD
In-licensing_JJ
14,15,18,21,22,57_CD
Diversity_NOMZ
25_CD
Business_NOMZ
and_CC
the_DT
Community_NOMZ
26_CD
Intangible_JJ
assets_NN
,_,
Divested_JJ
businesses_NOMZ
88_CD
Business_NOMZ
performance_NN
,_,
122,125-133_CD
,137_CD
Divested_JJ
products_NN
66,67,69,148_CD
Intellectual_NN
property_NN
Dividends_NN
,_,
Business_NOMZ
segments_NOMZ
6,86-88_CD
,132,134,135_CD
,_,
Interest_NN
cover_NN
52_CD
139-141_CD
,148_CD
Interest_NN
rate_NN
risk_NN
management_NOMZ
63,110_CD
Internal_NN
control_NN
34,35_CD
E_NN
C_NN
Investments_NOMZ
,_,
Earnings_GER
per_PIN
share_NN
,_,
Capital_NN
employed_VBD
80,149,150_CD
Capital_NN
expenditure_NN
61,78,79,124,150_CD
Investor_NN
information_NOMZ
151-156_CD
Employees_NN
Cardiovascular_NN
7-9_CD
,15_CD
costs_NN
90,114-118_CD
Cash_NN
flow_NN
J_NN
diversity_NOMZ
25 128-132_CD
Joint_NN
ventures_NN
and_PHC
involvement_NOMZ
29_CD
Cautionary_JJ
statement_NOMZ
2_CD
associates_NN
numbers_NN
114,150_CD
Central_NN
nervous_JJ
system_NN
CNS_NN
7,8_CD
,_,
10,54-56_CD
,_,
96,134_CD
performance_NN
and_PHC
reward_NN
24_CD
66-68_CD
,144_CD
-148_JJ
share_NN
schemes_NN
118-121_CD
Centres_NN
of_PIN
Excellence_NN
for_PIN
Drug_NN
Discovery_NN
CEDD_NN
L_NN
development_NOMZ
25_CD
20,21_CD
Leases_NN
Employee_NN
Share_NN
Ownership_NN
Trusts_NN
ESOTs_NN
60,61_CD
,_,
Chairman_NN
and_PHC
Chief_NN
Executive_NN
Legal_NN
proceedings_GER
23,37,64,65,103-107_JJ
Officers_NN
statement_NOMZ
3,4_CD
Liquid_NN
investments_NOMZ
,_,
Environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
26,37,83,98,107_CD
,_,
Charitable_JJ
donations_NOMZ
27-29_JJ
124,126,128_CD
153_CD
Chlorofluorocarbons_NN
CFCs_NN
17-19_CD
Loans_NN
and_PHC
overdrafts_NN
80,90,99,110,111_CD
Equity_NOMZ
risk_NN
management_NOMZ
63_CD
Combined_NN
Code_NN
37,40,74_CD
Lymphatic_NN
Filariasis_NN
4,28,29_NN
Exchange_NN
controls_VPRT
155_CD
Commitments_NOMZ
Exchange_NN
rates_NN
2,5_CD
,_,
,_,
M_NN
Community_NOMZ
investment_NOMZ
26-29_CD
124,152_CD
Malaria_NN
7,8_CD
,_,
10,15,17,18,21,27-29_CD
Competition_NOMZ
External_NN
suppliers_NN
14_CD
Manufacture_NN
and_PHC
supply_NN
6,13,14_CD
Consumer_NN
Healthcare_NN
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
82,83_CD
,_,
business_NOMZ
sector_NN
segment_NOMZ
6,86-88_CD
,132,134_CD
,_,
F_NN
135,148_CD
Fair_NN
values_NN
,_,
Market_NN
capitalization_NOMZ
40,64,152_CD
competition_NOMZ
11,57,69_CD
128-133_CD
,137_CD
-138_CD
Marketing_GER
and_PHC
distribution_NOMZ
13_CD
manufacturing_GER
and_PHC
supply_NN
13_CD
Finanial_NN
Results_NN
Committee_NN
34_CD
Maturity_NOMZ
and_PHC
counterparty_NN
risk_NN
63_CD
marketing_GER
and_PHC
distribution_NOMZ
14_CD
Financial_NN
assets_NN
and_PHC
liabilities_NOMZ
63,110,111_CD
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
155_CD
products_NN
9_CD
Financial_NN
instruments_NOMZ
62,63,85,100,110-113_CD
Merger_NN
accounting_GER
adjustments_NOMZ
85_CD
sales_NN
Financial_JJ
period_NN
82,150_CD
Metabolic_NN
and_CC
gastro-intestinal_JJ
7,8_CD
,_,
10,15,20,21_CD
,_,
research_NN
and_PHC
development_NOMZ
22_CD
Financial_NN
position_NOMZ
60,137_CD
regulation_NOMZ
12_CD
Financial_NN
record_NN
trade_NN
marks_NN
23_CD
N_NN
5_CD
year_NN
record_NN
148-150_CD
Constant_JJ
exchange_NN
rate_NN
CER_NN
2,9_CD
,_,
51,55-59_CD
,_,
Net_JJ
debt_NN
quarterly_JJ
trend_NN
142-147_CD
64,67,142-148_CD
Net_JJ
interest_NN
payable_JJ
,_,
Financial_JJ
reporting_GER
calendar_NN
153_CD
Contact_NN
details_NN
inside_PLACE
back_JJ
cover_NN
142,149_CD
Financial_NN
Reporting_GER
Standards_NN
FRS_NN
2,52,58-60_CD
,63_CD
,_,
Contaminated_VBN
land_NN
65_CD
New_NN
products_NN
Contingent_JJ
liabilities_NOMZ
60,61,98,125_CD
Nominations_NOMZ
Committee_NN
34,40_CD
Financial_NN
statements_NOMZ
73-141_CD
Control_NN
of_PIN
company_NN
155_CD
Non-Executive_JJ
Directors_NN
32,34,40,45-47_NN
Financial_NN
summary_NN
2_CD
Corporate_NN
Administration_NOMZ
&_CC
Noon_NN
buying_VBG [WZPRES]
rate_NN
71_CD
Financial_NN
trends_NN
and_PHC
ratios_NN
52_CD
Transactions_NOMZ
Committee_NN
34_CD
Nutritional_NN
healthcare_NN
6,9_CD
,_,
11,13,14,22,57,69_CD
,_,
Fixed_VBN
asset_NN
investments_NOMZ
96,97,123_CD
86,148_CD
Foreign_JJ
exchange_NN
risk_NN
management_NOMZ
63,110_CD
160_CD
GlaxoSmithKline_NN
Index_NN
page_NN
page_NN
page_NN
O_NN
S_NN
V_NN
Oncology_NN
and_PHC
emesis_NN
,_,
Sales_NN
Vaccines_NN
144-148_CD
Consumer_NN
Healthcare_NN
52,57,69,86,134,135_CD
,_,
82,86,105,144-148_CD
Operating_GER
and_CC
financial_JJ
review_NN
142,148_CD
W_NN
and_PHC
prospects_NN
51-72_CD
Pharmaceuticals_NN
,_,
World_NN
economy_NN
53_CD
Oral_NN
care_NN
6,9_CD
,_,
69,86,142-148_CD
World_NN
market_NN
53_CD
Other_JJ
operating_GER
income_NN
expense_NN
57,58,69,70_CD
,_,
SB_NN
Clinical_NN
laboratories_NN
107,108_CD
76,89,126,142_CD
Segment_NOMZ
information_NOMZ
6,86-88_CD
,132,134,135_CD
,_,
Outlook_NN
53,64_CD
139-141_CD
,148_CD
Over-the-counter_NN
OTC_NN
medicines_NN
6,9_CD
,_,
11,13,57,69_CD
Selected_VBN
financial_JJ
data_NN
71_CD
82,86,148_CD
Senior_JJ
management_NOMZ
compensation_NOMZ
and_PHC
interests_NN
50_CD
P_NN
Share_NN
buy-back_NN
Patents_NN
3,4_CD
,_,
Share_NN
capital_NN
Payment_NOMZ
policies_NN
62_CD
Share_NN
premium_NN
80,81,85,101,150_CD
Pension_NN
and_CC
other_JJ
post-retirement_JJ
Share_NN
price_NN
46,48,49,53,152-154_JJ
benefits_NN
,_,
Share_NN
purchases_NN
62,63_CD
Share_NN
statistics_NN
149_CD
Pharmaceuticals_NN
Shareholder_NN
information_NOMZ
153_CD
approvals_NN
and_PHC
submissions_NN
11,12,19_CD
Shareholder_NN
return_NN
42,119,120,152_CD
business_NOMZ
sector_NN
Shareholders_NN
funds_NN
60,80,82_CD
competition_NOMZ
10_CD
Shareholdings_GER
analysis_NN
155_CD
manufacturing_GER
and_PHC
supply_NN
13,14_CD
Statement_NOMZ
of_PIN
total_JJ
marketing_GER
and_PHC
distribution_NOMZ
13_CD
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
76,77_CD
products_NN
7-14_JJ
,19,53,54,58,64_CD
sales_NN
,_,
T_NN
142-148_CD
Taxation_NOMZ
,_,
research_NN
and_PHC
development_NOMZ
10,14-22_CD
,25,37,52_CD
,_,
,_,
Taxation_NOMZ
information_NOMZ
for_PIN
shareholders_NN
156_CD
142,150_CD
Tax_NN
rate_NN
regulation_NOMZ
11-12_CD
Trade_NN
marks_NN
5,23_CD
patents_NN
and_PHC
trade_NN
marks_NN
5,23_CD
Treasury_NN
operations_NOMZ
37,62,85_CD
Pipeline_NN
14-17_CD
Treasury_NN
policies_NN
62,63_CD
Presentation_NOMZ
of_PIN
financial_JJ
statements_NOMZ
82_CD
Tuberculosis_NN
27_CD
Price_NN
controls_NN
12,64_CD
Profit_NN
and_PHC
loss_NN
account_NN
,_,
U_NN
UK_NN
segment_NOMZ
88_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
25,125_CD
US_FPP1
GAAP_NN
reconciliation_NOMZ
to_PIN
US_FPP1
accounting_GER
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
60,61,80,90_CD
principles_NN
122-138_JJ
consolidated_JJ
balance_NN
sheet_NN
125_CD
R_NN
consolidated_JJ
income_NN
statement_NOMZ
126,127_CD
Reconciliation_NOMZ
of_PIN
equity_NOMZ
of_PIN
movements_NOMZ
comprehensive_JJ
income_NN
and_CC
in_PIN
equity_NOMZ
shareholders_NN
funds_NN
80,82_CD
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
126,127_CD
Registrar_NN
153_CD
consolidated_JJ
statement_NOMZ
of_PIN
cash_NN
flows_VPRT
124,128_CD
Regulation_NOMZ
11,12_CD
earnings_GER
per_PIN
share_NN
ADS_NN
133_CD
Remuneration_NOMZ
Committee_NN
34,40_CD
material_NN
differences_NN
between_PIN
Remuneration_NOMZ
report_NN
39-50_CD
UK_NN
and_PHC
US_FPP1
GAAP_NN
122-124_CD
Report_NN
of_PIN
the_DT
Directors_NN
2-72_JJ
post-retirement_NOMZ
benefits_NN
123,136-138_CD
Research_NN
collaborations_NOMZ
21,110_CD
purchase_NN
accounting_GER
130,131_CD
Research_NN
and_PHC
development_NOMZ
results_NN
under_IN
US_FPP1
accounting_GER
principles_NN
72_CD
accounting_GER
policy_NN
83_CD
segment_NOMZ
information_NOMZ
134,135_CD
animals_NN
and_PHC
research_NN
22_CD
selected_VBN
financial_JJ
data_NN
71_CD
Consumer_NN
Healthcare_NN
22_CD
taxation_NOMZ
133_CD
diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
21,27_CD
expenditure_NN
Pharmaceuticals_NN
14-22_JJ
pipeline_NN
14-17_CD
Respiratory_NN
,_,
144-148_CD
Return_NN
on_PIN
capital_NN
employed_VBN
149_CD
Revenue_NN
accounting_GER
policy_NN
83_CD
Risk_NN
factors_NN
64,65_CD
Risk_NN
Oversight_NN
and_PHC
Compliance_NN
Council_NN
ROCC_NN
36_CD
Contact_NN
details_NN
INTERNET_NN
Information_NOMZ
for_PIN
investors_NN
and_CC
about_IN
the_DT
company_NN
is_VPRT [BEMA]
available_PRED
on_PIN
GlaxoSmithKlines_NN
corporate_JJ
website_NN
at_PIN
www_NN
._.
com_NN
HEAD_NN
OFFICE_NN
AND_PHC
REGISTERED_NN
OFFICE_NN
GlaxoSmithKline_NN
plc_NN
980_CD
Great_NN
West_NN
Road_NN
Brentford_NN
Middlesex_NN
TW8_NN
9GS_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5000_CD
UNITED_NN
KINGDOM_NN
UNITED_NN
STATES_NN
OF_PIN
AMERICA_NN
Investor_NN
relations_NOMZ
Investor_NN
relations_NOMZ
980_CD
Great_NN
West_NN
Road_NN
One_CD
Franklin_NN
Plaza_NN
Brentford_NN
PO_NN
Box_NN
7929_CD
Middlesex_NN
TW8_NN
9GS_NN
Philadelphia_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5557 5558_CD
PA_NN
19101_CD
Fax_NN
:_:
44_CD
0_CD
20 8047 7807_CD
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Tel_NN
:_:
1_CD
215 751 7003_CD
outside_PLACE
the_DT
USA_NN
Registrar_NN
Fax_NN
:_:
1_CD
215 751 3233_CD
Lloyds_NN
TSB_NN
Registrars_NN
The_DT
Causeway_NN
ADR_NN
program_NN
administrator_NN
Worthing_GER
The_NN
Bank_NN
of_PIN
New_NN
York_NN
West_NN
Sussex_NN
BN99_NN
6DA_NN
Shareholder_NN
Relations_NOMZ
www_NN
._.
co._FW
uk_FW
PO_FW
Box_NN
11258_CD
Church_NN
Street_NN
Station_NOMZ
General_NN
enquiries_NN
,_,
Annual_JJ
Report_NN
orderline_NN
and_PHC
New_NN
York_NN
NY_NN
10286-1258_CD
Corporate_JJ
Nominee_NN
service_NN
www_NN
._.
com_NN
Tel_NN
:_:
0870 600 3991_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
1_CD
877 353 1154_CD
toll_NN
free_JJ
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
outside_PLACE
the_DT
UK_NN
Tel_NN
:_:
1_CD
610 312 5315_CD
outside_PLACE
the_DT
USA_NN
Shareholder_NN
Investment_NOMZ
Plans_NN
Customer_NN
response_NN
center_NN
Dividend_NN
re-investment_JJ
enquiries_NN
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Tel_NN
:_:
0870 241 3018_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
44_CD
0_CD
1903 604 516_CD
outside_PLACE
the_DT
UK_NN
Monthly_JJ
Savings_GER
Plan_NN
enquiries_VPRT
Tel_NN
:_:
0870 606 0268_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
44_CD
0_CD
131 527 3746_CD
outside_PLACE
the_DT
UK_NN
ISA_NN
enquiries_VPRT
Tel_NN
:_:
0870 242 4244_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
44_CD
0_CD
1903 604 594_CD
outside_PLACE
the_DT
UK_NN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
corporate_JJ
PEPs_NN
The_DT
Share_NN
Centre_NN
Limited_NN
Oxford_NN
House_NN
Oxford_NN
Road_NN
Aylesbury_NN
Bucks_NN
HP21_NN
8SZ_NN
Tel_NN
:_:
44_CD
0_CD
1296 414 144_CD
Corporate_JJ
share_NN
dealing_VBG [WZPRES]
facility_NOMZ
NatWest_NN
Stockbrokers_NN
Corporate_NN
&_CC
Employee_NN
Service_NN
55_CD
Mansell_NN
Street_NN
London_NN
E1_NN
8AN_NN
Tel_NN
:_:
0870 600 3080_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
44_CD
0_CD
20 7895 5923_CD
outside_PLACE
the_DT
UK_NN
email_NN
:_:
contactces@natwest_JJ
._.
com_NN
quoting_VBG [WZPRES]
GSK_NN
Shareholders_NN
Service_NN
Printed_NN
by_PIN
St._NN
Ives_NN
Westerham_NN
Press_NN
in_PIN
the_DT
UK_NN
._.
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
the_DT
production_NOMZ
of_PIN
this_DEMO
document_NOMZ
is_VPRT [PASS]
made_VBN
from_PIN
pulp_NN
harvested_VBN [WZPAST]
from_PIN
sustainable_JJ
forests_NN
,_,
also_RB
using_VBG
sawmill_NN
residues_NN
and_PHC
forest_NN
thinnings_GER
._.
The_DT
Impact_NN
of_PIN
Medicines_NN
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_JJ
Annual_JJ
Review_NN
2002_CD
Front_NN
cover_NN
photograph_NN
Although_CONC
a_DT
generation_NOMZ
separates_VPRT
them_TPP3
,_,
Bettina_NN
Bartels_NN
and_CC
her_TPP3
son_NN
Philippe_NN
are_VPRT [BEMA]
able_PRED
to_TO
lead_VB
active_JJ
lives_NN
despite_PIN
both_DT
suffering_VBG
from_PIN
asthma_NN
._.
Our_FPP1
feature_NN
story_NN
on_PIN
pages_NN
4_CD
and_CC
5_CD
traces_NN
the_DT
advances_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
asthma_NN
._.
Contents_NN
01_CD
Chairman_NN
and_PHC
CEOs_NN
statement_NOMZ
17_CD
The_DT
Corporate_JJ
Executive_NN
Team_NN
04_CD
Patients_NN
and_PHC
product_NN
development_NOMZ
18_CD
Business_NOMZ
operating_GER
review_NN
06_CD
R&D_NN
productivity_NOMZ
20_CD
Responsibility_NOMZ
statements_NOMZ
08_CD
Innovative_JJ
science_NN
21_CD
Corporate_JJ
governance_NN
10_CD
Diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
22_CD
Summary_NN
financial_JJ
statements_NOMZ
12_CD
Our_FPP1
people_NN
24_CD
Summary_NN
information_NOMZ
under_IN
US_FPP1
GAAP_NN
14_CD
Corporate_JJ
and_PHC
social_JJ
responsibility_NOMZ
25_CD
Summary_NN
remuneration_NOMZ
report_NN
15_CD
Product_NN
portfolio_NN
27_CD
Shareholder_NN
information_NOMZ
16_CD
The_NN
Board_NN
29_CD
Contact_NN
details_NN
ANNUAL_NN
REVIEW_NN
2002_CD
01_CD
CHAIRMAN_NN
AND_CC
CHIEF_JJ
EXECUTIVE_NN
OFFICERS_NN
STATEMENT_NOMZ
The_DT
purpose_NN
of_PIN
GlaxoSmithKline_NN
is_VPRT
to_TO
deliver_VB
medicines_NN
that_TSUB
have_VPRT
a_DT
positive_JJ
impact_NN
on_PIN
the_DT
quality_NOMZ
of_PIN
human_JJ
life_NN
._.
We_FPP1
have_VPRT [PEAS]
chosen_VBN
this_DEMO
fundamental_JJ
and_PHC
challenging_JJ
objective_NN
as_IN
the_DT
theme_NN
of_PIN
this_DEMO
years_NN
Annual_JJ
Review_NN
._.
We_FPP1
are_VPRT [BEMA]
pleased_PRED
to_TO
report_VB [PUBV]
that_THVC
2002_CD
was_VBD [BEMA]
from_PIN
our_FPP1
key_JJ
therapy_NN
areas_NN
including_VBG [WZPRES]
a_DT
year_NN
of_PIN
significant_JJ
progress_NN
in_PIN
establishing_VBG [PRIV]
central_JJ
nervous_JJ
system_NN
,_,
respiratory_JJ
,_,
anti-virals_JJ
GlaxoSmithKline_NN
as_IN
one_CD
of_PIN
the_DT
worlds_NN
leading_VBG [WZPRES]
and_CC
vaccines_NN
._.
We_FPP1
achieved_VBD
strong_JJ
financial_JJ
results_NN
in_PIN
2002_CD
,_,
despite_PIN
the_DT
Our_FPP1
business_NOMZ
performance_NN
earnings_GER
per_PIN
share_NN
entry_NN
of_PIN
generic_JJ
competition_NOMZ
in_PIN
the_DT
USA_NN
grew_VBD
by_PIN
13_CD
per_PIN
cent_NN
,_,
delivering_VBG [PRESP]
on_PIN
our_FPP1
to_PIN
Augmentin_NN
,_,
one_CD
of_PIN
our_FPP1
major_JJ
products_NN
._.
guidance_NN
and_CC
demonstrating_VBG [PRIV]
the_DT
continuing_VBG
financial_JJ
strength_NN
that_TSUB
will_PRMD
provide_VB
the_DT
Group_NN
Our_FPP1
progress_NN
stems_VPRT
from_PIN
the_DT
Groups_NN
key_JJ
with_PIN
a_DT
sound_JJ
platform_NN
for_PIN
the_DT
future_NN
._.
strengths_NN
:_:
a_DT
broadly_RB
based_VBN
product_NN
portfolio_NN
,_,
strong_JJ
financial_JJ
capability_NOMZ
and_CC
a_DT
promising_JJ
GlaxoSmithKline_NN
has_VPRT [PEAS]
made_VBN
good_JJ
progress_NN
early_TIME
stage_NN
pipeline_NN
of_PIN
products_NN
._.
We_FPP1
have_VPRT
with_PIN
its_PIT
merger_NN
and_PHC
manufacturing_GER
built_VBN [WZPAST]
on_PIN
each_QUAN
of_PIN
these_DEMO
core_NN
attributes_VPRT
in_PIN
2002_CD
restructuring_GER
plans_NN
and_CC
we_FPP1
remain_VPRT
on_PIN
track_NN
and_CC
we_FPP1
are_VPRT [BEMA]
confident_PRED
that_THAC
they_TPP3
will_PRMD
help_VB
to_TO
deliver_VB
forecast_NN
total_JJ
annual_JJ
merger_NN
and_PHC
GlaxoSmithKline_NN
to_TO
continue_VB
to_TO
deliver_VB
manufacturing_VBG
restructuring_GER
savings_GER
of_PIN
success_NN
in_PIN
the_DT
future_NN
._.
We_FPP1
are_VPRT
not_XX0
stopping_VBG
there_RB
:_:
our_FPP1
continuous_JJ
improvement_NOMZ
While_OSUB
achieving_VBG
business_NOMZ
success_NN
it_PIT
is_VPRT [BEMA]
essential_JJ
program_NN
,_,
Operational_NN
Excellence_NN
,_,
that_THVC
we_FPP1
demonstrate_VPRT [PRIV]
to_PIN
all_QUAN
our_FPP1
stakeholders_NN
,_,
is_VPRT
delivering_VBG
additional_JJ
savings_GER
and_CC
will_PRMD
around_PLACE
the_DT
world_NN
,_,
how_RB
we_FPP1
conduct_VPRT
our_FPP1
continue_VPRT
to_TO
do_VB
so_RB
._.
business_NOMZ
with_PIN
integrity_NOMZ
and_CC
continue_VB
to_TO
make_VB
a_DT
positive_JJ
contribution_NOMZ
to_PIN
society_NN
._.
NEW_NN
PRODUCT_NN
GROWTH_NN
DRIVES_NN
COMMERCIAL_NN
STRENGTH_NN
GOOD_NN
FINANCIAL_NN
PERFORMANCE_NN
The_DT
success_NN
of_PIN
our_FPP1
new_JJ
products_NN
is_VPRT
providing_VBG
We_FPP1
delivered_VBD
a_DT
very_AMP
solid_JJ
financial_JJ
the_DT
fuel_NN
for_PIN
future_JJ
growth_NN
,_,
with_PIN
new_JJ
products_NN
performance_NN
in_PIN
2002_CD
in_PIN
a_DT
challenging_JJ
now_TIME
representing_VBG
27_CD
per_PIN
cent_NN
of_PIN
total_JJ
operating_GER
environment_NOMZ
._.
Global_JJ
pharmaceutical_JJ
pharmaceutical_JJ
sales_NN
,_,
up_RB
36_CD
per_PIN
cent_NN
in_PIN
2002_CD
._.
sales_NN
grew_VBD
eight_CD
per_PIN
cent_NN
to_TO
nearly_DWNT
18_CD
billion_CD
Sales_NN
of_PIN
Seretide_NN
Advair_NN
for_PIN
asthma_NN
,_,
now_DPAR
our_FPP1
and_CC
US_FPP1
pharmaceutical_JJ
sales_NN
grew_VBD
13_CD
per_PIN
cent_NN
,_,
second_RB
largest_JJ
product_NN
,_,
continued_VBD
to_TO
grow_VB
despite_PIN
generic_JJ
competition_NOMZ
to_PIN
Augmentin_NN
._.
impressively_RB
,_,
up_RB
96_CD
per_PIN
cent_NN
to_PIN
1.6_CD
billion_CD
._.
The_DT
Group_NN
demonstrated_VBD [PRIV]
continued_VBN
financial_JJ
We_FPP1
recently_TIME
launched_VBD
Avandamet_NN
for_PIN
type_NN
2_CD
strength_NN
with_PIN
total_JJ
sales_NN
up_IN
seven_CD
per_PIN
cent_NN
diabetes_NN
and_PHC
Avodart_NN
for_PIN
benign_JJ
prostatic_JJ
and_CC
business_NOMZ
performance_NN
trading_GER
profit_NN
up_IN
hyperplasia_NN
,_,
as_RB
well_RB
as_IN
important_JJ
line_NN
15_CD
per_PIN
cent_NN
._.
There_EX
were_VBD
strong_JJ
performances_NN
extensions_NN
of_PIN
Augmentin_NN
and_PHC
Paxil_NN
._.
Our_FPP1
global_JJ
quest_NN
is_VPRT
to_TO
improve_VB
the_DT
quality_NOMZ
of_PIN
human_JJ
life_NN
by_PIN
enabling_VBG
people_NN
to_TO
do_VB
more_EMPH
,_,
feel_VB [PRIV]
better_JJ
and_CC
live_VPRT
longer_RB
._.
We_FPP1
at_PIN
GlaxoSmithKline_NN
will_PRMD
dedicate_VB
ourselves_FPP1
to_TO
delivering_VBG
innovative_JJ
medicines_NN
and_PHC
products_NN
that_TSUB
help_VPRT
millions_NN
of_PIN
people_NN
around_PLACE
the_DT
world_NN
live_RB
longer_RB
,_,
healthier_RB
and_CC
happier_JJ
lives_NN
._.
CHAIRMAN_NN
AND_CC
CHIEF_JJ
EXECUTIVE_NN
OFFICERS_NN
STATEMENT_NOMZ
CONTINUED_VBD
During_PIN
2003-2004_CD
we_FPP1
look_VPRT
forward_RB
to_PIN
SUCCESS_NN
AS_NN
PARTNER_NN
OF_PIN
CHOICE_NN
A_DT
federal_JJ
judge_NN
in_PIN
Chicago_NN
recently_TIME
ruled_VBD [SUAV] [THATD]
that_DEMP
launching_VBG
12_CD
new_JJ
compounds_NN
and_PHC
line_NN
The_DT
size_NN
and_PHC
quality_NOMZ
of_PIN
our_FPP1
global_JJ
R&D_NN
GlaxoSmithKlines_NN
patent_NN
in_PIN
the_DT
USA_NN
covering_VBG [WZPRES]
extensions_NN
._.
These_DEMP
include_VPRT
Levitra_NN
,_,
a_DT
new_JJ
organization_NOMZ
,_,
together_RB
with_PIN
the_DT
strength_NN
the_DT
hemihydrate_JJ
form_NN
of_PIN
Paxil_NN
was_VBD [BEMA]
valid_PRED
but_CC
treatment_NOMZ
for_PIN
erectile_JJ
dysfunction_NOMZ
,_,
which_WDT [SERE]
of_PIN
our_FPP1
sales_NN
and_PHC
marketing_GER
teams_NN
,_,
have_VPRT [PEAS]
not_XX0
infringed_VBN
by_PIN
generics_NN
company_NN
Apotexs_NN
we_FPP1
are_VPRT [BEMA]
co-promoting_PRED
with_PIN
Bayer_NN
,_,
and_ANDC
enabled_VBD
GlaxoSmithKline_NN
to_TO
become_VB
the_DT
product_NN
._.
We_FPP1
believe_VPRT [PRIV]
our_FPP1
patent_NN
to_TO
be_VB [PASS]
infringed_VBN
Wellbutrin_NN
XL_NN
,_,
a_DT
new_JJ
and_PHC
improved_JJ
version_NN
partner_NN
of_PIN
choice_NN
in_PIN
the_DT
industry_NN
._.
We_FPP1
have_VPRT
by_PIN
Apotexs_NN
product_NN
and_CC
will_PRMD
appeal_VB
against_PIN
of_PIN
our_FPP1
successful_JJ
anti-depressant_JJ
._.
signed_VBD
an_DT
unprecedented_JJ
24_CD
major_JJ
external_JJ
the_DT
ruling_NN
._.
Also_RB
,_,
we_FPP1
will_PRMD
continue_VB
to_TO
pursue_VB
collaborations_NOMZ
in_PIN
the_DT
last_JJ
two_CD
years_NN
which_WDT [WHOBJ]
litigation_NOMZ
for_PIN
infringement_NOMZ
of_PIN
other_JJ
patents_NN
CREATING_VBG [WZPRES]
THE_DT
MOST_EMPH
PRODUCTIVE_NN
has_VPRT [PEAS]
helped_VBN
to_TO
boost_VB
our_FPP1
product_NN
portfolio_NN
._.
relating_VBG [PRESP]
to_PIN
Paxil_NN
against_PIN
Apotex_NN
and_CC
other_JJ
R&D_NN
ORGANISATION_NOMZ
It_PIT
has_VPRT [SPAU] [PEAS]
also_RB
provided_VBN
some_QUAN
exciting_JJ
new_JJ
generics_NN
companies_NN
in_PIN
the_DT
USA_NN
._.
At_PIN
the_DT
outset_NN
of_PIN
the_DT
merger_NN
we_FPP1
rethought_VPRT
the_DT
opportunities_NOMZ
in_PIN
a_DT
number_NN
of_PIN
areas_NN
of_PIN
unmet_JJ
way_NN
R&D_NN
was_VBD [PASS]
carried_VBN
out_PIN
at_PIN
GlaxoSmithKline_NN
,_,
medical_JJ
need_NN
such_JJ
as_IN
erectile_JJ
dysfunction_NOMZ
,_,
As_CONJ
a_NULL
result_NULL
of_PIN
these_DEMP
pending_VBG
matters_NN
,_,
the_DT
with_PIN
the_DT
aim_NN
of_PIN
creating_VBG
the_DT
most_EMPH
productive_JJ
obesity_NOMZ
and_PHC
HIV_NN
._.
possible_JJ
timing_NN
of_PIN
generic_JJ
competition_NOMZ
to_PIN
R&D_NN
organization_NOMZ
in_PIN
the_DT
industry_NN
._.
We_FPP1
established_VBD [PRIV]
Paxil_NN
in_PIN
the_DT
USA_NN
is_VPRT [BEMA]
unclear_PRED
._.
Consequently_CONJ
,_,
six_CD
therapeutically_RB
focused_VBD
Centres_NN
of_PIN
Excellence_NN
PATENT_NN
CHALLENGES_NN
GlaxoSmithKlines_NN
published_VBD
earnings_GER
guidance_NN
for_PIN
Drug_NN
Discovery_NN
CEDDs_NN
._.
The_DT
CEDDs_NN
are_VPRT
Over_IN
the_DT
last_JJ
year_NN
there_EX
have_VPRT [PEAS]
been_VBN
a_DT
number_NN
for_PIN
2003_CD
remains_VPRT
as_IN
previously_TIME
stated_VBN [PUBV]
._.
The_DT
nimble_JJ
and_PHC
entrepreneurial_JJ
with_PIN
the_DT
range_NN
of_PIN
of_PIN
developments_NOMZ
involving_VBG [WZPRES]
the_DT
patents_NN
on_PIN
guidance_NN
is_VPRT [BEMA]
for_PIN
high_JJ
single_JJ
digit_NN
percentage_NN
skills_NN
and_PHC
scale_NN
of_PIN
resources_NN
required_VBN [SUAV]
to_TO
drive_VB
some_QUAN
of_PIN
our_FPP1
key_JJ
products_NN
._.
growth_NN
in_PIN
business_NOMZ
performance_NN
earnings_GER
mid-stage_NN
development_NOMZ
projects_NN
through_PIN
to_PIN
per_PIN
share_NN
at_PIN
constant_JJ
exchange_NN
rates_NN
,_,
their_TPP3
key_JJ
decision_NN
point_NN
,_,
proof_NN
of_PIN
concept_NN
,_,
In_PIN
July_NN
,_,
in_PIN
the_DT
USA_NN
,_,
the_DT
first_JJ
generic_JJ
version_NN
assuming_VBG [PRIV] [WZPRES]
there_EX
is_VPRT
no_SYNE
generic_JJ
competition_NOMZ
before_IN
large-scale_JJ
phase_NN
III_NN
clinical_JJ
trials_NN
._.
This_DEMP
followed_VBD
a_DT
to_PIN
Paxil_NN
in_PIN
the_DT
USA_NN
._.
If_COND
a_DT
generic_JJ
launch_NN
of_PIN
ruling_NN
by_PIN
a_DT
federal_JJ
judge_NN
that_TOBJ
our_FPP1
Augmentin_NN
paroxetine_NN
hydrochloride_NN
became_VBD
imminent_JJ
,_,
After_IN
two_CD
years_NN
of_PIN
activity_NOMZ
by_PIN
the_DT
new_JJ
R&D_NN
patents_NN
were_VBD [BEMA]
invalid_PRED
._.
We_FPP1
are_VPRT
appealing_VBG
against_PIN
GlaxoSmithKline_NN
would_PRMD
reassess_NN
this_DEMO
guidance_NN
._.
organization_NOMZ
,_,
we_FPP1
are_VPRT
seeing_VBG [PRIV]
significant_JJ
progress_NN
this_DEMO
decision_NN
,_,
in_PIN
the_DT
firm_NN
belief_NN
that_TOBJ
our_FPP1
patents_NN
as_IN
we_FPP1
advance_VPRT
our_FPP1
promising_JJ
early_TIME
stage_NN
are_VPRT [BEMA]
valid_PRED
._.
Meanwhile_RB
,_,
we_FPP1
have_VPRT [SPAU] [PEAS]
already_RB
offset_VBN
Uptake_NN
of_PIN
Paxil_NN
CR_NN
,_,
our_FPP1
enhanced_JJ
form_NN
of_PIN
pipeline_NN
of_PIN
pharmaceutical_JJ
products_NN
through_PIN
some_QUAN
of_PIN
the_DT
impact_NN
of_PIN
generics_NN
with_PIN
recent_JJ
the_DT
antidepressant_JJ
launched_VBN
in_PIN
2002_CD
,_,
has_VPRT [PEAS]
been_VBN [BEMA]
clinical_JJ
development_NOMZ
._.
successful_JJ
launches_NN
of_PIN
new_JJ
improved_VBN
versions_NN
excellent_JJ
and_CC
it_PIT
now_TIME
represents_VPRT
over_IN
30_CD
per_PIN
cent_NN
of_PIN
Augmentin_NN
the_DT
ES_NN
and_PHC
XR_NN
formulations_NOMZ
._.
of_PIN
Paxils_NN
new_JJ
prescriptions_NOMZ
in_PIN
the_DT
USA_NN
._.
GlaxoSmithKline_NN
has_VPRT
123_CD
projects_NN
in_PIN
clinical_JJ
development_NOMZ
,_,
of_PIN
which_WDT [PIRE]
61_CD
are_VPRT [BEMA]
new_JJ
chemical_NN
GlaxoSmithKline_NN
is_VPRT [SPAU] [PASS]
also_RB
involved_VBN
in_PIN
litigation_NOMZ
We_FPP1
also_RB
have_VPRT
patent_NN
challenges_NN
to_PIN
a_DT
number_NN
entities_NOMZ
in_PIN
a_DT
number_NN
of_PIN
therapy_NN
areas_NN
,_,
and_ANDC
over_IN
the_DT
patents_NN
on_PIN
Wellbutrin_NN
SR_NN
and_PHC
Zyban_NN
of_PIN
other_JJ
products_NN
such_JJ
as_IN
Zofran_NN
and_PHC
Lamictal_NN
._.
The_DT
number_NN
of_PIN
new_JJ
chemical_NN
in_PIN
the_DT
USA_NN
._.
We_FPP1
are_VPRT
awaiting_VBG
the_DT
outcome_NN
These_DEMO
cases_NN
illustrate_VPRT
an_DT
industry-wide_JJ
trend_NN
entities_NOMZ
starting_VBG [WZPRES]
phase_NN
II_NN
clinical_JJ
trials_NN
has_VPRT
more_EMPH
of_PIN
our_FPP1
appeal_NN
against_PIN
a_DT
judgement_NOMZ
last_JJ
year_NN
in_PIN
which_WDT [PIRE]
generics_NN
companies_NN
are_VPRT
filing_VBG
more_EMPH
than_PIN
doubled_VBD
since_OSUB
the_DT
merger_NN
._.
We_FPP1
are_VPRT [BEMA]
in_PIN
favor_NN
of_PIN
Andrx_NN
Corporation_NOMZ
,_,
which_WDT [SERE]
patent_NN
challenges_NN
earlier_TIME
._.
We_FPP1
will_PRMD
obviously_RB
confident_JJ
that_THAC
,_,
as_IN
these_DEMP
and_CC
our_FPP1
phase_NN
I_FPP1
has_VPRT [PEAS]
applied_VBN
to_PIN
market_NN
generic_JJ
versions_NN
defend_VPRT
our_FPP1
intellectual_JJ
property_NN
vigorously_RB
._.
pipeline_NN
move_NN
through_PIN
development_NOMZ
,_,
we_FPP1
will_PRMD
of_PIN
the_DT
products_NN
._.
build_VB
the_DT
best_JJ
late_TIME
stage_NN
pharmaceutical_JJ
CONTRIBUTION_NOMZ
TO_PIN
SOCIETY_NN
pipeline_NN
in_PIN
the_DT
industry_NN
._.
We_FPP1
plan_VPRT
to_TO
provide_VB
Seroxat_NN
Paxil_NN
continues_VPRT
to_TO
be_VB [BEMA]
subject_PRED
to_PIN
The_DT
responsible_JJ
behavior_NN
of_PIN
all_QUAN
types_NN
a_DT
detailed_JJ
update_VPRT
on_PIN
progress_NN
in_PIN
R&D_NN
towards_PIN
threat_NN
of_PIN
generic_JJ
competition_NOMZ
,_,
particularly_RB
of_PIN
organizations_NOMZ
,_,
including_VBG
multinational_JJ
the_DT
end_NN
of_PIN
2003_CD
._.
in_PIN
the_DT
USA_NN
._.
companies_NN
,_,
governments_NOMZ
and_PHC
charities_NOMZ
,_,
is_VPRT [BEMA]
high_PRED
Our_FPP1
contribution_NOMZ
to_PIN
society_NN
._.
At_PIN
GlaxoSmithKline_NN
we_FPP1
are_VPRT [SPAU] [PASS]
fundamentally_RB
committed_VBN
to_TO
making_VBG
a_DT
significant_JJ
contribution_NOMZ
to_PIN
the_DT
societies_NN
in_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
02_CD
|_NN
03_CD
on_PIN
the_DT
public_JJ
agenda_NN
._.
Last_JJ
year_NN
,_,
in_PIN
our_FPP1
first_JJ
continue_VPRT
to_TO
grow_VB
significantly_RB
year_NN
on_PIN
year_NN
._.
controls_NN
and_CC
a_DT
number_NN
of_PIN
governance_NN
issues_NN
._.
report_NN
of_PIN
corporate_JJ
and_PHC
social_JJ
responsibility_NOMZ
,_,
In_PIN
September_NN
2002_CD
,_,
we_FPP1
further_RB
reduced_VBD
the_DT
GlaxoSmithKline_NN
regularly_RB
undertakes_VPRT
thorough_JJ
we_FPP1
set_VPRT
out_PIN
our_FPP1
commitment_NOMZ
to_TO
reflecting_VBG [PRIV]
preferential_JJ
prices_NN
of_PIN
our_FPP1
HIV_NN
AIDS_NN
medicines_NN
reviews_NN
of_PIN
the_DT
Groups_NN
internal_JJ
control_NN
systems_NN
ethical_JJ
,_,
social_JJ
and_PHC
environmental_JJ
concerns_NN
by_PIN
up_RB
to_PIN
33_CD
per_PIN
cent_NN
._.
and_ANDC
is_VPRT [PASS]
committed_VBN
to_TO
remaining_VBG
a_DT
leader_NN
in_PIN
in_PIN
our_FPP1
business_NOMZ
decisions_NN
._.
Our_FPP1
second_JJ
report_NN
,_,
governance_NN
processes_NN
and_PHC
structure_NN
._.
updating_VBG [PRESP]
our_FPP1
activities_NOMZ
in_PIN
2002_CD
,_,
is_VPRT
being_VBG
Positive_NN
Action_NOMZ
,_,
our_FPP1
international_JJ
program_NN
published_VBN [WZPAST]
at_PIN
the_DT
same_JJ
time_NN
as_IN
this_DEMO
Annual_JJ
of_PIN
HIV_NN
AIDS_NN
education_NOMZ
,_,
care_NN
and_PHC
support_NN
has_VPRT
ACKNOWLEDGEMENTS_NOMZ
Review_NN
and_CC
covers_VPRT
the_DT
issues_NN
that_TSUB
have_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
established_VBN [PRIV]
for_PIN
ten_CD
years_NN
backing_VBG [WZPRES]
Our_FPP1
business_NOMZ
is_VPRT
to_TO
discover_VB [PRIV] [THATD]
effective_JJ
medicines_NN
generated_VBD
significant_JJ
interest_NN
from_PIN
stakeholders_NN
._.
and_ANDC
healthcare_NN
products_NN
for_PIN
people_NN
throughout_PIN
the_DT
world_NN
and_CC
,_,
as_CONJ
a_NULL
result_NULL
,_,
create_VB
shareholder_NN
The_DT
Corporate_JJ
and_CC
Social_NN
Responsibility_NOMZ
Report_NN
GlaxoSmithKline_NN
is_VPRT [BEMA]
a_DT
key_JJ
partner_NN
in_PIN
the_DT
global_JJ
value_NN
._.
We_FPP1
are_VPRT [BEMA]
in_PIN
a_DT
great_JJ
position_NOMZ
to_TO
build_VB
on_PIN
also_RB
includes_VPRT
some_QUAN
indicators_NN
to_TO
show_VB [PRIV]
our_FPP1
effort_NN
to_TO
eliminate_VB
lymphatic_JJ
filariasis_NN
._.
This_DEMO
the_DT
success_NN
of_PIN
the_DT
last_JJ
year_NN
,_,
to_TO
build_VB
the_DT
best_JJ
progress_NN
in_PIN
addressing_VBG
these_DEMO
issues_NN
._.
disabling_VBG
and_PHC
disfiguring_VBG
disease_NN
currently_RB
pipeline_NN
in_PIN
the_DT
industry_NN
and_PHC
launch_NN
further_JJ
affects_VPRT
120_CD
million_CD
people_NN
and_CC
threatens_VPRT
new_JJ
products_NN
._.
We_FPP1
extend_VPRT
our_FPP1
thanks_NN
to_PIN
all_QUAN
Corporate_JJ
responsibility_NOMZ
is_VPRT [BEMA]
an_DT
integral_JJ
part_NN
a_DT
further_JJ
one_CD
billion_CD
in_PIN
some_QUAN
of_PIN
the_DT
poorest_JJ
our_FPP1
employees_NN
who_WP [WHSUB]
are_VPRT [BEMA]
so_EMPH
committed_PRED
to_PIN
of_PIN
our_FPP1
business_NOMZ
and_CC
inherent_JJ
in_PIN
our_FPP1
mission_NN
._.
To_PIN
date_NN
,_,
GlaxoSmithKline_NN
making_VBG [WZPRES]
this_DEMP
happen_VB
._.
GlaxoSmithKline_NN
makes_VPRT
a_DT
significant_JJ
positive_JJ
has_VPRT [PEAS]
donated_VBN
145_CD
million_CD
tablets_NN
as_IN
part_NN
of_PIN
our_FPP1
contribution_NOMZ
to_PIN
society_NN
around_PLACE
the_DT
world_NN
,_,
20-year_JJ
commitment_NOMZ
to_TO
eradicate_VB
this_DEMO
disease_NN
._.
Bob_NN
Ingram_NN
,_,
Chief_NN
Operating_GER
Officer_NN
and_CC
through_PIN
the_DT
medicines_NN
,_,
vaccines_NN
and_PHC
President_NN
,_,
Pharmaceutical_NN
Operations_NOMZ
,_,
retired_VBD
healthcare_NN
products_NN
that_TOBJ
we_FPP1
research_NN
,_,
The_DT
Guardian_NN
newspapers_NN
Giving_GER
List_NN
,_,
at_PIN
the_DT
end_NN
of_PIN
December_NN
but_CC
will_PRMD
continue_VB
develop_VB
,_,
manufacture_VB
and_PHC
sell_VB
._.
recently_TIME
recognized_VBN [PRIV]
that_THVC
GlaxoSmithKline_NN
's_POS
to_TO
work_VB
part_NN
time_NN
as_IN
Vice_NN
Chairman_NN
of_PIN
total_JJ
global_JJ
community_NOMZ
expenditure_NN
in_PIN
2001_CD
Pharmaceuticals_NN
and_CC
special_JJ
advisor_NN
to_PIN
Our_FPP1
products_NN
must_NEMD
improve_VB
peoples_NN
lives_NN
was_VBD [BEMA]
greater_PRED
than_PIN
that_DEMO
of_PIN
any_QUAN
other_JJ
British_JJ
the_DT
Group_NN
._.
We_FPP1
would_PRMD
like_VB
to_TO
express_VB
our_FPP1
and_CC
ensure_VB [SUAV] [PRIV]
a_DT
profitable_JJ
and_PHC
sustainable_JJ
future_JJ
company_NN
._.
We_FPP1
increased_VBD
our_FPP1
comprehensive_JJ
appreciation_NOMZ
for_PIN
his_TPP3
contribution_NOMZ
to_PIN
the_DT
for_PIN
our_FPP1
business_NOMZ
._.
We_FPP1
also_RB
understand_VPRT [PRIV]
that_THVC
program_NN
of_PIN
social_JJ
investment_NOMZ
in_PIN
2002_CD
,_,
company_NN
and_CC
,_,
in_CONJ
particular_NULL
,_,
for_PIN
his_TPP3
significant_JJ
stakeholders_NN
,_,
including_VBG
employees_NN
,_,
want_VPRT
investing_VBG
239_CD
million_CD
in_PIN
support_NN
of_PIN
global_JJ
role_NN
in_PIN
making_VBG
the_DT
merger_NN
a_DT
success_NN
._.
to_TO
know_VB [PRIV]
how_RB [WHCL]
we_FPP1
make_VPRT
this_DEMO
profit_NN
,_,
and_ANDC
need_VPRT
community_NOMZ
programs_NN
,_,
product_NN
donations_NOMZ
to_TO
be_VB [PASS]
reassured_VBN
of_PIN
the_DT
sound_JJ
ethical_JJ
basis_NN
for_PIN
and_CC
charitable_JJ
contributions_NOMZ
._.
On_PIN
behalf_NN
of_PIN
the_DT
Board_NN
and_CC
the_DT
Corporate_JJ
our_FPP1
business_NOMZ
._.
Executive_NN
Team_NN
,_,
we_FPP1
also_RB
thank_VPRT
you_SPP2
,_,
our_FPP1
CORPORATE_JJ
GOVERNANCE_NN
shareholders_NN
,_,
for_PIN
your_SPP2
support_NN
and_PHC
hope_NN
Our_FPP1
focus_NN
on_PIN
making_VBG
a_DT
contribution_NOMZ
to_PIN
Corporate_JJ
governance_NN
continues_VPRT
to_TO
be_VB [BEMA]
a_DT
that_DEMO
you_SPP2
share_VPRT
our_FPP1
enthusiasm_NN
for_PIN
the_DT
improving_VBG
healthcare_NN
and_CC
alleviating_VBG
suffering_VBG
high_JJ
profile_NN
issue_NN
with_PIN
the_DT
publication_NOMZ
of_PIN
the_DT
company_NN
and_CC
look_VB
forward_RB
to_PIN
its_PIT
continued_VBN
in_PIN
the_DT
developing_VBG
world_NN
has_VPRT [SPAU] [PEAS]
never_RB
been_VBN
Higgs_NN
Review_NN
of_PIN
the_DT
role_NN
and_PHC
effectiveness_NOMZ
of_PIN
success_NN
in_PIN
2003_CD
._.
greater_JJ
._.
Significant_JJ
progress_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
Non-Executive_JJ
Directors_NN
and_PHC
Sir_NN
Robert_NN
Smiths_NN
towards_PIN
tackling_VBG
the_DT
enormous_JJ
challenge_NN
Report_NN
on_PIN
audit_NN
committees_NN
._.
By_PIN
the_DT
end_NN
of_PIN
2002_CD
,_,
we_FPP1
had_VBD
Sarbanes-Oxley_NN
Act_NN
became_VBD
law_NN
in_PIN
July_NN
2002_CD
secured_VBN
some_QUAN
120_CD
arrangements_NOMZ
to_TO
supply_VB
and_CC
will_PRMD
have_VB
an_DT
impact_NN
on_PIN
GlaxoSmithKline_NN
HIV_NN
AIDS_NN
medicines_NN
to_PIN
in_PIN
relation_NOMZ
to_PIN
certification_NOMZ
of_PIN
the_DT
Annual_JJ
Report_NN
50_CD
of_PIN
the_DT
worlds_NN
poorest_JJ
countries_NN
._.
Shipments_NOMZ
on_PIN
Form_NN
20-F_NN
,_,
disclosure_NN
processes_NN
,_,
our_FPP1
SIR_NN
CHRISTOPHER_NN
HOGG_NN
JP_NN
GARNIER_NN
of_PIN
these_DEMO
medicines_NN
to_PIN
the_DT
developing_VBG
world_NN
relationship_NN
with_PIN
external_JJ
auditors_NN
,_,
internal_JJ
CHAIRMAN_NN
CHIEF_JJ
EXECUTIVE_NN
OFFICER_NN
TRADING_GER
PROFIT_NN
GROWTH_NN
million_CD
AN_DT
R&D_NN
ORGANISATION_NOMZ
ON_PIN
TRACK_NN
TO_TO
DELIVER_VB
A_DT
FULL_JJ
LATE_TIME
STAGE_NN
PRODUCT_NN
TRADING_GER
PROFIT_NN
UP_RP
15_CD
%_NN
TO_PIN
00_CD
5,026_CD
PIPELINE_NN
,_,
WITH_PIN
AN_DT
R&D_NN
UPDATE_NN
01_CD
6,053_CD
MEETING_GER
EXPECTED_VBN [PRIV]
TO_TO
TAKE_VB
PLACE_NN
02_CD
6,694_CD
6.7_CD
BILLION_NN
TOWARDS_PIN
THE_DT
END_NN
OF_PIN
2003_CD
._.
Earnings_GER
per_PIN
share_NN
growth_NN
of_PIN
13_CD
%_NN
demonstrates_VPRT [PRIV]
the_DT
continued_JJ
financial_JJ
strength_NN
that_TSUB
will_PRMD
provide_VB
the_DT
company_NN
with_PIN
a_DT
sound_JJ
platform_NN
for_PIN
future_JJ
growth_NN
._.
All_QUAN
percentage_NN
growth_NN
rates_NN
throughout_PIN
this_DEMO
Review_NN
are_VPRT [BEMA]
at_PIN
constant_JJ
exchange_NN
rates_NN
,_,
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
see_VPRT [PRIV] [THATD]
Business_NOMZ
operating_VBG [WZPRES]
review_NN
on_PIN
page_NN
19_CD
._.
These_DEMP
are_VPRT [PASS]
based_VBN
on_PIN
business_NOMZ
performance_NN
results_NN
._.
GlaxoSmithKline_NN
is_VPRT [BEMA]
instrumental_PRED
in_PIN
improving_VBG
the_DT
lives_NN
of_PIN
Bettina_NN
and_PHC
Philippe_NN
Bartels_NN
Bettina_NN
Bartels_NN
,_,
a_DT
physiotherapist_NN
from_PIN
Munich_NN
,_,
Germany_NN
,_,
has_VPRT [PEAS]
lived_VBN
with_PIN
asthma_NN
from_PIN
the_DT
age_NN
of_PIN
seven_CD
._.
Her_TPP3
condition_NOMZ
affected_VBD
her_TPP3
involvement_NOMZ
in_PIN
sport_NN
and_CC
she_TPP3
also_RB
found_VBD [PRIV]
it_PIT
difficult_JJ
to_TO
breathe_VB
during_PIN
her_TPP3
favorite_JJ
hobby_NN
,_,
horse_NN
riding_VBG [WZPRES]
._.
She_TPP3
now_TIME
controls_VPRT
her_TPP3
asthma_NN
with_PIN
an_DT
inhaler_NN
millions_NN
and_CC
is_VPRT [BEMA]
able_PRED
to_TO
take_VB
part_NN
in_PIN
activities_NOMZ
such_JJ
as_IN
swimming_GER
with_PIN
her_TPP3
son_NN
,_,
Philippe_NN
._.
Philippe_NN
,_,
who_WP
is_VPRT [BEMA]
nearly_DWNT
eight_CD
,_,
has_VPRT [PEAS]
been_VBN [BEMA]
able_PRED
of_PIN
people_NN
around_PLACE
the_DT
to_TO
take_VB
advantage_NN
of_PIN
more_EMPH
modern_JJ
inhalers_NN
and_CC
also_RB
understands_VPRT [PRIV]
his_TPP3
condition_NOMZ
much_QUAN
better_RB
as_CONJ
a_NULL
result_NULL
of_PIN
attending_VBG
a_DT
special_JJ
asthma_NN
school_NN
world_NN
every_QUAN
day_NN
._.
where_RB
the_DT
disease_NN
and_CC
its_PIT
effects_NN
are_VPRT [PASS]
explained_VBN [PUBV]
._.
A_DT
keen_JJ
footballer_NN
,_,
Philippe_NN
plays_VPRT
three_CD
times_NN
a_DT
week_NN
for_PIN
a_DT
local_JJ
team_NN
._.
When_RB
I_FPP1
was_VBD [BEMA]
seven_CD
,_,
there_EX
was_VBD
not_XX0
a_DT
great_JJ
deal_NN
of_PIN
information_NOMZ
about_IN
asthma_NN
and_ANDC
how_RB
to_TO
live_VB
with_PIN
it_PIT
._.
Today_TIME
the_DT
situation_NOMZ
has_VPRT [PEAS]
changed_VBN
considerably_RB
and_CC
Philippe_NN
is_VPRT [BEMA]
able_PRED
to_TO
deal_VB
much_QUAN
better_RB
with_PIN
his_TPP3
asthma_NN
,_,
said_VBD [PUBV]
Bettina_NN
._.
PATIENTS_NN
AND_PHC
PRODUCT_NN
DEVELOPMENT_NOMZ
GlaxoSmithKline_NN
has_VPRT
a_DT
tradition_NOMZ
of_PIN
creating_VBG
significant_JJ
improvements_NOMZ
in_PIN
asthma_NN
healthcare_NN
._.
We_FPP1
pioneered_VBD
the_DT
early_TIME
standard_NN
treatments_NOMZ
such_JJ
as_IN
Ventolin_NN
in_PIN
the_DT
early_TIME
1970s_NN
and_CC
in_PIN
the_DT
last_JJ
few_QUAN
years_NN
have_VPRT [PEAS]
delivered_VBN
another_DT
major_JJ
leap_NN
forward_RB
with_PIN
Seretide_NN
Advair_NN
,_,
the_DT
first_JJ
product_NN
to_TO
treat_VB
the_DT
two_CD
main_JJ
components_NN
of_PIN
asthma_NN
,_,
inflammation_NOMZ
and_PHC
bronchoconstriction_NOMZ
,_,
in_PIN
one_CD
easy-to-use_JJ
inhaler_NN
._.
Development_NOMZ
of_PIN
our_FPP1
inhaled_JJ
asthma_NN
treatments_NOMZ
Despite_PIN
these_DEMO
continuous_JJ
advances_NN
,_,
however_CONJ
,_,
millions_NN
of_PIN
people_NN
still_RB
suffer_VPRT
from_PIN
asthma_NN
and_CC
,_,
whilst_OSUB
their_TPP3
quality_NOMZ
of_PIN
life_NN
has_VPRT [PEAS]
improved_VBN
,_,
there_EX
is_VPRT
still_RB
a_EMPH
lot_NULL
of_PIN
work_NN
to_TO
do_VB [PROD]
._.
Whats_NN
more_EMPH
,_,
the_DT
worldwide_JJ
incidence_NN
of_PIN
asthma_NN
is_VPRT
increasing_VBG
._.
1970s_NN
Ventolin_NN
bronchodilator_NN
1970s_CD
Becotide_NN
Beclovent_NN
GlaxoSmithKline_NN
is_VPRT [SPAU]
still_RB
pushing_VBG
the_DT
boundaries_NN
of_PIN
science_NN
to_TO
learn_VB [PRIV]
more_EMPH
corticosteroid_JJ
about_IN
asthma_NN
._.
An_DT
exciting_JJ
example_NN
of_PIN
this_DEMO
work_NN
is_VPRT [BEMA]
the_DT
recent_JJ
publication_NOMZ
1990s_CD
Serevent_NN
bronchodilator_NN
by_PIN
our_FPP1
scientists_NN
of_PIN
the_DT
detailed_JJ
structure_NN
of_PIN
a_DT
vital_JJ
part_NN
of_PIN
the_DT
human_JJ
glucocorticoid_NN
receptor_NN
._.
This_DEMO
receptor_NN
is_VPRT [PASS]
known_VBN [PRIV]
to_TO
control_VB
the_DT
response_NN
1990s_CD
Flixotide_NN
Flovent_NN
corticosteroid_VBD
to_PIN
common_JJ
asthma_NN
medicines_NN
and_CC
so_RB
an_DT
understanding_GER
of_PIN
its_PIT
structure_NN
Today_TIME
Seretide_NN
Advair_NN
may_POMD
lead_VB
to_TO
still_RB
more_EMPH
innovative_JJ
therapies_NN
._.
bronchodilator_NN
corticosteroid_NN
In_PIN
respiratory_JJ
medicine_NN
,_,
as_IN
in_PIN
our_FPP1
other_JJ
therapy_NN
areas_NN
,_,
we_FPP1
strive_VPRT
to_TO
improve_VB
peoples_NN
lives_NN
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
04_CD
|_NN
05_CD
The_DT
incidence_NN
of_PIN
asthma_NN
among_PIN
children_NN
in_PIN
the_DT
UK_NN
is_VPRT [BEMA]
now_TIME
six_CD
times_NN
higher_JJ
than_PIN
it_PIT
was_VBD [BEMA]
25_CD
years_NN
ago_RB
._.
SCALE_VB
OF_PIN
THE_DT
PROBLEM_NN
GLAXOSMITHKLINE_NN
IS_VPRT
COMMITTED_NN
TO_PIN
DEVELOPING_GER
NEW_NN
RESPIRATORY_NN
PRODUCTS_NN
WITH_PIN [STPR]
,_,
WHERE_NN
RELEVANT_NN
,_,
EASY-TO-USE_JJ
DEVICES_NN
._.
DISKUS_NN
,_,
In_PIN
Germany_NN
,_,
there_EX
are_VPRT
an_DT
estimated_VBN [PRIV]
AN_DT
AWARD-WINNING_GER
DEVICE_NN
,_,
IS_VPRT [BEMA]
ONE_CD
SUCH_JJ
PRODUCT_NN
._.
The_DT
number_NN
of_PIN
asthmatics_NN
in_PIN
the_DT
USA_NN
has_VPRT [PEAS]
leapt_VBN
by_PIN
over_IN
60_CD
per_PIN
cent_NN
since_OSUB
the_DT
early_TIME
1980s_CD
and_CC
deaths_NN
have_VPRT [PEAS]
doubled_VBN
to_PIN
5,000_CD
a_DT
year_NN
._.
In_PIN
Western_NN
Europe_NN
,_,
cases_NN
of_PIN
asthma_NN
have_VPRT [PEAS]
doubled_VBN
in_PIN
ten_CD
years_NN
._.
There_EX
are_VPRT
three_CD
million_CD
asthmatics_NN
in_PIN
Japan_NN
._.
In_PIN
Australia_NN
,_,
one_CD
child_NN
in_PIN
six_CD
under_IN
the_DT
age_NN
of_PIN
16_CD
is_VPRT [PASS]
affected_VBN
._.
GlaxoSmithKline_NN
is_VPRT [BEMA]
also_RB
the_DT
CENTRES_NN
OF_PIN
EXCELLENCE_NN
leader_NN
in_PIN
in-licensing_JJ
deals_NN
._.
FOR_PIN
DRUG_NN
DISCOVERY_NN
1_CD
CARDIOVASCULAR_NN
&_CC
UROGENITAL_NN
DISEASES_NN
2_CD
METABOLIC_NN
&_CC
VIRAL_NN
DISEASES_NN
24_CD
The_DT
results_NN
of_PIN
1,536_CD
single_JJ
3_CD
MICROBIAL_NN
,_,
MUSCULOSKELETAL_NN
experiments_NOMZ
can_POMD
be_VB [BYPA]
read_VBN
by_PIN
&_CC
PROLIFERATIVE_NN
DISEASES_NN
major_JJ
external_JJ
4_CD
NEUROLOGY_NN
our_FPP1
computers_NN
in_PIN
0.5_CD
seconds_NN
._.
collaborations_NOMZ
have_VPRT
5_CD
PSYCHIATRY_NN
been_VBN [PASS]
signed_VBN
since_OSUB
6_CD
RESPIRATORY_NN
&_CC
INFLAMMATION_NOMZ
GLAXOSMITHKLINE_NN
CURRENTLY_NN
HAS_VPRT
MORE_EMPH
THAN_PIN
ONE_CD
MILLION_NN
December_NN
2000_CD
._.
HIGH_JJ
QUALITY_NOMZ
COMPOUNDS_VPRT
IN_PIN
ITS_PIT
COLLECTION_NOMZ
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
06_CD
|_NN
07_CD
Over_IN
ONL10_CD
Y_CD
%_NN
of_PIN
all_QUAN
drugs_NN
that_TSUB
reach_VPRT
clinical_JJ
trials_NN
in_PIN
the_DT
pharmaceutical_JJ
industry_NN
make_VPRT
it_PIT
to_PIN
the_DT
market_NN
place_NN
._.
15,000_CD
An_DT
automated_JJ
compound_NN
store_NN
houses_NN
hundreds_NN
of_PIN
thousands_NN
of_PIN
compounds_NN
._.
A_DT
number_NN
of_PIN
R&D_NN
staff_NN
are_VPRT [PASS]
based_VBN
at_PIN
these_DEMP
will_PRMD
interact_VB
with_PIN
drug_NN
targets_NN
during_PIN
screening_VBG
and_PHC
become_VB
potential_JJ
medicines_NN
._.
more_EMPH
than_PIN
20_CD
sites_NN
in_PIN
GlaxoSmithKline_NN
aims_VPRT
to_TO
have_VB
one_CD
of_PIN
the_DT
largest_JJ
and_CC
,_,
more_EMPH
importantly_RB
,_,
the_DT
highest_JJ
quality_NOMZ
collection_NOMZ
in_PIN
the_DT
eight_CD
countries_NN
._.
The_DT
compound_NN
store_NN
pictured_VBN [WZPAST]
here_RB
at_PIN
Stevenage_NN
in_PIN
the_DT
UK_NN
holds_VPRT [PRIV]
nearly_DWNT
half_PDT
a_DT
million_CD
compounds_NN
._.
Work_NN
has_VPRT [SPAU] [PEAS]
just_EMPH
been_VBN [PASS]
completed_VBN
on_PIN
a_DT
stateof-the-art_JJ
compound_NN
store_NN
at_PIN
Tres_NN
Cantos_NN
in_PIN
Spain_NN
which_WDT [WHSUB]
has_VPRT
capacity_NOMZ
for_PIN
over_IN
two_CD
million_CD
compounds_NN
._.
Such_JJ
investment_NOMZ
in_PIN
technology_NN
is_VPRT [SPAU]
already_RB
paying_VBG
dividends_NN
._.
GlaxoSmithKline_NN
has_VPRT
one_CD
of_PIN
the_DT
strongest_JJ
early_TIME
stage_NN
pipelines_NN
in_PIN
the_DT
industry_NN
._.
There_EX
are_VPRT
currently_RB
123_CD
projects_NN
in_PIN
clinical_JJ
development_NOMZ
._.
R&D_NN
PRODUCTIVITY_NOMZ
GlaxoSmithKlines_NN
aim_NN
is_VPRT
to_TO
become_VB
the_DT
most_EMPH
productive_JJ
R&D_NN
organization_NOMZ
in_PIN
the_DT
industry_NN
._.
The_DT
merger_NN
that_TSUB
brought_VBD
about_RB
GlaxoSmithKline_JJ
accelerated_VBD
a_DT
radical_JJ
rethink_NN
in_PIN
the_DT
way_NN
R&D_NN
is_VPRT [PASS]
organised_VBN
and_PHC
conducted_VBN
._.
R&D_NN
at_PIN
GlaxoSmithKline_NN
takes_VPRT
advantage_NN
of_PIN
its_PIT
size_NN
in_PIN
areas_NN
such_JJ
as_IN
genetics_NN
,_,
molecular_JJ
screening_GER
and_CC
clinical_JJ
research_NN
,_,
where_RB
scale_NN
is_VPRT [BEMA]
important_PRED
._.
However_CONJ
,_,
in_PIN
some_QUAN
areas_NN
of_PIN
drug_NN
discovery_NN
,_,
GlaxoSmithKline_NN
has_VPRT [PEAS]
formed_VBN
six_CD
therapy-area_NN
focused_VBD
and_CC
entrepreneurial_JJ
units_NN
known_VBN [PRIV]
as_IN
Centres_NN
of_PIN
Excellence_NN
for_PIN
Drug_NN
Discovery_NN
CEDDs_NN
._.
Their_TPP3
brief_NN
is_VPRT
to_TO
focus_VB
on_PIN
just_EMPH
one_CD
thing_NN
advancing_VBG [WZPRES]
lead_NN
compounds_NN
to_PIN
the_DT
point_NN
where_RB
a_DT
therapeutic_JJ
concept_NN
has_VPRT [PEAS]
been_VBN [PASS]
demonstrated_VBN [PRIV]
and_CC
large-scale_JJ
clinical_JJ
trials_NN
can_POMD
begin_VB
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
focused_VBN
enormous_JJ
amounts_NN
of_PIN
energy_NN
and_PHC
resource_NN
on_PIN
automation_NOMZ
to_TO
broaden_VB
the_DT
scope_NN
and_CC
quicken_VB
the_DT
pace_NN
of_PIN
the_DT
search_NN
for_PIN
new_JJ
medicines_NN
._.
High_NN
throughput_NN
technology_NN
,_,
for_CONJ
example_NULL
,_,
increases_VPRT
the_DT
number_NN
of_PIN
hits_NN
identified_VBN
,_,
improves_VPRT
the_DT
quality_NOMZ
of_PIN
the_DT
lead_NN
compounds_NN
and_CC
reduces_VPRT
the_DT
time_NN
taken_VBN
to_TO
optimise_VB
them_TPP3
for_PIN
further_JJ
development_NOMZ
._.
Meanwhile_RB
,_,
we_FPP1
are_VPRT
scrutinising_VBG
each_QUAN
step_NN
in_PIN
the_DT
discovery_NN
and_PHC
development_NOMZ
process_NN
to_TO
reduce_VB
the_DT
element_NOMZ
of_PIN
chance_NN
and_CC
identify_VB
potential_JJ
problems_NN
earlier_TIME
._.
USING_NN
INNOVATIVE_NN
SCIENCE_NN
TO_TO
ENHANCE_VB
R&D_NN
The_DT
application_NOMZ
of_PIN
the_DT
latest_JJ
scientific_JJ
advances_NN
to_PIN
the_DT
drug_NN
discovery_NN
and_PHC
Kevin_NN
Kershner_NN
,_,
pictured_VBD
right_RB
,_,
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Transcriptome_NN
development_NOMZ
processes_NN
will_PRMD
ensure_VB [SUAV] [PRIV]
GlaxoSmithKlines_NN
leadership_NN
position_NOMZ
._.
Analysis_NN
TA_NN
team_NN
at_PIN
Upper_NN
Merion_NN
,_,
New_NN
technology_NN
has_VPRT [PEAS]
opened_VBN
up_RP
novel_NN
avenues_NN
of_PIN
research_NN
exploring_VBG [WZPRES]
the_DT
Pennsylvania_NN
._.
His_TPP3
area_NN
of_PIN
expertise_NN
fundamental_JJ
bases_NN
of_PIN
health_NN
and_PHC
disease_NN
._.
is_VPRT [BEMA]
robotic_JJ
automation_NOMZ
to_TO
profile_VB
gene_NN
expression_NN
patterns_NN
in_PIN
normal_JJ
and_PHC
diseased_JJ
tissues_NN
._.
Gene-related_JJ
research_NN
,_,
in_CONJ
particular_NULL
,_,
presents_VPRT
an_DT
enormous_JJ
opportunity_NOMZ
._.
Pharmacogenetics_NN
identifies_VPRT
genetic_JJ
patterns_NN
to_TO
help_VB
predict_VB [PUBV]
how_RB [WHCL]
individual_JJ
Automation_NOMZ
decreases_VPRT
human_JJ
patients_NN
will_PRMD
respond_VB
to_PIN
medicines_NN
._.
In_PIN
short_JJ
,_,
getting_VBG [PRESP]
the_DT
right_JJ
medicine_NN
to_PIN
interaction_NOMZ
and_CC
allows_VPRT [SUAV]
the_DT
robot_NN
to_TO
produce_VB
samples_NN
in_PIN
a_DT
highthe_JJ
right_NN
patient_NN
._.
Everyone_QUPR
wants_VPRT
more_EMPH
effective_JJ
and_PHC
safer_JJ
medicines_NN
and_PHC
throughput_NN
manner_NN
._.
It_PIT
also_RB
frees_VPRT
if_COND
we_FPP1
can_POMD [SPAU]
easily_RB
identify_VB
which_WDT
patients_NN
respond_VPRT
well_RB
to_PIN
particular_JJ
drugs_NN
we_FPP1
scientists_NN
to_TO
concentrate_VB
on_PIN
other_JJ
can_POMD
use_VB
this_DEMO
information_NOMZ
to_PIN
further_JJ
refine_VB
therapy_NN
._.
challenges_NN
in_PIN
their_TPP3
research_NN
,_,
ultimately_RB
increasing_VBG
productivity_NOMZ
and_PHC
efficiency_NN
in_PIN
a_DT
shorter_JJ
time_NN
,_,
GlaxoSmithKline_NN
is_VPRT [SPAU]
also_RB
using_VBG
information_NOMZ
gleaned_VBN [WZPAST]
from_PIN
the_DT
human_JJ
genome_NN
without_PIN
compromising_VBG
data_NN
quality_NOMZ
._.
to_TO
identify_VB
new_JJ
ways_NN
to_TO
tackle_VB
disease_NN
._.
By_PIN
finding_VBG [PRIV]
out_PIN
what_WP
specific_JJ
genes_NN
do_EMPH
Introducing_VBG
robotic_JJ
automation_NOMZ
and_CC
their_TPP3
role_NN
in_PIN
disease_NN
,_,
we_FPP1
can_POMD
identify_VB
whole_JJ
new_JJ
approaches_NN
to_PIN
medicine_NN
._.
to_PIN
the_DT
TA_NN
group_NN
will_PRMD
help_VB
team_NN
Our_FPP1
studies_NN
of_PIN
the_DT
human_JJ
genome_NN
have_VPRT [PEAS]
identified_VBN
new_JJ
drug_NN
targets_NN
for_PIN
bone_NN
members_NN
become_VPRT
more_EMPH
effective_JJ
loss_NN
and_CC
for_PIN
atherosclerosis_NN
,_,
the_DT
fundamental_JJ
pathology_NN
behind_PLACE
most_EMPH
deaths_NN
and_CC
more_EMPH
productive_JJ
,_,
said_VBD [PUBV]
Kevin_NN
._.
Therapies_NN
directed_VBD
against_PIN
these_DEMO
targets_NN
are_VPRT [BEMA]
now_TIME
It_PIT
will_PRMD [SPAU]
also_RB
enable_VB
team_NN
members_NN
in_PIN
clinical_JJ
studies_NN
._.
to_TO
generate_VB
high_JJ
quality_NOMZ
data_NN
which_WDT [WHSUB]
will_PRMD
lead_VB
to_PIN
a_DT
better_JJ
understanding_GER
For_PIN
all_QUAN
the_DT
powerful_JJ
capabilities_NOMZ
that_TOBJ
GlaxoSmithKline_NN
has_VPRT [PEAS]
built_VBN
within_PIN
its_PIT
own_JJ
of_PIN
gene_NN
expression_NN
and_PHC
disease_NN
._.
R&D_NN
organization_NOMZ
,_,
we_FPP1
recognize_VPRT [PRIV]
that_THVC
we_FPP1
do_VPRT
not_XX0
have_VB
a_DT
monopoly_NN
on_PIN
good_JJ
ideas_NN
._.
To_TO
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
stay_VPRT
at_PIN
the_DT
leading_VBG
edge_NN
of_PIN
biomedical_JJ
research_NN
,_,
we_FPP1
have_VPRT [PEAS]
entered_VBN
into_PIN
hundreds_NN
of_PIN
collaborations_NOMZ
with_PIN
other_JJ
companies_NN
and_CC
academic_JJ
and_CC
government_NOMZ
institutions_NOMZ
._.
Using_VBG
genetic_JJ
research_NN
will_PRMD
enable_VB
us_FPP1
to_TO
get_VB
the_DT
right_JJ
medicine_NN
for_PIN
the_DT
right_JJ
patient_NN
and_CC
find_VB [PRIV]
new_JJ
ways_NN
to_TO
tackle_VB
disease_NN
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
08_CD
|_NN
09_CD
FOCUS_NN
ON_PIN
GENETICS_NN
AND_PHC
GENOMICS_NN
OUR_FPP1
AREAS_NN
OF_PIN
FOCUS_NN
In_PIN
the_DT
1990s_CD
,_,
GlaxoSmithKline_NN
made_VBD
a_DT
commitment_NOMZ
to_TO
focus_VB
on_PIN
genetics_NN
Pharmacogenetics_NN
and_PHC
genomics_NN
in_PIN
its_PIT
drug_NN
research_NN
and_PHC
development_NOMZ
efforts_NN
,_,
making_VBG [PRESP]
it_PIT
an_DT
industry_NN
leader_NN
._.
Drug_NN
target_NN
identification_NOMZ
Gene-disease_NN
GLAXOSMITHKLINE_NN
GENETIC_NN
RESEARCHERS_NN
associations_NOMZ
HAVE_NN
IDENTIFIED_NN
LIKELY_NN
SUSCEPTIBILITY_NOMZ
GENES_NN
FOR_PIN
ALZHEIMERS_NN
DISEASE_NN
,_,
PSORIASIS_NN
,_,
MIGRAINE_NN
AND_PHC
PARKINSONS_NN
DISEASE_NN
._.
OUR_FPP1
CONTRIBUTION_NOMZ
2002_CD
HIGHLIGHTS_NN
We_FPP1
have_VPRT
120_CD
arrangements_NOMZ
to_TO
supply_VB
HIV_NN
AIDS_NN
medicines_NN
to_PIN
50_CD
of_PIN
the_DT
worlds_NN
poorest_JJ
countries_NN
._.
We_FPP1
commenced_VBD
human_JJ
clinical_JJ
trials_NN
of_PIN
our_FPP1
HIV_NN
vaccine_NN
._.
Grants_NN
totalling_VBG [WZPRES]
1_CD
million_CD
awarded_VBN
under_IN
our_FPP1
African_JJ
Malaria_NN
Partnership_NN
._.
In_PIN
2002_CD
we_FPP1
donated_VBD
66_CD
million_CD
albendazole_NN
tablets_NN
to_TO
support_VB
the_DT
Global_JJ
Alliance_NN
to_TO
Eliminate_VB
Lymphatic_NN
Filariasis_NN
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
10_CD
|_NN
11_CD
In_CONJ
addition_NULL
to_TO
providing_VBG
products_NN
to_TO
treat_VB
diseases_NN
in_PIN
the_DT
developing_VBG
GSK_NN
is_VPRT
conducting_VBG
world_NN
,_,
GlaxoSmithKline_NN
also_RB
supports_VPRT
charitable_JJ
and_CC
community_NOMZ
work_VPRT
throughout_PIN
the_DT
world_NN
._.
R&D_NN
for_PIN
the_DT
prevention_NOMZ
One_CD
such_JJ
charity_NOMZ
is_VPRT
Project_NN
HOPE_NN
which_WDT [WHOBJ]
for_PIN
the_DT
last_JJ
25_CD
years_NN
has_VPRT [PEAS]
run_VBN
health_NN
education_NOMZ
programs_NN
in_PIN
and_CC
treatment_NOMZ
of_PIN
Guatemala_NN
where_RB
this_DEMO
picture_NN
of_PIN
local_JJ
people_NN
in_PIN
traditional_JJ
Mayan_JJ
costume_NN
was_VBD [PASS]
taken_VBN
._.
all_QUAN
three_CD
of_PIN
the_DT
World_NN
Health_NN
Organizations_NOMZ
top_JJ
priorities_NOMZ
:_:
HIV_NN
AIDS_NN
,_,
TB_NN
and_PHC
malaria_NN
._.
DISEASES_NN
OF_PIN
THE_DT
DEVELOPING_VBG
WORLD_NN
GlaxoSmithKline_NN
makes_VPRT
an_DT
innovative_JJ
,_,
responsible_JJ
and_PHC
sustainable_JJ
contribution_NOMZ
to_TO
improving_VBG
healthcare_NN
in_PIN
the_DT
developing_VBG
world_NN
in_PIN
four_CD
key_JJ
areas_NN
._.
In_CONJ
addition_NULL
to_TO
providing_VBG
drugs_NN
and_PHC
vaccines_NN
for_PIN
current_JJ
needs_NN
,_,
we_FPP1
invest_VPRT
in_PIN
R&D_NN
to_TO
meet_VB
future_JJ
needs_NN
._.
The_DT
Group_NN
also_RB
offers_VPRT
sustainable_JJ
preferential_JJ
pricing_GER
in_PIN
the_DT
developing_VBG
world_NN
and_CC
works_VPRT
in_PIN
partnership_NN
with_PIN
communities_NOMZ
to_TO
foster_VB
effective_JJ
healthcare_NN
._.
This_DEMP
is_VPRT [BEMA]
against_PIN
a_DT
background_NN
where_RB
access_NN
to_PIN
the_DT
most_EMPH
basic_JJ
healthcare_NN
services_NN
does_VPRT
not_XX0
exist_VB
for_PIN
millions_NN
of_PIN
people_NN
in_PIN
developing_VBG
countries_NN
and_ANDC
where_RB
lifethreatening_VBG
diseases_NN
such_JJ
as_IN
tuberculosis_NN
TB_NN
,_,
malaria_NN
and_PHC
HIV_NN
AIDS_NN
have_VPRT [PEAS]
created_VBN
a_DT
healthcare_NN
crisis_NN
._.
GlaxoSmithKline_NN
has_VPRT
an_DT
extensive_JJ
portfolio_NN
of_PIN
research_NN
projects_NN
and_PHC
products_NN
for_PIN
diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
DDW_NN
._.
We_FPP1
have_VPRT [PEAS]
created_VBN
a_DT
dedicated_JJ
DDW_NN
It_PIT
would_PRMD
be_VB [BEMA]
tough_PRED
for_PIN
me_FPP1
to_TO
go_VB
home_NN
every_QUAN
night_NN
and_CC
have_VPRT
to_TO
say_VB [PUBV]
group_NN
within_PIN
our_FPP1
R&D_NN
organization_NOMZ
which_WDT [WHSUB]
includes_VPRT
a_DT
facility_NOMZ
in_PIN
Tres_NN
Cantos_NN
,_,
I_FPP1
know_VPRT [PRIV]
how_RB [WHCL]
to_TO
discover_VB [PRIV]
drugs_NN
for_PIN
Spain_NN
,_,
focused_VBD
on_PIN
drug_NN
discovery_NN
for_PIN
malaria_NN
and_PHC
TB_NN
._.
people_NN
who_WP [WHSUB]
are_VPRT
dying_VBG
but_CC
am_VPRT
not_XX0
doing_VBG [PROD]
anything_QUPR
about_IN
it_PIT
._.
This_DEMO
facility_NOMZ
is_VPRT [BEMA]
only_DWNT
a_DT
part_NN
of_PIN
our_FPP1
wider_JJ
R&D_NN
activity_NOMZ
into_PIN
diseases_NN
that_TSUB
affect_VPRT
We_FPP1
believe_VB [PRIV]
the_DT
focused_VBN
drug_NN
the_DT
developing_VBG
world_NN
._.
Our_FPP1
effort_NN
to_TO
discover_VB [PRIV]
new_JJ
HIV_NN
AIDS_NN
therapies_NN
is_VPRT [PASS]
led_VBN
from_PIN
discovery_NN
effort_NN
at_PIN
Tres_NN
Cantos_NN
will_PRMD
Research_NN
Triangle_NN
Park_NN
in_PIN
the_DT
USA_NN
,_,
while_OSUB
GlaxoSmithKline_NN
Biologicals_NN
at_PIN
Rixensart_NN
,_,
provide_VPRT
a_DT
rich_JJ
early_TIME
pipeline_NN
that_TSUB
will_PRMD
enable_VB
GlaxoSmithKline_NN
to_PIN
Belgium_NN
,_,
is_VPRT [PASS]
focused_VBN
on_PIN
the_DT
discovery_NN
and_PHC
development_NOMZ
of_PIN
vaccines_NN
,_,
including_VBG
launch_NN
new_JJ
products_NN
for_PIN
diseases_NN
those_DEMO
for_PIN
malaria_NN
,_,
TB_NN
and_PHC
HIV_NN
._.
We_FPP1
also_RB
have_VPRT
extensive_JJ
clinical_JJ
trials_NN
programs_NN
of_PIN
the_DT
developing_VBG
world_NN
on_PIN
a_DT
across_PLACE
the_DT
developing_VBG
world_NN
._.
regular_JJ
basis_NN
in_PIN
future_JJ
years_NN
._.
Dr_NN
Federico_NN
Gmez_NN
fide_NN
las_VPRT
Heras_NN
,_,
Owing_NN
to_PIN
the_DT
challenges_NN
of_PIN
healthcare_NN
provision_NN
in_PIN
some_QUAN
developing_VBG
countries_NN
Director_NN
Diseases_NN
of_PIN
the_DT
Developing_VBG
World_NN
,_,
Tres_NN
Cantos_NN
,_,
Spain_NN
._.
and_ANDC
the_DT
lack_NN
of_PIN
a_DT
commercially-viable_JJ
market_NN
for_PIN
DDW_NN
treatments_NOMZ
,_,
public_JJ
private_JJ
partnerships_NN
and_PHC
initiatives_NN
are_VPRT [BEMA]
essential_PRED
to_PIN
direct_JJ
resources_NN
effectively_RB
and_CC
deliver_VB
treatments_NOMZ
to_PIN
those_DEMP
who_WP
need_VPRT
them_TPP3
._.
As_CONJ
a_NULL
result_NULL
of_PIN
one_CD
effective_JJ
public_JJ
private_JJ
partnership_NN
we_FPP1
have_VPRT [SPAU] [PEAS]
recently_TIME
filed_VBN
a_DT
licence_NN
application_NOMZ
for_PIN
a_DT
new_JJ
anti-malarial_JJ
product_NN
,_,
Lapdap_NN
._.
OUR_FPP1
PEOPLE_NN
Our_FPP1
global_JJ
team_NN
consists_VPRT
of_PIN
over_IN
100,000_CD
people_NN
._.
Our_FPP1
staff_NN
are_VPRT [PASS]
dedicated_VBN
to_PIN
our_FPP1
mission_NN
and_CC
striving_VBG
to_TO
achieve_VB
excellence_NN
in_PIN
every_QUAN
area_NN
of_PIN
our_FPP1
business_NOMZ
._.
We_FPP1
have_VPRT
a_DT
dynamic_JJ
and_CC
focused_VBD
R&D_NN
operation_NOMZ
,_,
a_DT
highly_AMP
efficient_JJ
manufacturing_GER
system_NN
and_PHC
sales_NN
and_PHC
marketing_GER
teams_NN
that_TSUB
are_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
their_TPP3
creative_JJ
drive_NN
and_PHC
scale_NN
of_PIN
operation_NOMZ
._.
We_FPP1
are_VPRT [PASS]
committed_VBN
to_PIN
the_DT
principles_NN
of_PIN
diversity_NOMZ
,_,
equality_NOMZ
of_PIN
opportunity_NOMZ
and_CC
equal_JJ
treatment_NOMZ
and_CC
we_FPP1
are_VPRT
aiming_VBG
to_TO
attract_VB
,_,
retain_VB
and_PHC
motivate_VB
the_DT
very_AMP
best_JJ
people_NN
at_PIN
GlaxoSmithKline_NN
._.
As_IN
part_NN
of_PIN
this_DEMO
we_FPP1
recognize_VPRT [PRIV]
that_THVC
our_FPP1
people_NN
choose_VB
to_TO
work_VB
for_PIN
us_FPP1
because_CAUS
they_TPP3
believe_VPRT [PRIV] [THATD]
we_FPP1
play_VB
a_DT
positive_JJ
role_NN
in_PIN
society_NN
at_PIN
large_JJ
._.
This_DEMP
means_VPRT [PRIV]
that_THVC
our_FPP1
corporate_JJ
and_PHC
social_JJ
responsibilities_NOMZ
are_VPRT [PASS]
embedded_VBN
in_PIN
our_FPP1
decision-making_JJ
processes_NN
and_PHC
practices_NN
._.
Our_FPP1
global_JJ
team_NN
is_VPRT
aiming_VBG
for_PIN
excellence_NN
in_PIN
performance_NN
and_PHC
excellence_NN
in_PIN
terms_NN
of_PIN
its_PIT
contribution_NOMZ
to_PIN
the_DT
economies_NN
and_CC
the_DT
communities_NOMZ
in_PIN
which_WDT [PIRE]
it_PIT
operates_VPRT
._.
In_PIN
sales_NN
terms_NN
,_,
GlaxoSmithKline_NN
is_VPRT [BEMA]
the_DT
number_NN
one_CD
pharmaceutical_JJ
company_NN
in_PIN
Europe_NN
._.
By_PIN
building_VBG
on_PIN
the_DT
strengths_NN
of_PIN
all_QUAN
our_FPP1
employees_NN
,_,
we_FPP1
can_POMD
create_VB
a_DT
new_JJ
way_NN
of_PIN
working_VBG
OUR_FPP1
PHARMACEUTICAL_NN
INTERNATIONAL_NN
REGION_NN
COVERS_VPRT
118_CD
COUNTRIES_NN
,_,
that_DEMP
will_PRMD
give_VB
GlaxoSmithKline_NN
23_CD
TIME_NN
ZONES_NN
AND_CC
100_CD
MONETARY_JJ
CURRENCIES_NN
._.
a_DT
clear_JJ
advantage_NN
in_PIN
the_DT
marketplace_NN
and_CC
ultimately_RB
EMPLOYING_VBG
NEARLY_DWNT
12,000_CD
PEOPLE_NN
,_,
OUR_FPP1
US_FPP1
MANUFACTURING_GER
SITES_NN
IN_PIN
38_CD
COUNTRIES_NN
._.
help_NN
millions_NN
of_PIN
people_NN
around_PLACE
PHARMACEUTICAL_NN
COMPANY_NN
IS_VPRT [BEMA]
A_DT
LEADER_NN
IN_PIN
FOUR_NN
the_DT
world_NN
to_TO
live_VB
longer_RB
,_,
MAJOR_NN
THERAPEUTIC_NN
AREAS_NN
IN_PIN
THE_DT
USA_NN
happier_JJ
,_,
healthier_RB
lives_NN
._.
ANTI-INFECTIVES_NN
,_,
CENTRAL_NN
NERVOUS_NN
SYSTEM_NN
,_,
RESPIRATORY_NN
AND_PHC
METABOLIC_NN
AND_PHC
GASTRO-INTESTINAL_NN
._.
JP_NN
GARNIER_NN
,_,
Chief_NN
Executive_NN
Officer_NN
ANNUAL_NN
REVIEW_NN
2002_CD
12_CD
|_NN
13_CD
And_CC
over_IN
100,000_CD
people_NN
are_VPRT
working_VBG
at_PIN
GlaxoSmithKline_NN
to_TO
ensure_VB [SUAV] [PRIV]
excellence_NN
and_PHC
success_NN
today_TIME
._.
Comprising_VBG [PRESP]
one_CD
global_JJ
workforce_NN
in_PIN
business_NOMZ
areas_NN
as_IN
diverse_JJ
as_IN
R&D_NN
,_,
manufacturing_GER
and_PHC
supply_NN
,_,
sales_NN
,_,
marketing_GER
and_PHC
distribution_NOMZ
,_,
GlaxoSmithKline_NN
people_NN
are_VPRT [PASS]
committed_VBN
to_TO
bringing_VBG
innovative_JJ
medicines_NN
,_,
vaccines_NN
and_PHC
consumer_NN
healthcare_NN
products_NN
to_PIN
people_NN
throughout_PIN
the_DT
world_NN
._.
CORPORATE_JJ
AND_PHC
SOCIAL_JJ
RESPONSIBILITY_NOMZ
GlaxoSmithKline_NN
is_VPRT [PASS]
committed_VBN
to_TO
enhancing_VBG
its_PIT
position_NOMZ
as_IN
a_DT
responsible_JJ
corporate_JJ
citizen_NN
and_CC
to_TO
building_VBG
community_NOMZ
partnerships_NN
._.
CORPORATE_JJ
AND_PHC
SOCIAL_JJ
RESPONSIBILITY_NOMZ
Lymphatic_JJ
filariasis_NN
GlaxoSmithKline_NN
aims_VPRT
to_TO
be_VB [BEMA]
a_DT
valued_VBN
The_DT
mosquito-borne_JJ
lymphatic_JJ
filariasis_NN
corporate_JJ
citizen_NN
wherever_RB
it_PIT
does_VPRT [PROD]
business_NOMZ
._.
LF_NN
or_CC
elephantiasis_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
worlds_NN
most_EMPH
disabling_JJ
diseases_NN
._.
We_FPP1
are_VPRT [BEMA]
committed_PRED
We_FPP1
make_VPRT
a_DT
significant_JJ
and_PHC
positive_JJ
to_TO
continuing_VBG
as_IN
an_DT
active_JJ
member_NN
of_PIN
contribution_NOMZ
to_PIN
society_NN
through_PIN
our_FPP1
the_DT
Global_JJ
Alliance_NN
to_TO
Eliminate_VB
Lymphatic_JJ
medicines_NN
,_,
vaccines_NN
and_PHC
healthcare_NN
products_NN
._.
In_PIN
2002_CD
,_,
the_DT
fourth_JJ
year_NN
of_PIN
the_DT
Our_FPP1
products_NN
must_NEMD
improve_VB
peoples_NN
lives_VPRT
program_NN
,_,
66_CD
million_CD
tablets_NN
,_,
worth_JJ
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
profitable_JJ
and_PHC
sustainable_JJ
8.7_CD
million_CD
at_PIN
wholesale_JJ
acquisition_NOMZ
future_NN
for_PIN
our_FPP1
business_NOMZ
._.
Understandably_RB
,_,
cost_NN
were_VBD [PASS]
donated_VBN
to_PIN
31_CD
countries_NN
._.
stakeholders_NN
including_VBG [WZPRES]
employees_NN
want_VPRT
to_TO
know_VB [PRIV]
how_RB [WHCL]
we_FPP1
make_VPRT
this_DEMO
profit_NN
._.
HIV_NN
AIDS_NN
Through_PIN
Positive_NN
Action_NOMZ
,_,
GlaxoSmithKline_NN
We_FPP1
publish_VB
a_DT
separate_JJ
report_NN
on_PIN
corporate_JJ
works_NN
in_PIN
partnership_NN
with_PIN
networks_NN
of_PIN
and_CC
social_JJ
responsibility_NOMZ
,_,
including_VBG
access_NN
people_NN
living_VBG [WZPRES]
with_PIN
HIV_NN
AIDS_NN
,_,
community_NOMZ
to_PIN
medicines_NN
in_PIN
the_DT
developing_VBG
world_NN
,_,
groups_NN
,_,
international_JJ
agencies_NN
,_,
and_ANDC
nonR_NN
&_CC
D_NN
for_PIN
diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
,_,
governmental_JJ
organizations_NOMZ
to_TO
intensify_VB
preferential_JJ
pricing_GER
arrangements_NOMZ
and_PHC
community_NOMZ
responses_NN
to_PIN
HIV_NN
AIDS_NN
._.
environmental_JJ
,_,
health_NN
and_PHC
safety_NN
performance_NN
._.
Our_FPP1
program_NN
of_PIN
HIV_NN
education_NOMZ
,_,
care_NN
and_PHC
community_NOMZ
support_NN
marked_VBD
its_PIT
tenth_NN
COMMUNITY_NOMZ
PROGRAMMES_NN
AND_PHC
anniversary_NN
in_PIN
2002_CD
._.
During_PIN
the_DT
year_NN
,_,
Positive_NN
Action_NOMZ
supported_VBD
25_CD
international_JJ
CORPORATE_JJ
DONATIONS_NOMZ
Many_QUAN
of_PIN
our_FPP1
community_NOMZ
programs_NN
are_VPRT
programs_NN
in_PIN
partnership_NN
with_PIN
22_CD
long-term_JJ
commitments_NOMZ
that_TSUB
help_VPRT
bring_VB
community-based_JJ
organizations_NOMZ
in_PIN
about_IN
sustainable_JJ
change_NN
._.
spent_VBN
239_CD
million_CD
in_PIN
support_NN
of_PIN
community_NOMZ
programs_NN
,_,
product_NN
donations_NOMZ
and_PHC
Malaria_NN
charitable_JJ
contributions_NOMZ
._.
In_PIN
2002_CD
,_,
we_FPP1
launched_VBD
the_DT
African_JJ
Malaria_NN
Partnership_NN
to_TO
help_VB
combat_VB
a_DT
disease_NN
that_TOBJ
These_DEMO
activities_NOMZ
are_VPRT [PASS]
focused_VBN
on_PIN
disease_NN
kills_VPRT
more_EMPH
than_PIN
one_CD
million_CD
people_NN
every_QUAN
programs_NN
,_,
regional_JJ
community_NOMZ
initiatives_NN
,_,
year_NN
._.
Three_CD
behavioural_JJ
development_NOMZ
education_NOMZ
,_,
product_NN
donations_NOMZ
and_PHC
employee_NN
programs_NN
in_PIN
seven_CD
countries_NN
will_PRMD
share_VB
involvement_NOMZ
._.
Three_CD
of_PIN
our_FPP1
largest_JJ
programs_NN
grants_NN
of_PIN
1.0_CD
million_CD
over_IN
the_DT
next_JJ
three_CD
are_VPRT [BEMA]
major_JJ
initiatives_NN
in_PIN
public_JJ
health_NN
:_:
years_NN
and_CC
will_PRMD
benefit_VB
nearly_DWNT
two_CD
million_CD
people_NN
in_PIN
malaria-endemic_JJ
communities_NOMZ
._.
In_PIN
2002_CD
,_,
the_DT
Personal_NN
Hygiene_NN
and_PHC
Sanitation_NOMZ
Education_NOMZ
project_NN
in_PIN
Africa_NN
and_PHC
South_NN
America_NN
won_VBD
an_DT
award_NN
for_PIN
International_NN
Corporate_NN
Citizenship_NN
._.
In_PIN
seven_CD
years_NN
,_,
GlaxoSmithKline_NN
has_VPRT [PEAS]
provided_VBN
more_EMPH
than_PIN
2.7_CD
million_CD
to_PIN
the_DT
Barretstown_NN
Gang_NN
in_PIN
Ireland_NN
which_WDT [WHSUB]
offers_VPRT
therapeutic_JJ
recreation_NOMZ
for_PIN
seriously_RB
ill_JJ
children_NN
._.
Positive_JJ
Action_NOMZ
funds_NN
a_DT
program_NN
to_TO
assist_VB
the_DT
scale-up_NN
of_PIN
HIV_NN
AIDS_NN
voluntary_JJ
organizations_NOMZ
in_PIN
Africa_NN
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
14_CD
|_NN
15_CD
PRODUCT_NN
PORTFOLIO_NN
Across_PLACE
the_DT
Groups_NN
portfolio_NN
of_PIN
products_NN
,_,
six_CD
major_JJ
therapeutic_JJ
areas_NN
experienced_VBD
double-digit_JJ
percentage_NN
growth_NN
for_PIN
2002_CD
including_VBG
the_DT
fast_JJ
growing_VBG
franchises_NN
of_PIN
central_JJ
nervous_JJ
system_NN
17_CD
%_NN
,_,
respiratory_JJ
16_CD
%_NN
,_,
anti-virals_JJ
12_CD
%_NN
and_PHC
vaccines_NN
16_CD
%_NN
._.
TR_NN
Top_NN
10_CD
pharmaceutical_JJ
products_NN
SEROXAT_NN
PAXIL_NN
SERETIDE_NN
ADVAIR_NN
AUGMENTIN_NN
WELLBUTRIN_NN
AVANDIA_NN
2.1_CD
bn_NN
$_$
3.1_CD
bn_NN
1.6_CD
bn_NN
$_$
2.4_CD
bn_NN
1.2_CD
bn_NN
$_$
1.8_CD
bn_NN
882m_CD
$_$
1.3_CD
bn_NN
809m_CD
$_$
1.2_CD
bn_NN
Central_NN
Nervous_NN
System_NN
Respiratory_NN
Anti-bacterials_NN
CNS_NN
Metabolic_NN
&_CC
CNS_NN
A_NN
combination_NOMZ
of_PIN
Serevent_NN
An_DT
antibiotic_JJ
for_PIN
the_DT
An_DT
anti-depressant_JJ
available_JJ
gastro-intestinal_JJ
A_DT
selective_JJ
serotonin_NN
and_PHC
Flixotide_NN
that_TSUB
offers_VPRT
treatment_NOMZ
of_PIN
most_EMPH
in_PIN
the_DT
USA_NN
in_PIN
normal_JJ
tablet_NN
A_DT
member_NN
of_PIN
the_DT
newest_JJ
re-uptake_NN
inhibitor_NN
for_PIN
a_DT
long-acting_JJ
bronchodilator_NN
common_JJ
respiratory_JJ
or_CC
sustained_VBN
release_NN
tablet_NN
class_NN
of_PIN
oral_JJ
treatments_NOMZ
the_DT
treatment_NOMZ
of_PIN
depression_NN
and_CC
an_DT
anti-inflammatory_JJ
tract_NN
infections_NOMZ
._.
IMIGRAN_NN
IMITREX_NN
FLIXOTIDE_NN
FLOVENT_NN
ZOFRAN_NN
COMBIVIR_NN
FLIXONASE_NN
FLONASE_NN
798m_VBD
$_$
1.2_CD
bn_NN
783m_CD
$_$
1.2_CD
bn_NN
708m_CD
$_$
1.1_CD
bn_NN
588m_CD
$_$
882m_CD
534m_CD
$_$
801m_CD
CNS_NN
Respiratory_NN
Oncology_NN
&_CC
emesis_NN
Anti-virals_NN
Respiratory_NN
A_NN
5HT_NN
receptor_NN
agonist_NN
An_DT
inhaled_JJ
steroid_NN
for_PIN
the_DT
Used_VBN
to_TO
prevent_VB
nausea_NN
A_DT
combination_NOMZ
of_PIN
Retrovir_NN
An_DT
intra-nasal_JJ
1_CD
for_PIN
the_DT
treatment_NOMZ
of_PIN
severe_JJ
treatment_NOMZ
of_PIN
inflammation_NOMZ
and_CC
vomiting_VBG
associated_VBN
and_CC
Epivir_NN
which_WDT [WHSUB]
reduces_VPRT
preparation_NOMZ
for_PIN
the_DT
or_CC
frequent_JJ
migraine_NN
and_CC
associated_VBN
with_PIN
respiratory_JJ
with_PIN
chemotherapy_JJ
and_CC
the_DT
pill_NN
burden_NN
faced_VBN [WZPAST]
by_PIN
treatment_NOMZ
of_PIN
perennial_JJ
cluster_NN
headaches_NN
._.
HIV_NN
patients_NN
with_PIN
multiple_JJ
and_PHC
seasonal_JJ
rhinitis_NN
._.
Major_JJ
launches_NN
in_PIN
2002_CD
Vaccines_NN
PAXIL_NN
CR_NN
AVANDAMET_NN
AUGMENTIN_NN
XR_NN
HEPATITIS_NN
VACCINES_NN
INFANRIX_NN
CNS_NN
Metabolic_NN
&_CC
Anti-bacterials_NN
483m_CD
$_$
725m_CD
254m_CD
$_$
381m_CD
Launched_VBN
in_PIN
the_DT
USA_NN
in_PIN
gastro-intestinal_JJ
A_DT
new_JJ
enhanced_JJ
A_DT
range_NN
of_PIN
treatments_NOMZ
A_DT
range_NN
of_PIN
vaccines_NN
April_NN
,_,
Paxil_NN
CR_NN
combines_VPRT
Avandamet_NN
was_VBD [PASS]
launched_VBN
formulation_NOMZ
of_PIN
protecting_VBG
against_PIN
hepatitis_NN
for_PIN
diphtheria_NN
,_,
tetanus_NN
the_DT
efficacy_NN
of_PIN
Paxil_NN
with_PIN
in_PIN
the_DT
USA_NN
in_PIN
November_NN
,_,
Augmentin_NN
for_PIN
adults_NN
A_DT
Havrix_NN
and_PHC
hepatitis_NN
B_NN
and_CC
whooping_JJ
cough_NN
._.
a_DT
controlled_JJ
release_NN
combining_VBG [WZPRES]
Avandia_NN
,_,
which_WDT [SERE]
to_TO
treat_VB
communityEngerix-B_NN
._.
The_DT
first_JJ
technology_NN
for_PIN
the_DT
targets_NN
insulin_NN
resistance_NN
,_,
acquired_VBD
pneumonia_NN
,_,
combined_VBN
hepatitis_NN
A_NN
and_PHC
B_NN
treatment_NOMZ
of_PIN
major_JJ
and_CC
metformin_NN
,_,
an_DT
oral_JJ
acute_JJ
bacterial_JJ
sinusitis_NN
vaccine_NN
Twinrix_NN
protects_VPRT
depressive_JJ
disorder_NN
diabetes_NN
therapy_NN
,_,
in_PIN
one_CD
and_CC
chronic_JJ
bronchitis_NN
._.
against_PIN
both_DT
diseases_NN
in_PIN
and_CC
panic_VB
disorder_NN
._.
Top_JJ
5_CD
consumer_NN
healthcare_NN
products_NN
AQUAFRESH_NN
LUCOZADE_NN
NICODERM_NN
CQ_NN
SENSODYNE_NN
RIBENA_NN
344m_CD
$_$
516m_CD
214m_CD
$_$
321m_CD
NIQUITIN_NN
CQ_NN
NICABATE_NN
192m_CD
$_$
288m_CD
192m_CD
$_$
288m_CD
One_CD
of_PIN
the_DT
worlds_NN
The_DT
glucose_NN
energy_NN
193m_CD
$_$
290m_CD
A_DT
toothpaste_NN
which_WDT [WHOBJ]
A_DT
range_NN
of_PIN
juice_NN
drinks_NN
largest_JJ
toothpaste_NN
drink_NN
which_WDT [WHSUB]
provides_VPRT
Nicotine_JJ
replacement_NOMZ
addresses_NN
dental_JJ
sensitivity_NOMZ
rich_JJ
in_PIN
vitamin_NN
C._NN
and_CC
toothbrush_JJ
brands_NN
._.
nutrients_NN
to_TO
complement_VB
therapy_NN
available_JJ
as_IN
a_DT
patch_NN
and_PHC
pain_NN
._.
THE_DT
BOARD_NN
The_NN
Board_NN
of_PIN
Directors_NN
is_VPRT [BEMA]
ultimately_RB
accountable_PRED
for_PIN
the_DT
Groups_NN
activities_NOMZ
,_,
strategy_NN
and_CC
financial_JJ
performance_NN
._.
BDFH_NN
DHJ_NN
SIR_NN
CHRISTOPHER_NN
HOGG_NN
JOHN_NN
MCARTHUR_NN
Non-Executive_NN
Director_NN
Aged_VBD
68_CD
Non-Executive_NN
Chairman_NN
Aged_VBD
66_CD
Sir_NN
Christopher_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
Mr_NN
McArthur_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
Non-Executive_JJ
Chairman_NN
of_PIN
Reuters_NN
Group_NN
PLC_NN
,_,
and_ANDC
a_DT
member_NN
Director_NN
of_PIN
BCE_NN
Inc._NN
._.
BCE_NN
Emergis_NN
Inc._NN
._.
Cabot_NN
Corporation_NOMZ
,_,
HCA_NN
Corporation_NOMZ
Koc_NN
Holdings_GER
A._NN
S._NN
of_PIN
the_DT
Supervisory_NN
Board_NN
of_PIN
Air_NN
Liquide_NN
S._NN
A._NN
and_PHC
Chairman_NN
of_PIN
The_DT
Royal_NN
National_NN
Theatre_NN
._.
Rohm_NN
and_PHC
Haas_NN
Company_NN
,_,
Telsat_NN
Canada_NN
and_CC
The_DT
AES_NN
Corporation_NOMZ
._.
He_TPP3
is_VPRT [BEMA]
also_RB
Senior_JJ
Advisor_NN
DHJ_NN
SIR_NN
ROGER_NN
HURN_NN
to_PIN
the_DT
President_NN
of_PIN
the_DT
World_NN
Bank_NN
._.
Non-Executive_JJ
Deputy_NN
Chairman_NN
Aged_VBD
64_CD
DEH_NN
Sir_NN
Roger_NN
was_VBD [PASS]
appointed_VBN
a_DT
Non-Executive_JJ
Director_NN
DONALD_NN
MCHENRY_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
in_PIN
1996_CD
and_CC
Deputy_NN
Chairman_NN
Non-Executive_NN
Director_NN
Aged_VBD
66_CD
Mr_NN
McHenry_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
in_PIN
1997_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Cazenove_NN
Group_NN
plc._NN
._.
He_TPP3
is_VPRT
also_RB
Chairman_NN
of_PIN
the_DT
Court_NN
of_PIN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Distinguished_NN
Professor_NN
in_PIN
the_DT
Practice_NN
of_PIN
Diplomacy_NN
at_PIN
the_DT
School_NN
Governors_NN
of_PIN
Henley_NN
College_NN
._.
of_PIN
Foreign_NN
Service_NN
at_PIN
Georgetown_NN
University_NOMZ
D_NN
DR_NN
JEAN-PIERRE_NN
GARNIER_NN
and_PHC
President_NN
of_PIN
the_DT
IRC_NN
Group_NN
,_,
LLC_NN
._.
His_TPP3
other_JJ
Chief_NN
Executive_NN
Officer_NN
Aged_VBD
55_CD
Non-Executive_JJ
directorships_NN
include_VPRT
The_DT
Coca-Cola_NN
Dr_NN
Garnier_NN
was_VBD [PASS]
appointed_VBN
an_DT
Executive_NN
Director_NN
Company_NN
,_,
FleetBoston_NN
Financial_NN
Corporation_NOMZ
,_,
of_PIN
SmithKline_NN
Beecham_NN
plc_NN
in_PIN
1992_CD
,_,
and_ANDC
became_VBD
International_NN
Paper_NN
Company_NN
and_PHC
AT&T_NN
Corporation_NOMZ
._.
Chief_NN
Executive_NN
Officer_NN
in_PIN
April_NN
2000_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
He_TPP3
previously_TIME
served_VBD
as_IN
Ambassador_NN
and_PHC
US_FPP1
Non-Executive_NN
Director_NN
of_PIN
United_NN
Technologies_NN
Permanent_NN
Representative_NN
to_PIN
the_DT
United_NN
Nations_NOMZ
._.
Corporation_NOMZ
and_CC
a_DT
member_NN
of_PIN
the_DT
Board_NN
of_PIN
Trustees_NN
BDG_NN
of_PIN
the_DT
Eisenhower_NN
Exchange_NN
Fellowships_NN
._.
He_TPP3
holds_VPRT [PRIV]
SIR_NN
IAN_NN
PROSSER_NN
Non-Executive_NN
Director_NN
Aged_VBD
59_CD
a_DT
PhD_NN
in_PIN
pharmacology_NN
from_PIN
the_DT
University_NOMZ
of_PIN
Sir_NN
Ian_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
Louis_NN
Pasteur_NN
in_PIN
France_NN
and_CC
an_DT
MBA_NN
from_PIN
Stanford_NN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
is_VPRT
Executive_NN
University_NOMZ
in_PIN
the_DT
USA_NN
._.
Chairman_NN
of_PIN
Six_CD
Continents_NN
PLC_NN
and_CC
the_DT
World_NN
D_NN
JOHN_NN
COOMBE_NN
Travel_NN
&_CC
Tourism_NN
Council_NN
and_PHC
Non-Executive_NN
Deputy_NN
Chief_NN
Financial_NN
Officer_NN
Aged_VBD
57_CD
Chairman_NN
of_PIN
BP_NN
plc._FW
._.
He_TPP3
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
CBI_NN
Mr_NN
Coombe_NN
was_VBD [BEMA]
formerly_TIME
an_DT
Executive_NN
Director_NN
Presidents_NN
Committee_NN
._.
of_PIN
Glaxo_NN
Wellcome_NN
plc_NN
where_RB
he_TPP3
was_VBD [BEMA]
responsible_JJ
AD_NN
for_PIN
Finance_NN
and_PHC
Investor_NN
Relations_NOMZ
._.
He_TPP3
is_VPRT [BEMA]
a_DT
member_NN
DR_NN
RONALDO_NN
SCHMITZ_NN
Non-Executive_NN
Director_NN
Aged_VBD
64_CD
of_PIN
the_DT
Supervisory_NN
Board_NN
of_PIN
Siemens_NN
AG_NN
,_,
the_DT
UK_NN
Accounting_GER
Standards_NN
Board_NN
and_CC
the_DT
Code_NN
Dr_NN
Schmitz_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Director_NN
Committee_NN
of_PIN
the_DT
UK_NN
Takeover_NN
Panel_NN
._.
of_PIN
Legal_NN
&_CC
General_NN
Group_NN
plc_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
DI_NN
PAUL_NN
ALLAIRE_NN
Board_NN
of_PIN
Directors_NN
of_PIN
Rohm_NN
and_PHC
Haas_NN
Company_NN
and_PHC
Non-Executive_NN
Director_NN
Aged_NN
64_CD
Cabot_NN
Corporation_NOMZ
._.
Mr_NN
Allaire_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
DF_NN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
DR_NN
LUCY_NN
SHAPIRO_NN
Director_NN
of_PIN
Lucent_NN
Technologies_NN
Inc._NN
and_PHC
priceline_NN
._.
com_NN
Non-Executive_NN
Director_NN
Aged_VBD
62_CD
Dr_NN
Shapiro_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_NN
Director_NN
Inc._NN
._.
He_TPP3
is_VPRT
Chairman_NN
of_PIN
The_DT
Ford_NN
Foundation_NOMZ
._.
She_TPP3
is_VPRT
Ludwig_NN
Professor_NN
DFJ_NN
DR_NN
MICHLE_NN
BARZACH_NN
of_PIN
Cancer_NN
Research_NN
in_PIN
the_DT
Department_NOMZ
of_PIN
Non-Executive_NN
Director_NN
Aged_VBD
59_CD
Developmental_JJ
Biology_NN
and_PHC
Director_NN
of_PIN
the_DT
Beckman_NN
Dr_NN
Barzach_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
Centre_NN
for_PIN
Molecular_NN
and_PHC
Genetic_NN
Medicine_NN
at_PIN
the_DT
of_PIN
Glaxo_NN
Wellcome_NN
plc._NN
._.
She_TPP3
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Stanford_NN
University_NOMZ
School_NN
of_PIN
Medicine_NN
._.
She_TPP3
holds_VPRT [PRIV]
International_NN
Cooperation_NOMZ
High_NN
Council_NN
,_,
Chairman_NN
a_DT
PhD_NN
in_PIN
molecular_JJ
biology_NN
from_PIN
the_DT
Albert_NN
Einstein_NN
of_PIN
the_DT
Board_NN
of_PIN
Equilibres_NN
et_FW
Populations_NOMZ
and_PHC
Director_NN
College_NN
of_PIN
Medicine_NN
._.
of_PIN
the_DT
Board_NN
of_PIN
Project_NN
Hope_NN
._.
International_NN
consultant_NN
on_PIN
health_NN
strategy_NN
,_,
she_TPP3
was_VBD [BEMA]
formerly_TIME
French_JJ
Minister_NN
Other_JJ
Directors_NN
of_PIN
Health_NN
and_CC
the_DT
Family_NN
._.
Sir_NN
Richard_NN
Sykes_NN
,_,
Non-Executive_NN
Chairman_NN
,_,
BDJ_NN
Sir_NN
Peter_NN
Walters_NN
,_,
Non-Executive_NN
Deputy_NN
Chairman_NN
,_,
SIR_NN
PETER_NN
JOB_NN
and_PHC
Mr_NN
John_NN
Young_NN
,_,
Non-Executive_NN
Director_NN
,_,
Non-Executive_NN
Director_NN
Aged_VBD
61_CD
all_QUAN
retired_VBN
from_PIN
the_DT
Board_NN
on_PIN
20th_JJ
May_POMD
2002_CD
._.
Sir_NN
Peter_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Glaxo_NN
Wellcome_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Schroders_NN
plc_NN
,_,
Shell_NN
Transport_NN
and_PHC
Trading_GER
Company_NN
plc_NN
,_,
TIBCO_NN
Software_NN
Inc_NN
,_,
Instinet_NN
Group_NN
Inc._NN
and_PHC
Multex_NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
member_NN
of_PIN
the_DT
Supervisory_NN
Boards_NN
of_PIN
Deutsche_NN
Bank_NN
AG_NN
and_PHC
Bertelsmann_NN
AG_NN
._.
Membership_NN
of_PIN
Board_NN
committees_NN
is_VPRT [BYPA]
indicated_VBN [PRIV]
by_PIN
the_DT
following_VBG
symbols_NN
:_:
CHAIRMAN_NN
MEMBER_NN
Audit_NN
A_NN
B_NN
Corporate_NN
Administration_NOMZ
D_NN
&_CC
Transactions_NOMZ
Corporate_JJ
Social_NN
Responsibility_NOMZ
E_NN
F_NN
Financial_NN
Results_NN
D_NN
Nominations_NOMZ
G_NN
H_NN
Remuneration_NOMZ
I_FPP1
J_NN
ANNUAL_NN
REVIEW_NN
2002_CD
16_CD
|_NN
17_CD
CORPORATE_JJ
EXECUTIVE_NN
The_DT
executive_NN
management_NOMZ
of_PIN
the_DT
Group_NN
is_VPRT [BEMA]
through_PIN
the_DT
TEAM_NN
Corporate_NN
Executive_NN
Team_NN
CET_NN
,_,
comprising_VBG [PRESP]
the_DT
Chief_NN
Executive_NN
Officer_NN
,_,
the_DT
Chief_NN
Financial_NN
Officer_NN
and_CC
other_JJ
senior_JJ
managers_NN
._.
JP_NN
GARNIER_NN
DAVID_NN
STOUT_NN
Chief_NN
Executive_NN
Officer_NN
President_NN
As_IN
Chief_NN
Executive_NN
Officer_NN
,_,
JP_NN
is_VPRT [BEMA]
the_DT
link_NN
between_PIN
Pharmaceutical_NN
Operations_NOMZ
David_NN
was_VBD
President_NN
of_PIN
US_FPP1
Pharmaceuticals_NN
until_IN
the_DT
Board_NN
and_PHC
staff_NN
,_,
and_ANDC
oversees_VPRT
all_QUAN
operational_JJ
aspects_NN
including_VBG [WZPRES]
establishing_VBG [PRIV]
policies_NN
,_,
objectives_NN
he_TPP3
was_VBD [PASS]
appointed_VBN
to_PIN
his_TPP3
current_JJ
position_NOMZ
in_PIN
January_NN
2003_CD
._.
He_TPP3
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
global_JJ
pharmaceuticals_NN
and_PHC
initiatives_NN
,_,
and_ANDC
directing_VBG
long_JJ
term_NN
strategy_NN
._.
He_TPP3
was_VBD
formerly_TIME
Chief_NN
Executive_NN
Officer_NN
of_PIN
SmithKline_NN
business_NOMZ
as_RB
well_RB
as_IN
the_DT
global_JJ
vaccines_NN
business_NOMZ
._.
He_TPP3
joined_VBD
SmithKline_NN
Beecham_NN
in_PIN
1996_CD
as_IN
head_NN
Beecham_NN
,_,
having_VBG [PEAS]
joined_VBN
the_DT
Group_NN
in_PIN
1990_CD
._.
of_PIN
its_PIT
US_FPP1
Sales_NN
and_PHC
Marketing_GER
function_NOMZ
,_,
and_ANDC
in_PIN
1998_CD
RUPERT_NN
BONDY_NN
became_VBD
President_NN
,_,
Pharmaceuticals_NN
,_,
North_NN
America_NN
._.
Senior_JJ
Vice_NN
President_NN
and_PHC
General_NN
Counsel_NN
Rupert_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
legal_JJ
matters_NN
across_PLACE
the_DT
CHRIS_NN
VIEHBACHER_NN
President_NN
Group_NN
,_,
together_RB
with_PIN
environmental_JJ
,_,
health_NN
and_PHC
US_FPP1
Pharmaceuticals_NN
safety_NN
issues_NN
,_,
insurance_NN
and_PHC
security_NOMZ
._.
He_TPP3
was_VBD [BEMA]
a_DT
lawyer_NN
Responsible_JJ
for_PIN
European_JJ
pharmaceuticals_NN
operations_NOMZ
in_PIN
private_JJ
practice_NN
before_IN
joining_VBG
SmithKline_NN
Beecham_NN
until_IN
the_DT
end_NN
of_PIN
2002_CD
,_,
Chris_NN
took_VBD
over_RP
the_DT
US_FPP1
in_PIN
1995_CD
as_IN
Senior_JJ
Counsel_NN
._.
FORD_NN
CALHOUN_NN
He_TPP3
joined_VBD
Wellcome_NN
in_PIN
1988_CD
and_CC
became_VBD
Director_NN
,_,
Chief_NN
Information_NOMZ
Officer_NN
Continental_NN
Europe_NN
,_,
at_PIN
Glaxo_NN
Wellcome_NN
in_PIN
1999_CD
._.
Ford_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
information_NOMZ
technology_NN
,_,
ANDREW_NN
WITTY_VBD
a_DT
global_JJ
function_NOMZ
that_TSUB
enables_VPRT
key_JJ
business_NOMZ
processes_VPRT
President_NN
across_PLACE
all_QUAN
parts_NN
of_PIN
the_DT
Group_NN
._.
With_PIN
doctoral_JJ
and_CC
Pharmaceuticals_NN
Europe_NN
post-doctoral_JJ
training_GER
in_PIN
microbiology_NN
,_,
genetics_NN
,_,
Andrew_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
pharmaceuticals_NN
biomathematics_NN
and_PHC
computer_NN
science_NN
,_,
Ford_NN
joined_VBD
operations_NOMZ
in_PIN
Europe_NN
,_,
a_DT
post_NN
he_TPP3
took_VBD
up_RP
in_PIN
January_NN
Smith_NN
Kline_NN
&_CC
French_NN
in_PIN
1984_CD
._.
2003_CD
when_RB
he_TPP3
was_VBD [PASS]
appointed_VBN
to_PIN
the_DT
CET_NN
._.
Andrew_NN
JOHN_NN
COOMBE_NN
joined_VBD
Glaxo_NN
in_PIN
1985_CD
and_CC
at_PIN
GlaxoSmithKline_NN
was_VBD
Chief_NN
Financial_NN
Officer_NN
Senior_NN
Vice_NN
President_NN
,_,
Asia_NN
Pacific_NN
,_,
until_IN
his_TPP3
As_IN
head_NN
of_PIN
the_DT
finance_NN
function_NOMZ
,_,
John_NN
is_VPRT [BEMA]
responsible_JJ
current_JJ
post_NN
._.
for_PIN
activities_NOMZ
such_JJ
as_IN
financial_JJ
reporting_GER
and_PHC
control_NN
,_,
TACHI_NN
YAMADA_NN
tax_NN
and_PHC
treasury_NN
,_,
investor_NN
relations_NOMZ
,_,
finance_NN
systems_NN
,_,
Chairman_NN
internal_JJ
audit_NN
and_CC
real_JJ
estate_NN
._.
He_TPP3
joined_VBD
Glaxo_NN
in_PIN
Research_NN
&_CC
Development_NOMZ
1986_CD
as_IN
Group_NN
Financial_NN
Controller_NN
and_CC
was_VBD
Tachi_NN
leads_VPRT
the_DT
Groups_NN
complex_JJ
business_NOMZ
of_PIN
drug_NN
appointed_VBN
Group_NN
Finance_NN
Director_NN
in_PIN
1992_CD
._.
discovery_NN
and_PHC
development_NOMZ
creating_VBG [WZPRES]
new_JJ
medicines_NN
DAN_NN
PHELAN_NN
through_PIN
research_NN
._.
He_TPP3
joined_VBD
SmithKline_NN
Beecham_NN
in_PIN
Senior_NN
Vice_NN
President_NN
1994_CD
as_IN
a_DT
Non-Executive_JJ
member_NN
of_PIN
the_DT
Board_NN
and_PHC
Human_NN
Resources_NN
became_VBD
Chairman_NN
,_,
R&D_NN
,_,
Pharmaceuticals_NN
in_PIN
1999_CD
._.
Dan_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
benefits_NN
,_,
compensation_NOMZ
,_,
JENNIE_NN
YOUNGER_NN
recruitment_NOMZ
,_,
organization_NOMZ
development_NOMZ
,_,
leadership_NN
Senior_JJ
Vice_NN
President_NN
development_NOMZ
and_PHC
succession_NN
planning_GER
,_,
human_JJ
Corporate_JJ
Communications_NOMZ
&_CC
Community_NOMZ
resource_NN
information_NOMZ
systems_NN
and_PHC
employee_NN
health_NN
Partnerships_NN
management_NOMZ
._.
He_TPP3
joined_VBD
Smith_NN
Kline_NN
&_CC
French_NN
in_PIN
1981_CD
Jennie_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
internal_JJ
and_CC
and_CC
in_PIN
1994_CD
was_VBD [PASS]
appointed_VBN
Senior_JJ
Vice_NN
President_NN
and_CC
external_JJ
communications_NOMZ
,_,
its_PIT
image_NN
and_PHC
partnerships_NN
Director_NN
,_,
Human_NN
Resources_NN
,_,
SmithKline_NN
Beecham_NN
._.
with_PIN
communities_NOMZ
of_PIN
the_DT
world_NN
._.
She_TPP3
joined_VBD
Glaxo_NN
HOWARD_NN
PIEN_NN
Wellcome_NN
in_PIN
1996_CD
as_IN
Director_NN
of_PIN
Investor_NN
Relations_NOMZ
._.
President_NN
JACK_NN
ZIEGLER_NN
Pharmaceuticals_NN
International_NN
President_NN
Howard_NN
leads_VPRT
the_DT
pharmaceutical_JJ
operations_NOMZ
outside_PLACE
Consumer_NN
Healthcare_NN
the_DT
USA_NN
and_CC
most_EMPH
of_PIN
Europe_NN
,_,
covering_VBG
more_EMPH
than_PIN
Jack_NN
is_VPRT
head_NN
of_PIN
the_DT
global_JJ
Consumer_NN
Healthcare_NN
100_CD
countries_NN
that_TSUB
account_VPRT
for_PIN
over_IN
82_CD
per_PIN
cent_NN
business_NOMZ
,_,
which_WDT [SERE]
produces_VPRT
oral_JJ
healthcare_NN
,_,
overof_VPRT
the_DT
worlds_NN
population_NOMZ
._.
He_TPP3
joined_VBD
SmithKline_NN
the-counter_NN
medicines_NN
and_CC
nutritional_JJ
healthcare_NN
Beecham_NN
in_PIN
1991_CD
and_CC
in_PIN
1998_CD
was_VBD [PASS]
appointed_VBN
products_NN
._.
He_TPP3
joined_VBD
SmithKline_NN
Beecham_NN
in_PIN
1991_CD
President_NN
,_,
Pharmaceuticals_NN
._.
and_ANDC
in_PIN
1998_CD
was_VBD [PASS]
appointed_VBN
President_NN
of_PIN
the_DT
DAVID_NN
PULMAN_NN
Consumer_NN
Healthcare_NN
business_NOMZ
._.
President_NN
Global_NN
Manufacturing_GER
&_CC
Supply_NN
Other_JJ
members_NN
Appointed_VBN [WZPAST]
to_PIN
the_DT
post_NN
in_PIN
December_NN
2002_CD
,_,
David_NN
James_NN
Palmer_NN
and_PHC
Tim_NN
Tyson_NN
left_VBD
the_DT
Group_NN
on_PIN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
global_JJ
manufacturing_GER
and_CC
1st_CD
December_NN
2002_CD
to_TO
pursue_VB
other_JJ
roles_NN
in_PIN
the_DT
supply_NN
chain_NN
network_NN
._.
He_TPP3
joined_VBD
Glaxo_NN
in_PIN
1978_CD
pharmaceutical_JJ
industry_NN
._.
Bob_NN
Ingram_NN
retired_VBD
on_PIN
and_CC
prior_RB
to_PIN
his_TPP3
most_EMPH
recent_JJ
posting_VBG
was_VBD [BEMA]
responsible_PRED
31st_CD
December_NN
2002_CD
but_CC
will_PRMD
continue_VB
to_TO
work_VB
for_PIN
the_DT
North_PLACE
American_JJ
supply_NN
network_NN
,_,
manufacturing_VBG
part-time_JJ
as_IN
Vice_NN
Chairman_NN
of_PIN
Pharmaceuticals_NN
,_,
acting_VBG
as_IN
a_DT
special_JJ
advisor_NN
to_PIN
the_DT
Group_NN
and_CC
will_PRMD
strategy_NN
and_PHC
logistics_NN
._.
attend_VB
CET_NN
meetings_GER
in_PIN
that_DEMO
capacity_NOMZ
._.
BUSINESS_NOMZ
OPERATING_GER
GlaxoSmithKline_NN
continues_VPRT
to_TO
deliver_VB
strong_JJ
financial_JJ
REVIEW_NN
performance_NN
,_,
providing_VBG [PRESP]
a_DT
sound_JJ
platform_NN
for_PIN
the_DT
future_NN
._.
Total_JJ
pharmaceutical_JJ
sales_NN
grew_VBD
eight_CD
per_PIN
cent_NN
to_PIN
18_CD
billion_CD
of_PIN
which_WDT [PIRE]
new_JJ
product_NN
sales_NN
totalled_VBD
4.8_CD
billion_CD
,_,
an_DT
increase_NN
of_PIN
36_CD
per_PIN
cent_NN
._.
PHARMACEUTICALS_NN
Anti-viral_JJ
sales_NN
grew_VBD
across_PLACE
all_QUAN
regions_NN
Within_PIN
vaccines_NN
,_,
the_DT
Hepatitis_NN
franchise_NN
In_PIN
the_DT
central_JJ
nervous_JJ
system_NN
therapy_NN
area_NN
,_,
and_ANDC
totalled_VBD
2.3_CD
billion_CD
,_,
up_RB
12_CD
per_PIN
cent_NN
._.
grew_VBD
12_CD
per_PIN
cent_NN
with_PIN
sales_NN
in_PIN
Europe_NN
sales_NN
of_PIN
GlaxoSmithKlines_NN
leading_VBG [WZPRES]
product_NN
Sales_NN
of_PIN
Trizivir_NN
,_,
GlaxoSmithKlines_NN
new_JJ
growing_VBG
ten_NN
per_PIN
cent_NN
._.
Vaccine_NN
sales_NN
in_PIN
the_DT
for_PIN
depression_NN
and_PHC
anxiety_NN
disorders_NN
,_,
triple_JJ
combination_NOMZ
therapy_NN
for_PIN
HIV_NN
,_,
grew_VBD
USA_NN
were_VBD [BEMA]
up_RB
16_CD
per_PIN
cent_NN
benefiting_VBG [WZPRES]
from_PIN
Seroxat_NN
Paxil_NN
,_,
were_VBD [BEMA]
up_RB
18_CD
per_PIN
cent_NN
in_PIN
the_DT
95_CD
per_PIN
cent_NN
to_PIN
315_CD
million_CD
._.
Valtrex_NN
for_PIN
the_DT
launch_NN
of_PIN
Twinrix_NN
and_CC
continued_VBD
growth_NN
USA_NN
._.
Paxil_NN
CR_NN
,_,
launched_VBN [PASTP]
in_PIN
the_DT
USA_NN
in_PIN
April_NN
,_,
herpes_VPRT
achieved_VBN
strong_JJ
sales_NN
growth_NN
of_PIN
in_PIN
Havrix_NN
,_,
driven_VBN [PASTP]
by_PIN
new_JJ
state_NN
mandates_VPRT
continues_VPRT
to_TO
gain_VB
acceptance_NN
due_JJ
to_PIN
its_PIT
26_CD
per_PIN
cent_NN
worldwide_NN
._.
In_PIN
September_NN
2002_CD
,_,
requiring_VBG [SUAV]
Hepatitis_NN
A_NN
vaccination_NOMZ
for_PIN
school_NN
strong_JJ
tolerability_NOMZ
profile_NN
._.
International_NN
Valtrex_NN
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
FDA_NN
for_PIN
the_DT
age_NN
children_NN
._.
In_PIN
the_DT
USA_NN
,_,
GlaxoSmithKlines_NN
sales_NN
of_PIN
Paxil_NN
grew_VBD
27_CD
per_PIN
cent_NN
led_VBN [WZPAST]
by_PIN
treatment_NOMZ
of_PIN
cold_JJ
sores_NN
in_PIN
healthy_JJ
adults_NN
new_JJ
Pediarix_NN
vaccine_NN
was_VBD [PASS]
launched_VBN
in_PIN
continued_VBN
strong_JJ
growth_NN
in_PIN
Japan_NN
,_,
where_RB
and_CC
in_PIN
October_NN
2002_CD
,_,
GlaxoSmithKline_NN
filed_VBD
January_NN
2003_CD
._.
the_DT
product_NN
was_VBD [PASS]
launched_VBN
only_DWNT
two_CD
years_NN
a_DT
further_JJ
application_NOMZ
for_PIN
Valtrex_NN
seeking_VBG [WZPRES]
ago_RB
._.
Sales_NN
of_PIN
Wellbutrin_NN
,_,
for_PIN
depression_NN
,_,
the_DT
first-ever_JJ
indication_NOMZ
to_TO
reduce_VB
the_DT
risk_NN
In_PIN
oncology_NN
,_,
Zofran_NN
sales_NN
grew_VBD
22_CD
per_PIN
cent_NN
grew_VBD
42_CD
per_PIN
cent_NN
,_,
reflecting_VBG [PRIV]
increased_VBN
of_PIN
transmission_NN
of_PIN
genital_JJ
herpes_NN
._.
to_PIN
708_CD
million_CD
driven_VBN
by_PIN
a_DT
strong_JJ
US_FPP1
physician_NN
awareness_NOMZ
of_PIN
the_DT
products_NN
performance_NN
,_,
up_IN
28_CD
per_PIN
cent_NN
to_PIN
525_CD
million_CD
._.
outstanding_JJ
efficacy_NN
and_CC
favourable_JJ
side_NN
Anti-bacterial_JJ
sales_NN
declined_VBD
12_CD
per_PIN
cent_NN
effect_NN
profile_NN
._.
Lamictal_NN
,_,
for_PIN
epilepsy_NN
,_,
worldwide_NN
and_CC
22_CD
per_PIN
cent_NN
in_PIN
the_DT
USA_NN
In_PIN
July_NN
,_,
GlaxoSmithKline_NN
received_VBD
approval_NN
continued_VBD
to_TO
grow_VB
across_PLACE
all_QUAN
regions_NN
._.
as_CONJ
a_NULL
result_NULL
of_PIN
generic_JJ
competition_NOMZ
for_PIN
from_PIN
the_DT
Swedish_JJ
regulatory_JJ
authorities_NOMZ
In_PIN
January_NN
2003_CD
,_,
the_DT
US_FPP1
FDA_NN
approved_VBD
Augmentin_NN
and_PHC
Ceftin_NN
._.
In_PIN
the_DT
USA_NN
,_,
for_PIN
Avodart_NN
dutasteride_NN
,_,
a_DT
DHT_NN
inhibitor_NN
the_DT
use_NN
of_PIN
Lamictal_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
GlaxoSmithKlines_NN
two_CD
new_JJ
antibiotics_NN
,_,
for_PIN
the_DT
treatment_NOMZ
of_PIN
symptomatic_JJ
benign_JJ
partial_JJ
seizures_NN
in_PIN
paediatric_JJ
patients_NN
aged_VBN
Augmentin_NN
ES_NN
for_PIN
children_NN
and_PHC
Augmentin_NN
prostatic_JJ
hyperplasia_NN
._.
GlaxoSmithKline_NN
two_CD
years_NN
and_CC
above_PLACE
._.
XR_NN
for_PIN
adults_NN
are_VPRT
performing_VBG
well_RB
._.
plans_NN
to_PIN
market_NN
Avodart_NN
in_PIN
all_QUAN
major_JJ
European_JJ
markets_NN
with_PIN
launches_NN
in_PIN
the_DT
In_PIN
respiratory_NN
,_,
GlaxoSmithKline_NN
continues_VPRT
In_PIN
metabolic_JJ
and_PHC
gastro-intestinal_JJ
the_DT
first_JJ
half_NN
of_PIN
2003_CD
._.
to_TO
be_VB [BEMA]
the_DT
global_JJ
leader_NN
with_PIN
sales_NN
of_PIN
its_PIT
Avandia_NN
franchise_NN
,_,
Avandia_NN
and_PHC
Avandamet_NN
,_,
three_CD
key_JJ
products_NN
Seretide_NN
Advair_NN
,_,
grew_VBD
19_CD
per_PIN
cent_NN
for_PIN
the_DT
year_NN
and_PHC
Avandia_NN
Levitra_NN
vardenafil_NN
a_DT
new_JJ
agent_NN
for_PIN
the_DT
Flixotide_NN
and_PHC
Serevent_NN
amounting_VBG [WZPRES]
to_TO
is_VPRT [SPAU] [PASS]
now_TIME
approved_VBN
in_PIN
81_CD
countries_NN
._.
Avandamet_NN
treatment_NOMZ
of_PIN
erectile_JJ
dysfunction_NOMZ
has_VPRT
nearly_DWNT
3_CD
billion_CD
,_,
up_RB
25_CD
per_PIN
cent_NN
._.
Sales_NN
Avandia_NN
and_CC
metformin_JJ
HCI_NN
,_,
launched_VBD
received_VBN
approval_NN
for_PIN
marketing_GER
in_PIN
Europe_NN
of_PIN
Seretide_NN
Advair_NN
grew_VBD
96_CD
per_PIN
cent_NN
and_CC
in_PIN
the_DT
fourth_JJ
quarter_NN
,_,
is_VPRT [BEMA]
the_DT
first_JJ
treatment_NOMZ
and_PHC
launches_NN
are_VPRT [PASS]
planned_VBN
for_PIN
March_NN
2003_CD
._.
Advair_NN
is_VPRT [BEMA]
now_TIME
the_DT
market_NN
leader_NN
in_PIN
the_DT
for_PIN
type_NN
2_CD
diabetes_NN
that_TSUB
targets_VPRT
insulin_NN
Levitra_NN
was_VBD [PASS]
researched_VBN
and_PHC
developed_VBN
by_PIN
US_FPP1
asthma_NN
market_NN
in_PIN
new_JJ
prescriptions_NOMZ
resistance_NN
and_CC
decreases_VPRT
glucose_NN
production_NOMZ
Bayer_NN
AG_NN
and_CC
will_PRMD
be_VB [PASS]
co-promoted_VBN
with_PIN
after_RB
less_JJ
than_PIN
two_CD
years_NN
on_PIN
the_DT
market_NN
._.
The_DT
Group_NN
expects_VPRT [PRIV]
European_JJ
marketing_GER
authorisation_NOMZ
within_PIN
the_DT
next_JJ
few_QUAN
months_NN
for_PIN
the_DT
use_NN
of_PIN
Seretide_NN
as_IN
a_DT
new_JJ
treatment_NOMZ
for_PIN
Chronic_NN
Obstructive_NN
Pulmonary_NN
Disease_NN
._.
GlaxoSmithKline_NN
aims_VPRT
to_TO
be_VB [BEMA]
the_DT
world_NN
leader_NN
in_PIN
consumer_NN
healthcare_NN
offering_GER
products_NN
in_PIN
oral_JJ
healthcare_NN
,_,
over-thecounter_JJ
medicines_NN
and_CC
nutritional_JJ
healthcare_NN
._.
A_DT
dynamic_JJ
R&D_NN
organization_NOMZ
of_PIN
over_IN
15,000_CD
employees_NN
based_VBN [WZPAST]
at_PIN
more_EMPH
than_PIN
20_CD
sites_NN
in_PIN
eight_CD
countries_NN
providing_VBG [WZPRES]
a_DT
leading_VBG
position_NOMZ
in_PIN
genomics_NN
genetics_NN
and_CC
new_JJ
drug_NN
discovery_NN
techniques_NN
._.
A_DT
manufacturing_GER
and_PHC
supply_NN
network_NN
comprising_VBG [WZPRES]
over_IN
1,200_CD
different_JJ
products_NN
created_VBN [WZPAST]
at_PIN
95_CD
sites_NN
in_PIN
38_CD
countries_NN
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
18_CD
|_NN
19_CD
CONSUMER_NN
HEALTHCARE_NN
IMPLEMENTATION_NOMZ
OF_PIN
NEW_NN
FINANCIAL_NN
LEGAL_NN
PROCEEDINGS_GER
Over-the-counter_JJ
sales_NN
were_VBD [BEMA]
1.6_CD
billion_CD
,_,
The_DT
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
REPORTING_GER
STANDARD_NN
up_IN
four_CD
per_PIN
cent_NN
,_,
reflecting_VBG [PRIV]
strong_JJ
growth_NN
The_DT
Group_NN
has_VPRT [PEAS]
implemented_VBN
Financial_NN
and_CC
administrative_JJ
proceedings_GER
principally_RB
in_PIN
the_DT
smoking_GER
control_NN
franchise_NN
._.
Nutritional_NN
Reporting_GER
Standard_NN
19_CD
Deferred_JJ
tax_NN
intellectual_JJ
property_NN
cases_NN
,_,
product_NN
liability_NOMZ
healthcare_NN
grew_VBD
three_CD
per_PIN
cent_NN
due_JJ
to_PIN
in_PIN
2002_CD
which_WDT
requires_VPRT [SUAV]
deferred_VBN
tax_NN
to_TO
and_CC
government_NOMZ
investigations_NOMZ
._.
Descriptions_NOMZ
strong_JJ
growth_NN
in_PIN
Europe_NN
for_PIN
Lucozade_NN
and_CC
be_VB [PASS]
accounted_VBN
for_PIN
on_PIN
a_DT
full_JJ
provision_NN
basis_NN
,_,
of_PIN
the_DT
most_EMPH
significant_JJ
of_PIN
those_DEMP
are_VPRT [PASS]
described_VBN
Ribena_NN
,_,
partly_DWNT
offset_VBN
by_PIN
the_DT
performance_NN
rather_RB
than_PIN
a_DT
partial_JJ
provision_NN
basis_NN
as_IN
under_IN
Legal_NN
proceedings_GER
in_PIN
the_DT
Notes_NN
to_PIN
of_PIN
Horlicks_NN
in_PIN
international_JJ
markets_NN
._.
Comparative_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [BEMA]
the_DT
financial_JJ
statements_NOMZ
in_PIN
the_DT
companys_NN
care_VPRT
sales_NN
were_VBD [BEMA]
down_RB
two_CD
per_PIN
cent_NN
to_TO
restated_VBN
as_RB
necessary_JJ
._.
The_DT
effect_NN
in_PIN
2001_CD
Annual_JJ
Report_NN
for_PIN
2002_CD
._.
1.1_CD
billion_CD
as_IN
growth_NN
from_PIN
Sensodyne_NN
,_,
is_VPRT
to_TO
increase_VB
the_DT
business_NOMZ
performance_NN
Polident_NN
and_PHC
Poligrip_NN
was_VBD [BYPA]
offset_VBN
by_PIN
weak_JJ
tax_NN
charge_NN
by_PIN
8_CD
million_CD
and_CC
the_DT
overall_JJ
CAUTIONARY_NN
STATEMENT_NOMZ
sales_NN
for_PIN
Aquafresh_NN
._.
The_DT
net_JJ
deferred_VBN
Under_IN
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
the_DT
tax_NN
asset_NN
at_PIN
31st_CD
December_NN
2001_CD
has_VPRT [PEAS]
been_VBN
US_FPP1
Private_NN
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
TRADING_GER
PROFIT_NN
AND_PHC
EARNINGS_GER
reduced_VBN [WZPAST]
by_PIN
127_CD
million_CD
._.
of_PIN
1995_CD
,_,
the_DT
company_NN
cautions_VPRT
investors_NN
that_TOBJ
any_QUAN
forward-looking_JJ
statements_NOMZ
or_CC
PER_PIN
SHARE_NN
Business_NOMZ
performance_NN
trading_GER
profit_NN
was_VBD [BEMA]
THE_DT
SARBANES-OXLEY_NN
ACT_NN
2002_CD
projections_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
company_NN
,_,
including_VBG [PRESP]
6.7_CD
billion_CD
with_PIN
a_DT
growth_NN
of_PIN
15_CD
per_PIN
cent_NN
,_,
Following_VBG [PRESP]
a_DT
number_NN
of_PIN
corporate_JJ
and_CC
those_DEMP
made_VBN
in_PIN
this_DEMO
Annual_JJ
Review_NN
,_,
are_VPRT [BEMA]
greater_PRED
than_PIN
sales_NN
growth_NN
of_PIN
seven_CD
per_PIN
cent_NN
,_,
accounting_VBG
scandals_NN
in_PIN
the_DT
USA_NN
,_,
Congress_NN
subject_NN
to_PIN
risks_NN
and_PHC
uncertainties_NN
that_TSUB
may_POMD
demonstrating_VBG [PRIV]
an_DT
improved_JJ
trading_GER
margin_NN
passed_VBD
the_DT
Sarbanes-Oxley_NN
Act_NN
2002_CD
cause_NN
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
of_PIN
2.1_CD
points_NN
to_PIN
31.6_CD
per_PIN
cent_NN
compared_VBN
Sarbanes-Oxley_NN
which_WDT [WHSUB]
took_VBD
effect_NN
on_PIN
those_DEMP
projected_VBN
._.
Factors_NN
that_TSUB
may_POMD
affect_VB
with_PIN
2001_CD
._.
This_DEMP
is_VPRT [BEMA]
mainly_RB
due_PRED
to_TO
cost_VB
30th_JJ
July_NN
2002_CD
._.
Sarbanes-Oxley_NN
establishes_VPRT [PRIV]
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
described_VBN
under_IN
savings_GER
derived_VBN [WZPAST]
from_PIN
merger_NN
integration_NOMZ
,_,
new_JJ
or_CC
enhanced_JJ
standards_NN
for_PIN
corporate_JJ
Risk_NN
factors_NN
in_PIN
the_DT
Operating_GER
and_CC
financial_JJ
manufacturing_GER
restructuring_GER
and_CC
other_JJ
accountability_NOMZ
in_PIN
the_DT
USA_NN
._.
A_DT
number_NN
review_NN
and_PHC
prospects_NN
in_PIN
the_DT
companys_NN
initiatives_NN
._.
Statutory_JJ
trading_GER
profit_NN
was_VBD [BEMA]
of_PIN
provisions_NN
of_PIN
Sarbanes-Oxley_NN
apply_VB
Annual_JJ
Report_NN
on_PIN
Form_NN
20-F_NN
,_,
filed_VBN [PASTP]
with_PIN
the_DT
5.7_CD
billion_CD
with_PIN
a_DT
growth_NN
of_PIN
26_CD
per_PIN
cent_NN
._.
to_PIN
GlaxoSmithKline_NN
and_CC
,_,
although_CONC
the_DT
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
._.
companys_NN
corporate_JJ
governance_NN
structure_NN
Full_NN
year_NN
business_NOMZ
performance_NN
earnings_GER
is_VPRT [PASS]
believed_VBN [PRIV]
to_TO
be_VB [BEMA]
robust_PRED
and_CC
in_PIN
line_NN
with_PIN
per_PIN
share_NN
EPS_NN
of_PIN
78.3_CD
pence_NN
increased_VBD
best_JJ
practice_NN
,_,
certain_JJ
changes_NN
were_VBD [BEMA]
13_CD
per_PIN
cent_NN
and_CC
eight_CD
per_PIN
cent_NN
in_PIN
sterling_GER
necessary_JJ
to_TO
ensure_VB [SUAV] [PRIV]
compliance_NN
._.
These_DEMO
terms_NN
reflecting_VBG [PRIV] [WZPRES]
a_DT
weakening_GER
of_PIN
the_DT
US_FPP1
are_VPRT [PASS]
described_VBN
under_IN
Corporate_JJ
governance_NN
dollar_NN
and_CC
other_JJ
currencies_NN
._.
Full_JJ
year_NN
in_PIN
the_DT
companys_NN
Annual_JJ
Report_NN
for_PIN
2002_CD
._.
statutory_JJ
EPS_NN
was_VBD [BEMA]
66.2_CD
pence_NN
,_,
an_DT
increase_NN
of_PIN
38_CD
per_PIN
cent_NN
._.
Business_NOMZ
performance_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
primary_JJ
Pharmaceutical_NN
sales_NN
by_PIN
therapeutic_JJ
area_NN
performance_NN
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
2002_CD
2001_CD
%_NN
CER_NN
is_VPRT [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposal_NN
m_NN
m_NN
GROWTH_NN
of_PIN
businesses_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
CNS_NN
4,511_CD
4,007_CD
17_CD
exclusion_NN
of_PIN
these_DEMO
non-recurring_JJ
items_NN
provides_VPRT
Respiratory_NN
3,987_CD
3,537_CD
16_CD
a_DT
better_JJ
comparison_NN
of_PIN
business_NOMZ
performance_NN
Anti-virals_NN
2,299_CD
2,128_CD
12_CD
for_PIN
the_DT
periods_NN
presented_VBN
._.
Statutory_JJ
results_NN
Anti-bacterials_JJ
2,210_CD
2,604_CD
12_CD
include_VPRT
these_DEMO
non-recurring_JJ
items_NN
._.
Metabolic_NN
and_CC
gastro-intestinal_JJ
1,429_CD
1,480_CD
1_CD
In_PIN
order_NN
to_TO
illustrate_VB
underlying_VBG
performance_NN
,_,
Vaccines_NN
1,080_CD
948_CD
16_CD
it_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
practice_NN
to_TO
discuss_VB
the_DT
results_NN
Oncology_NN
and_PHC
emesis_NN
977_CD
838_CD
21_CD
in_PIN
terms_NN
of_PIN
constant_JJ
exchange_NN
rates_NN
CER_NN
Cardiovascular_NN
655_CD
591_CD
14_CD
growth_NN
._.
This_DEMP
represents_VPRT
growth_NN
calculated_VBN [PRIV]
as_IN
Arthritis_NN
23_CD
156_CD
84_CD
if_COND
the_DT
exchange_NN
rates_NN
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
Other_JJ
824_CD
916_CD
5_CD
results_NN
of_PIN
overseas_PLACE
companies_NN
in_PIN
sterling_GER
had_VBD
Total_JJ
17,995_CD
17,205_CD
8_CD
remained_VBD
unchanged_JJ
from_PIN
those_DEMP
used_VBN
in_PIN
the_DT
previous_JJ
period_NN
._.
Growth_NN
rates_NN
are_VPRT [BEMA]
therefore_CONJ
at_PIN
CER_NN
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
RESPONSIBILITY_NOMZ
STATEMENTS_NOMZ
Annual_JJ
Review_NN
The_DT
Annual_JJ
Review_NN
,_,
including_VBG
Summary_NN
financial_JJ
statements_NOMZ
,_,
has_VPRT
The_DT
Annual_JJ
Review_NN
is_VPRT [BEMA]
a_DT
summary_NN
report_NN
and_CC
does_VPRT
not_XX0
contain_VB
been_VBN [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
sufficient_JJ
information_NOMZ
to_TO
allow_VB [SUAV]
as_IN
full_JJ
an_DT
understanding_GER
of_PIN
the_DT
results_NN
and_PHC
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Group_NN
as_IN
is_VPRT [BYPA]
provided_VBN
by_PIN
the_DT
full_JJ
Annual_JJ
Sir_NN
Christopher_NN
Hogg_NN
,_,
Report_NN
._.
Shareholders_NN
requiring_VBG [SUAV] [WZPRES]
more_EMPH
detailed_JJ
information_NOMZ
may_POMD
Chairman_NN
obtain_VB
,_,
free_JJ
of_PIN
charge_NN
,_,
a_DT
copy_NN
of_PIN
the_DT
Annual_JJ
Report_NN
for_PIN
2002_CD
10th_JJ
March_NN
2003_CD
and_CC
may_POMD [SPAU]
also_RB
elect_VB
to_TO
receive_VB
a_DT
copy_NN
of_PIN
the_DT
Annual_JJ
Report_NN
in_PIN
future_JJ
years_NN
refer_VPRT
to_PIN
Shareholder_NN
information_NOMZ
._.
Independent_NN
auditors_NN
statement_NOMZ
to_PIN
the_DT
members_NN
The_DT
Independent_NN
Auditors_NN
report_VPRT [PUBV]
on_PIN
the_DT
full_JJ
financial_JJ
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
plc_NN
of_PIN
the_DT
Group_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2002_CD
is_VPRT [BEMA]
unqualified_PRED
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
which_WDT [WHSUB]
comprise_VPRT
and_PHC
does_VPRT
not_XX0
contain_VB
any_QUAN
statement_NOMZ
concerning_VBG [WZPRES]
inadequate_JJ
the_DT
Summary_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
,_,
balance_NN
sheet_NN
and_PHC
accounting_GER
records_NN
or_CC
failure_NN
to_TO
obtain_VB
necessary_JJ
information_NOMZ
cash_NN
flow_NN
statement_NOMZ
and_CC
the_DT
summarised_VBN
Directors_NN
report_VPRT [PUBV]
including_VBG
and_CC
explanations_NOMZ
._.
Summary_JJ
financial_JJ
statements_NOMZ
Respective_JJ
responsibilities_NOMZ
of_PIN
Directors_NN
and_PHC
auditors_NN
A_DT
columnar_NN
presentation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
in_PIN
the_DT
Summary_NN
The_NN
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
Annual_JJ
Review_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
order_NN
to_TO
illustrate_VB
business_NOMZ
in_PIN
accordance_NN
with_PIN
applicable_JJ
law_NN
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
performance_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
the_DT
primary_JJ
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
._.
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
consistency_NN
of_PIN
the_DT
Summary_NN
financial_JJ
For_PIN
this_DEMO
purpose_NN
certain_JJ
items_NN
are_VPRT [PASS]
identified_VBN
separately_RB
and_CC
are_VPRT
statements_NOMZ
within_PIN
the_DT
Annual_JJ
Review_NN
with_PIN
the_DT
Annual_JJ
financial_JJ
excluded_VBN
from_PIN
business_NOMZ
performance_NN
._.
These_DEMP
comprise_VPRT
merger_NN
items_NN
,_,
statements_NOMZ
,_,
the_DT
Directors_NN
report_NN
and_CC
the_DT
Directors_NN
remuneration_NOMZ
including_VBG [WZPRES]
merger_NN
related_VBN
product_NN
divestments_NOMZ
,_,
costs_NN
relating_VBG [WZPRES]
report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
Section_NOMZ
to_TO [SPIN]
previously_TIME
announced_VBN [PUBV]
manufacturing_GER
and_CC
other_JJ
restructuring_GER
,_,
251_CD
of_PIN
the_DT
United_NN
Kingdom_NN
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
and_PHC
disposal_NN
of_PIN
businesses_NOMZ
._.
Business_NOMZ
performance_NN
is_VPRT [PASS]
discussed_VBN
made_VBN
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
Business_NOMZ
operating_VBG [WZPRES]
review_NN
._.
in_PIN
the_DT
Annual_JJ
Review_NN
and_CC
consider_VB [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
Information_NOMZ
is_VPRT [PASS]
provided_VBN
for_PIN
US_FPP1
shareholders_NN
in_PIN
accordance_NN
with_PIN
inconsistencies_NN
with_PIN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
._.
the_DT
requirements_NOMZ
of_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
The_DT
Summary_NN
financial_JJ
statements_NOMZ
under_IN
UK_NN
Generally_RB
Accepted_JJ
Accounting_GER
This_DEMO
statement_NOMZ
,_,
including_VBG [PRESP]
the_DT
opinion_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
and_CC
only_DWNT
Principles_NN
GAAP_NN
are_VPRT [PASS]
presented_VBN
in_PIN
US$_$
as_RB
well_RB
as_IN
in_PIN
sterling_GER
._.
for_PIN
the_DT
companys_NN
members_NN
as_IN
a_DT
body_NN
in_PIN
accordance_NN
with_PIN
Section_NOMZ
251_CD
Earnings_GER
and_PHC
shareholders_NN
funds_NN
are_VPRT [SPAU] [PASS]
also_RB
restated_VBN
in_PIN
accordance_NN
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
in_PIN
giving_VBG
this_DEMO
opinion_NN
,_,
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
for_PIN
any_QUAN
other_JJ
purpose_NN
or_CC
to_PIN
any_QUAN
other_JJ
person_NN
to_PIN
whom_WP [PIRE]
this_DEMO
statement_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
Statement_NOMZ
by_PIN
the_DT
Directors_NN
or_CC
into_PIN
whose_WPS [PIRE]
hands_NN
it_PIT
may_POMD
come_VB
save_IN
where_RB
expressly_RB
agreed_VBN [SUAV] [PUBV]
by_PIN
The_DT
Annual_JJ
Review_NN
2002_CD
is_VPRT [BEMA]
the_DT
Summary_NN
Directors_NN
report_NN
and_CC
our_FPP1
prior_JJ
consent_NN
in_PIN
writing_VBG [PUBV]
._.
includes_VPRT
the_DT
Summary_NN
financial_JJ
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2002_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
published_VBN
in_PIN
Basis_NN
of_PIN
opinion_NN
hard-copy_JJ
printed_VBN
form_NN
and_CC
on_PIN
the_DT
website_NN
._.
The_DT
Business_NOMZ
operating_GER
We_FPP1
conducted_VBD
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
Bulletin_NN
1999_CD
6_CD
,_,
review_NN
,_,
the_DT
Summary_NN
financial_JJ
statements_NOMZ
,_,
the_DT
Summary_NN
remuneration_NOMZ
The_DT
auditors_NN
statement_NOMZ
on_PIN
the_DT
Summary_NN
financial_JJ
statement_NOMZ
issued_VBN
report_NN
and_CC
the_DT
Statement_NOMZ
on_PIN
corporate_JJ
governance_NN
are_VPRT
summaries_NN
by_PIN
the_DT
Auditing_GER
Practices_NN
Board_NN
for_PIN
use_NN
in_PIN
the_DT
United_NN
Kingdom_NN
._.
of_PIN
information_NOMZ
in_PIN
the_DT
Annual_JJ
Report_NN
._.
Opinion_NN
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
maintenance_NN
and_PHC
integrity_NOMZ
In_PIN
our_FPP1
opinion_NN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
consistent_PRED
with_PIN
of_PIN
the_DT
Annual_JJ
Review_NN
on_PIN
the_DT
website_NN
in_PIN
accordance_NN
with_PIN
the_DT
UK_NN
the_DT
Annual_JJ
financial_JJ
statements_NOMZ
,_,
the_DT
Directors_NN
report_NN
and_CC
the_DT
Directors_NN
legislation_NOMZ
governing_VBG [WZPRES]
the_DT
preparation_NOMZ
and_PHC
dissemination_NOMZ
of_PIN
financial_JJ
remuneration_NOMZ
report_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
statements_NOMZ
._.
Access_NN
to_PIN
the_DT
website_NN
is_VPRT [BEMA]
available_PRED
from_PIN
outside_PLACE
the_DT
UK_NN
,_,
31st_CD
December_NN
2002_CD
and_CC
complies_VPRT
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
where_RB
comparable_JJ
legislation_NOMZ
may_POMD
be_VB [BEMA]
different_PRED
._.
of_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
Corporate_JJ
governance_NN
The_DT
Combined_NN
Code_NN
Principles_NN
of_PIN
Good_JJ
Governance_NN
and_PHC
Code_NN
of_PIN
LLP_NN
Best_JJ
Practice_NN
is_VPRT [BYPA]
specified_VBN
by_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
Authority_NOMZ
for_PIN
the_DT
guidance_NN
of_PIN
listed_VBN
companies_NN
._.
The_DT
Board_NN
considers_VPRT [PRIV]
Southwark_NN
Towers_NN
,_,
London_NN
,_,
England_NN
,_,
10th_JJ
March_NN
2003_CD
that_DEMO
throughout_PIN
2002_CD
and_CC
up_RB
to_PIN
the_DT
date_NN
of_PIN
approval_NN
of_PIN
this_DEMO
review_NN
,_,
GlaxoSmithKline_NN
plc_NN
applied_VBD
the_DT
principles_NN
of_PIN
the_DT
Combined_NN
Code_NN
and_CC
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
matters_NN
where_RB
the_DT
companys_NN
position_NOMZ
is_VPRT [PASS]
described_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
,_,
complied_VBN [PASTP]
with_PIN
the_DT
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
,_,
and_ANDC
the_DT
guidance_NN
on_PIN
internal_JJ
control_NN
issued_VBN [WZPAST]
by_PIN
the_DT
Turnbull_NN
Committee_NN
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
20_CD
|_NN
21_CD
CORPORATE_JJ
GOVERNANCE_NN
Governance_NN
and_PHC
policy_NN
The_DT
Board_NN
and_PHC
Executive_NN
The_NN
Directors_NN
listed_VBN
under_IN
The_DT
Board_NN
on_PIN
page_NN
16_CD
were_VBD [PASS]
appointed_VBN
The_DT
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
the_DT
terms_NN
of_PIN
service_NN
on_PIN
23rd_JJ
May_POMD
2000_CD
and_CC
have_VPRT [PEAS]
served_VBN
since_OSUB
that_DEMO
date_NN
._.
and_ANDC
remuneration_NOMZ
of_PIN
the_DT
Executive_NN
Directors_NN
and_CC
Corporate_JJ
Executives_NN
and_CC
with_PIN
the_DT
assistance_NN
of_PIN
external_JJ
independent_JJ
advisors_NN
The_DT
Board_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
it_PIT
evaluates_VPRT
and_PHC
makes_VPRT
recommendations_NOMZ
to_PIN
the_DT
Board_NN
on_PIN
the_DT
system_NN
of_PIN
corporate_JJ
governance_NN
and_CC
is_VPRT [BEMA]
ultimately_RB
accountable_JJ
remuneration_NOMZ
of_PIN
Non-Executive_JJ
Directors_NN
._.
The_DT
Committee_NN
consists_VPRT
for_PIN
the_DT
Groups_NN
activities_NOMZ
,_,
strategy_NN
and_CC
financial_JJ
performance_NN
._.
It_PIT
meets_VPRT
four_CD
times_NN
a_DT
year_NN
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
The_DT
Chairman_NN
and_PHC
CEO_NN
attend_VPRT
the_DT
meetings_GER
The_DT
Board_NN
comprises_VPRT
Executive_NN
and_PHC
Non-Executive_NN
Directors_NN
._.
except_PIN
when_RB
their_TPP3
own_JJ
remuneration_NOMZ
is_VPRT
being_VBG [PASS]
considered_VBN [PRIV]
._.
The_DT
Senior_JJ
The_DT
role_NN
of_PIN
Non-Executive_JJ
Directors_NN
is_VPRT
to_TO
bring_VB
independent_JJ
Vice_NN
President_NN
,_,
Human_NN
Resources_NN
,_,
also_RB
attends_VPRT
each_QUAN
meeting_GER
._.
judgement_NOMZ
to_PIN
Board_NN
deliberations_NOMZ
and_PHC
decisions_NN
._.
The_DT
Board_NN
considers_VPRT [PRIV]
each_QUAN
of_PIN
the_DT
Non-Executive_JJ
Directors_NN
to_TO
be_VB [BEMA]
independent_PRED
._.
The_DT
Nominations_NOMZ
Committee_NN
reviews_VPRT
the_DT
structure_NN
,_,
size_NN
and_PHC
composition_NOMZ
of_PIN
the_DT
Board_NN
and_CC
the_DT
appointment_NOMZ
of_PIN
Corporate_JJ
Sir_NN
Christopher_NN
Hogg_NN
was_VBD [PASS]
appointed_VBN
Non-Executive_NN
Chairman_NN
Executives_NN
and_CC
new_JJ
Board_NN
members_NN
and_CC
makes_VPRT
recommendations_NOMZ
following_VBG [WZPRES]
the_DT
retirement_NOMZ
of_PIN
Sir_NN
Richard_NN
Sykes_NN
on_PIN
20th_JJ
May_POMD
2002_CD
,_,
to_PIN
the_DT
Board_NN
as_IN
appropriate_JJ
._.
The_DT
Committee_NN
will_PRMD [SPAU]
also_RB
review_VB
the_DT
and_CC
Dr_NN
Jean-Pierre_NN
Garnier_NN
is_VPRT
Chief_NN
Executive_NN
Officer_NN
._.
Sir_NN
Roger_NN
Hurn_NN
managements_NOMZ
succession_NN
plan_NN
to_TO
ensure_VB [SUAV] [PRIV]
its_PIT
adequacy_NN
._.
The_DT
Committee_NN
is_VPRT [BEMA]
Non-Executive_JJ
Deputy_NN
Chairman_NN
and_PHC
Senior_NN
Independent_NN
Director_NN
._.
consists_VPRT
entirely_AMP
of_PIN
Non-Executive_JJ
Directors_NN
and_CC
meets_VPRT
at_PIN
least_JJ
once_TIME
a_DT
year_NN
to_TO
consider_VB [PRIV]
succession_NN
planning_GER
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
Board_NN
process_NN
The_NN
Board_NN
meets_VPRT
at_PIN
least_JJ
six_CD
times_NN
a_DT
year_NN
._.
It_PIT
has_VPRT
a_DT
formal_JJ
schedule_NN
The_DT
Corporate_NN
Administration_NOMZ
&_CC
Transactions_NOMZ
Committee_NN
of_PIN
matters_NN
reserved_VBN [WZPAST]
to_PIN
it_PIT
for_PIN
decision_NN
but_CC
otherwise_CONJ
delegates_NN
reviews_NN
and_CC
approves_VPRT
matters_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
administration_NOMZ
specific_JJ
responsibilities_NOMZ
to_PIN
Board_NN
committees_NN
,_,
as_IN
described_VBN
below_PLACE
._.
of_PIN
the_DT
Groups_NN
business_NOMZ
,_,
and_ANDC
of_PIN
certain_JJ
corporate_JJ
transactions_NOMZ
._.
The_DT
Board_NN
works_VPRT
to_PIN
an_DT
agreed_VBN [SUAV] [PUBV]
agenda_NN
in_PIN
reviewing_VBG
the_DT
key_JJ
The_DT
Committee_NN
consists_VPRT
of_PIN
the_DT
Directors_NN
,_,
CET_NN
members_NN
and_PHC
activities_NOMZ
of_PIN
the_DT
business_NOMZ
,_,
and_ANDC
receives_VPRT
papers_NN
and_PHC
presentations_NOMZ
the_DT
Company_NN
Secretary_NN
._.
The_DT
Committee_NN
meets_VPRT
as_RB
necessary_JJ
._.
to_TO
enable_VB
it_PIT
to_TO
do_VB
so_RB
effectively_RB
._.
The_DT
Board_NN
considers_VPRT [PRIV]
and_PHC
reviews_VPRT
the_DT
work_NN
undertaken_VBN [WZPAST]
by_PIN
its_PIT
Committees_NN
._.
The_DT
Corporate_JJ
Social_NN
Responsibility_NOMZ
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
Non-Executive_JJ
Directors_NN
and_CC
provides_VPRT
a_DT
Board_NN
level_NN
forum_NN
for_PIN
the_DT
The_NN
Company_NN
Secretary_NN
is_VPRT [BEMA]
responsible_PRED
to_PIN
the_DT
Board_NN
and_CC
is_VPRT [BEMA]
regular_JJ
review_NN
of_PIN
external_JJ
issues_NN
that_TSUB
have_VPRT
the_DT
potential_NN
for_PIN
serious_JJ
available_JJ
to_PIN
individual_JJ
Directors_NN
in_PIN
respect_NN
of_PIN
Board_NN
procedures_NN
._.
impact_NN
upon_PIN
the_DT
Groups_NN
business_NOMZ
and_PHC
reputation_NOMZ
._.
The_DT
Committee_NN
The_NN
Company_NN
Secretary_NN
is_VPRT
Simon_NN
Bicknell_NN
who_WP [WHSUB]
was_VBD [PASS]
appointed_VBN
is_VPRT [BEMA]
also_RB
responsible_PRED
for_PIN
annual_JJ
governance_NN
oversight_NN
of_PIN
the_DT
Groups_NN
in_PIN
May_POMD
2000_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
barrister_NN
and_CC
joined_VBD
the_DT
Group_NN
in_PIN
1984_CD
._.
worldwide_JJ
donations_NOMZ
and_PHC
community_NOMZ
support_NN
._.
The_DT
Committee_NN
meets_VPRT
He_TPP3
is_VPRT
secretary_NN
to_PIN
all_QUAN
the_DT
Board_NN
Committees_NN
._.
formally_RB
twice_RB
a_DT
year_NN
and_CC
has_VPRT
further_JJ
meetings_GER
and_PHC
consultations_NOMZ
as_IN
required_VBN [SUAV]
._.
Board_NN
committees_VPRT
The_DT
Audit_NN
Committee_NN
reviews_VPRT
the_DT
financial_JJ
and_PHC
internal_JJ
reporting_GER
Corporate_NN
Executive_NN
Team_NN
process_NN
,_,
the_DT
system_NN
of_PIN
internal_JJ
control_NN
and_PHC
management_NOMZ
of_PIN
risks_NN
The_DT
executive_NN
management_NOMZ
of_PIN
the_DT
Group_NN
is_VPRT [BEMA]
the_DT
responsibility_NOMZ
of_PIN
and_CC
the_DT
external_JJ
and_PHC
internal_JJ
audit_NN
process_NN
._.
The_DT
Committee_NN
also_RB
the_DT
CEO_NN
and_CC
other_JJ
senior_JJ
managers_NN
,_,
who_WP
form_VPRT
the_DT
CET_NN
which_WDT [WHSUB]
meets_VPRT
proposes_VPRT [SUAV]
to_PIN
the_DT
shareholders_NN
the_DT
appointment_NOMZ
of_PIN
the_DT
external_JJ
11_CD
times_NN
a_DT
year_NN
._.
The_DT
members_NN
of_PIN
the_DT
CET_NN
and_CC
their_TPP3
responsibilities_NOMZ
auditors_NN
and_CC
is_VPRT [BEMA]
directly_RB
responsible_PRED
for_PIN
their_TPP3
remuneration_NOMZ
and_CC
are_VPRT [PASS]
given_VBN
on_PIN
page_NN
17_CD
._.
oversight_NN
of_PIN
their_TPP3
work_NN
._.
The_DT
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
Non-Executive_JJ
Directors_NN
._.
It_PIT
meets_VPRT
at_PIN
least_JJ
four_CD
times_NN
a_DT
year_NN
with_PIN
the_DT
Remuneration_NOMZ
of_PIN
Directors_NN
Chief_NN
Executive_NN
Officer_NN
CEO_NN
,_,
the_DT
Chief_NN
Financial_NN
Officer_NN
CFO_NN
,_,
Information_NOMZ
on_PIN
the_DT
remuneration_NOMZ
of_PIN
Directors_NN
is_VPRT [PASS]
given_VBN
in_PIN
the_DT
Summary_NN
the_DT
General_NN
Counsel_NN
,_,
the_DT
heads_NN
of_PIN
global_JJ
internal_JJ
audit_NN
and_PHC
remuneration_NOMZ
report_NN
on_PIN
pages_NN
25_CD
to_PIN
27_CD
._.
corporate_JJ
compliance_NN
and_PHC
representatives_NN
of_PIN
the_DT
external_JJ
auditors_NN
in_PIN
attendance_NN
._.
With_PIN
effect_NN
from_PIN
1st_CD
January_NN
2003_CD
the_DT
Committee_NN
Share_NN
buy-back_NN
program_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
pre-approving_VBG
all_QUAN
non-audit_JJ
services_NN
to_TO
be_VB [BEMA]
In_PIN
October_NN
2002_CD
,_,
following_VBG [PRESP]
the_DT
completion_NOMZ
of_PIN
the_DT
4_CD
billion_CD
share_NN
provided_VBN [WZPAST]
by_PIN
external_JJ
auditors_NN
._.
buy-back_JJ
program_NN
announced_VBN [PUBV] [WZPAST]
in_PIN
2001_CD
,_,
the_DT
company_NN
announced_VBD [PUBV]
plans_NN
for_PIN
a_DT
new_JJ
4_CD
billion_CD
share_NN
buy-back_JJ
program_NN
._.
The_DT
Financial_NN
Results_NN
Committee_NN
reviews_VPRT
and_PHC
approves_VPRT
,_,
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
,_,
the_DT
Annual_JJ
Report_NN
on_PIN
Form_NN
20-F_NN
and_CC
Annual_JJ
The_DT
program_NN
covers_VPRT
purchases_NN
by_PIN
the_DT
company_NN
of_PIN
shares_NN
for_PIN
Review_NN
and_CC
the_DT
convening_VBG
of_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
together_RB
cancellation_NOMZ
,_,
in_PIN
accordance_NN
with_PIN
the_DT
authority_NOMZ
given_VBN [WZPAST]
by_PIN
shareholders_NN
with_PIN
the_DT
preliminary_JJ
and_PHC
quarterly_JJ
statements_NOMZ
of_PIN
trading_GER
results_NN
._.
at_PIN
the_DT
Annual_JJ
General_NN
Meetings_GER
in_PIN
2001_CD
and_CC
2002_CD
._.
Each_QUAN
Director_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
committee_NN
and_CC
the_DT
quorum_NN
for_PIN
a_DT
meeting_GER
is_VPRT [BEMA]
any_QUAN
three_CD
members_NN
._.
To_TO
be_VB [BEMA]
quorate_PRED
,_,
each_QUAN
meeting_GER
In_PIN
total_JJ
2.2_CD
billion_CD
was_VBD [PASS]
spent_VBN
during_PIN
2002_CD
._.
In_PIN
May_POMD
2002_CD
the_DT
must_NEMD
include_VB
the_DT
Chairman_NN
or_CC
the_DT
Chairman_NN
of_PIN
the_DT
Audit_NN
company_NN
was_VBD [PASS]
authorised_VBN
to_TO
purchase_VB
a_DT
maximum_NN
of_PIN
617_CD
million_CD
Committee_NN
and_CC
the_DT
CEO_NN
or_CC
the_DT
CFO_NN
._.
shares_NN
623_CD
million_CD
shares_NN
in_PIN
May_POMD
2001_CD
and_CC
156_CD
million_CD
shares_NN
were_VBD [PASS]
purchased_VBN
for_PIN
cancellation_NOMZ
during_PIN
2002_CD
._.
The_DT
exact_JJ
amount_NN
and_PHC
timing_NN
of_PIN
future_JJ
purchases_NN
will_PRMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
company_NN
and_CC
is_VPRT [BEMA]
dependent_PRED
on_PIN
market_NN
conditions_NOMZ
and_CC
other_JJ
factors_NN
._.
SUMMARY_NN
FINANCIAL_NN
STATEMENTS_NOMZ
for_PIN
the_DT
year_NN
to_PIN
31st_CD
December_NN
2002_CD
Merger_NN
,_,
restructuring_GER
and_PHC
Business_NOMZ
performance_NN
disposal_NN
of_PIN
subsidiaries_NN
Statutory_NN
2001 2001 2001 2002_CD
restated_VBN
2002_CD
restated_VBN
2002_CD
restated_VBN
Summary_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
m_NN
m_NN
CER_NN
%_NN
m_NN
m_FW
m_FW
m_FW
Sales_NN
Pharmaceuticals_NN
17,995_CD
17,205_CD
8_CD
17,995_CD
17,205_CD
Consumer_NN
Healthcare_NN
3,217_CD
3,284_CD
2_CD
3,217_CD
3,284_CD
Total_JJ
sales_NN
21,212_CD
20,489_CD
7_CD
21,212_CD
20,489_CD
Cost_NN
of_PIN
sales_NN
4,243_CD
4,430_CD
2_CD
366_CD
303_CD
4,609_CD
4,733_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
7,543_CD
7,451_CD
5_CD
498_CD
957_CD
8,041_CD
8,408_CD
Research_NN
and_PHC
development_NOMZ
expenditure_NN
2,732_CD
2,555_CD
9_CD
168_CD
96_CD
2,900_CD
2,651_CD
Trading_GER
profit_NN
6,694_CD
6,053_CD
15_CD
1,032_CD
1,356_CD
5,662_CD
4,697_CD
Other_JJ
income_NN
and_PHC
expenses_NN
111_CD
37_CD
21_CD
296_CD
90_CD
259_CD
Income_NN
from_PIN
associates_NN
75_CD
167_CD
75_CD
167_CD
Net_JJ
interest_NN
payable_JJ
141_CD
88_CD
141_CD
88_CD
Profit_NN
before_IN
taxation_NOMZ
6,517_CD
6,169_CD
11_CD
1,011_CD
1,652_CD
5,506_CD
4,517_CD
Taxation_NOMZ
1,760_CD
1,655_CD
299_CD
322_CD
1,461_CD
1,333_CD
Profit_NN
after_IN
taxation_NOMZ
4,757_CD
4,514_CD
712_CD
1,330_CD
4,045_CD
3,184_CD
Minority_NOMZ
interests_NN
110_CD
97_CD
110_CD
97_CD
Preference_NN
share_NN
dividends_NN
20_CD
34_CD
20_CD
34_CD
Earnings_GER
4,627_CD
4,383_CD
11_CD
712_CD
1,330_CD
3,915_CD
3,053_CD
Earnings_GER
per_PIN
share_NN
78.3_CD
p_VPRT
72.3_CD
p_JJ
13_CD
66.2_CD
p_NN
50.3_CD
p_NN
Dividends_NN
2,346_CD
2,356_CD
To_TO
illustrate_VB
Business_NOMZ
performance_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
primary_JJ
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposal_NN
of_PIN
businesses_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
and_CC
an_DT
adjusted_JJ
EPS_NN
presented_VBD
._.
Business_NOMZ
performance_NN
growth_NN
is_VPRT [BEMA]
at_PIN
constant_JJ
exchange_NN
rates_NN
._.
2001_CD
2002_CD
restated_VBN
Summary_NN
consolidated_JJ
balance_NN
sheet_NN
m_NN [PASS]
m_NN [PASS]
Fixed_VBN
assets_NN
11,578_CD
11,920_CD
Current_JJ
assets_NN
10,749_CD
10,423_CD
Creditors_NN
:_:
amounts_NN
due_JJ
within_PIN
one_CD
year_NN
8,808_CD
9,430_CD
Net_JJ
current_JJ
assets_NN
1,941_CD
993_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
13,519_CD
12,913_CD
Creditors_NN
:_:
amounts_NN
due_RB
after_IN
one_CD
year_NN
3,298_CD
2,298_CD
Provision_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
2,833_CD
2,363_CD
Net_JJ
assets_NN
7,388_CD
8,252_CD
Equity_NOMZ
shareholders_NN
funds_NN
6,581_CD
7,390_CD
Minority_NOMZ
interests_NN
807_CD
862_CD
Capital_NN
employed_VBN
7,388_CD
8,252_CD
2002_CD
2001_CD
Summary_NN
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
m_NN
m_NN [BEMA]
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
7,255_CD
6,507_CD
Dividends_NN
from_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
2_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
237_CD
191_CD
Taxation_NOMZ
paid_VBD
1,633_CD
1,717_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
1,120_CD
1,779_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
20_CD
657_CD
Equity_NOMZ
dividends_NN
paid_VBD
2,327_CD
2,325_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
1,515_CD
450_CD
Increase_VPRT
decrease_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
405_CD
612_CD
ANNUAL_JJ
REVIEW_NN
2002_CD
22_CD
|_NN
23_CD
SUMMARY_NN
FINANCIAL_NN
STATEMENTS_NOMZ
IN_PIN
US_FPP1
DOLLARS_NN
for_PIN
the_DT
year_NN
to_PIN
31st_CD
December_NN
2002_CD
Merger_NN
,_,
restructuring_GER
and_PHC
Business_NOMZ
performance_NN
disposal_NN
of_PIN
subsidiaries_NN
Statutory_NN
2001 2001 2001 2002_CD
restated_VBN
2002_CD
restated_VBN
2002_CD
restated_VBN
Summary_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_VPRT
$_$
m_CD
$_$
m_CD [BEMA]
CER_CD
%_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Sales_NN
Pharmaceuticals_NN
26,993_CD
24,775_CD
8_CD
26,993_CD
24,775_CD
Consumer_NN
Healthcare_NN
4,826_CD
4,729_CD
2_CD
4,826_CD
4,729_CD
Total_JJ
sales_NN
31,819_CD
29,504_CD
7_CD
31,819_CD
29,504_CD
Cost_NN
of_PIN
sales_NN
6,364_CD
6,379_CD
2_CD
549_CD
437_CD
6,913_CD
6,816_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
11,315_CD
10,730_CD
5_CD
747_CD
1,378_CD
12,062_CD
12,108_CD
Research_NN
and_PHC
development_NOMZ
expenditure_NN
4,098_CD
3,679_CD
9_CD
252_CD
138_CD
4,350_CD
3,817_CD
Trading_GER
profit_NN
10,042_CD
8,716_CD
15_CD
1,548_CD
1,953_CD
8,494_CD
6,763_CD
Other_JJ
income_NN
and_PHC
expenses_NN
167_CD
54 31 426 136_CD
372_CD
Income_NN
from_PIN
associates_NN
113 240 113 240_CD
Net_JJ
interest_NN
payable_JJ
212 127 212 127_CD
Profit_NN
before_IN
taxation_NOMZ
9,776_CD
8,883_CD
11_CD
1,517_CD
2,379_CD
8,259_CD
6,504_CD
Taxation_NOMZ
2,640_CD
2,383_CD
449_CD
464_CD
2,191_CD
1,919_CD
Profit_NN
after_IN
taxation_NOMZ
7,136_CD
6,500_CD
10_CD
1,068_CD
1,915_CD
6,068_CD
4,585_CD
Minority_NOMZ
interests_NN
165 140 165 140_CD
Preference_NN
share_NN
dividends_NN
30_CD
49_CD
30_CD
49_CD
Earnings_GER
6,941_CD
6,311_CD
11_CD
1,068_CD
1,915_CD
5,873_CD
4,396_CD
Earnings_GER
per_PIN
ADS_NN
$_$
2.35_CD
$_$
2.08_CD
13_CD
$_$
1.99_CD
$_$
1.45_CD
Dividends_NN
3,519_CD
3,393_CD
To_TO
illustrate_VB
Business_NOMZ
performance_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
primary_JJ
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposal_NN
of_PIN
businesses_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
and_CC
an_DT
adjusted_JJ
EPS_NN
presented_VBD
._.
2001_CD
2002_CD
restated_VBN
Summary_NN
consolidated_JJ
balance_NN
sheet_NN
$_$
m_CD
$_$
m_CD [PASS]
Fixed_VBN
assets_NN
18,641_CD
17,284_CD
Current_JJ
assets_NN
17,306_CD
15,114_CD
Creditors_NN
:_:
amounts_NN
due_JJ
within_PIN
one_CD
year_NN
14,181_CD
13,674_CD
Net_JJ
current_JJ
assets_NN
3,125_CD
1,440_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
21,766_CD
18,724_CD
Creditors_NN
:_:
amounts_NN
due_RB
after_IN
one_CD
year_NN
5,310_CD
3,332_CD
Provision_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
4,561_CD
3,426_CD
Net_JJ
assets_NN
11,895_CD
11,966_CD
Equity_NOMZ
shareholders_NN
funds_NN
10,596_CD
10,716_CD
Minority_NOMZ
interests_NN
1,299_CD
1,250_CD
Capital_NN
employed_VBN
11,895_CD
11,966_CD
2002_CD
2001_CD
Summary_NN
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
10,882_CD
9,370_CD
Dividends_NN
from_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
3_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
355_CD
275_CD
Taxation_NOMZ
paid_VBD
2,449_CD
2,472_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
1,680_CD
2,562_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
30_CD
946_CD
Equity_NOMZ
dividends_NN
paid_VBD
3,491_CD
3,348_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
2,272_CD
648_CD
Increase_VPRT
decrease_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
608_CD
881_CD
The_DT
Summary_NN
financial_JJ
statements_NOMZ
above_PLACE
have_VPRT [PEAS]
been_VBN [PASS]
provided_VBN
in_PIN
US$_$
for_PIN
the_DT
convenience_NN
of_PIN
US_FPP1
shareholders_NN
._.
The_DT
profit_NN
and_PHC
loss_NN
account_NN
and_PHC
cash_NN
flow_NN
statement_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
translated_VBN
at_PIN
the_DT
average_JJ
exchange_NN
rate_NN
1_CD
US$_$
1.50_CD
2001_CD
:_:
1_CD
US$_$
1.44_CD
,_,
and_ANDC
the_DT
balance_NN
sheet_NN
at_PIN
the_DT
year_NN
end_NN
exchange_NN
rate_NN
1_CD
US$_$
1.61_CD
2001_CD
:_:
1_CD
US$_$
1.45_CD
._.
SUMMARY_NN
INFORMATION_NOMZ
UNDER_IN
US_FPP1
GAAP_NN
for_PIN
the_DT
year_NN
to_PIN
31st_CD
December_NN
2002_CD
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_TO
profit_VB
and_CC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
These_DEMO
adjustments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
income_NN
statements_NOMZ
and_PHC
balance_NN
sheet_NN
presented_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
._.
2001_CD
2002_CD
restated_VBN
Profit_NN
m_NN
m_NN
Profit_NN
attributable_JJ
to_PIN
shareholders_NN
under_IN
UK_NN
GAAP_NN
3,915_CD
3,053_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Fixed_JJ
assets_NN
45_CD
15_CD
Intangible_JJ
assets_NN
and_PHC
goodwill_NN
4,252_CD
3,667_CD
Inventory_NN
298_CD
Disposal_NN
of_PIN
investments_NOMZ
,_,
subsidiaries_NN
and_PHC
products_NN
7_CD
87_CD
Employee_NN
costs_NN
469_CD
174_CD
Provision_NN
against_PIN
ESOT_NN
shares_NN
51_CD
108_CD
Derivative_JJ
instruments_NOMZ
8_CD
15_CD
Restructuring_GER
37_CD
182_CD
Taxation_NOMZ
1,169_CD
827_CD
Impairment_NOMZ
of_PIN
equity_NOMZ
investments_NOMZ
8_CD
75_CD
Net_JJ
income_NN
loss_NN
under_IN
US_FPP1
GAAP_NN
before_IN
cumulative_JJ
changes_NN
in_PIN
accounting_GER
principles_NN
503_CD
143_CD
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
90_CD
Net_JJ
income_NN
loss_NN
under_IN
US_FPP1
GAAP_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
413_CD
143_CD
Basic_JJ
and_PHC
diluted_JJ
loss_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
:_:
Net_JJ
income_NN
loss_NN
before_IN
cumulative_JJ
changes_NN
in_PIN
accounting_GER
principles_NN
8.5_CD
p_NN
2.4_CD
p_NN
Changes_NN
in_PIN
accounting_GER
principles_NN
1.5_CD
p_NN
Net_JJ
income_NN
loss_NN
after_IN
changes_NN
in_PIN
accounting_GER
principles_NN
7.0_CD
p_NN
2.4_CD
p_NN
2001_CD
2002_CD
restated_VBN
Equity_NOMZ
shareholders_NN
funds_NN
m_VPRT
m_NN
Equity_NOMZ
shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
6,581_CD
7,390_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Fixed_JJ
assets_NN
215_CD
170_CD
Investments_NOMZ
829_CD
879_CD
Intangible_JJ
assets_NN
and_PHC
goodwill_NN
36,141_CD
40,478_CD
Unrealised_JJ
gains_NN
on_PIN
marketable_JJ
securities_NOMZ
113_CD
163_CD
Employee_NN
costs_NN
1,198_CD
299_CD
Employee_NN
Share_NN
Ownership_NN
Trust_NN
2,826_CD
2,936_CD
Restructuring_GER
costs_NN
6_CD
46_CD
Derivative_JJ
instruments_NOMZ
98_CD
29_CD
Dividends_NN
754_CD
718_CD
Deferred_JJ
taxation_NOMZ
5,779_CD
7,037_CD
Shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
34,922_CD
40,107_CD
Certain_NN
items_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2001_CD
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
for_PIN
comparative_JJ
purposes_NN
._.
A_DT
summary_NN
of_PIN
the_DT
material_NN
differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
that_TSUB
apply_VB
to_PIN
the_DT
Group_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Annual_JJ
Report_NN
2002_CD
._.
Changes_NN
arising_VBG [WZPRES]
in_PIN
2002_CD
are_VPRT
as_IN
follows_VPRT
:_:
During_PIN
2002_CD
FRS_NN
19_CD
Deferred_JJ
tax_NN
has_VPRT [PEAS]
been_VBN [BYPA]
implemented_VBN
by_PIN
the_DT
Group_NN
under_IN
UK_NN
GAAP_NN
._.
This_DEMO
FRS_NN
requires_VPRT [SUAV]
deferred_JJ
tax_NN
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
on_PIN
a_DT
full_JJ
provision_NN
basis_NN
,_,
rather_CONJ
than_PIN
a_DT
partial_JJ
provision_NN
basis_NN
as_IN
in_PIN
2001_CD
and_CC
earlier_TIME
years_NN
._.
This_DEMO
change_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
prior_JJ
period_NN
adjustment_NOMZ
for_PIN
UK_NN
GAAP_NN
purposes_NN
and_CC
comparative_JJ
adjustments_NOMZ
to_TO
arrive_VB
at_PIN
US_FPP1
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
as_RB
necessary_JJ
._.
This_DEMO
change_NN
has_VPRT [PEAS]
had_VBN
no_SYNE
impact_NN
on_PIN
US_FPP1
GAAP_NN
results_NN
._.
The_DT
Group_NN
adopted_VBD
SFAS_NN
142_CD
,_,
Goodwill_NN
and_CC
other_JJ
Intangible_NN
Assets_NN
as_IN
of_PIN
1st_CD
January_NN
2002_CD
._.
The_DT
implementation_NOMZ
of_PIN
SFAS_NN
142_CD
resulted_VBD
in_PIN
no_SYNE
impairment_NOMZ
of_PIN
the_DT
Groups_NN
goodwill_NN
and_CC
a_DT
revised_VBN
initial_JJ
impairment_NOMZ
of_PIN
173_CD
million_CD
127_CD
million_CD
net_NN
of_PIN
tax_NN
on_PIN
indefinite_JJ
lived_VBD
assets_NN
._.
This_DEMP
is_VPRT [PASS]
shown_VBN [PRIV]
as_IN
a_DT
cumulative_JJ
effect_NN
of_PIN
an_DT
accounting_GER
change_NN
._.
In_CONJ
addition_NULL
,_,
during_PIN
2002_CD
the_DT
Group_NN
decided_VBD [SUAV] [PRIV]
to_TO
align_VB
the_DT
measurement_NOMZ
date_NN
for_PIN
all_QUAN
of_PIN
its_PIT
pension_NN
plans_NN
._.
The_DT
impact_NN
,_,
reflected_VBD [PRIV]
as_IN
a_DT
cumulative_JJ
effect_NN
of_PIN
an_DT
accounting_GER
change_NN
,_,
was_VBD [BEMA]
a_DT
37_CD
million_CD
credit_NN
,_,
net_NN
of_PIN
tax_NN
,_,
to_PIN
income_NN
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
24_CD
|_NN
25_CD
SUMMARY_NN
REMUNERATION_NOMZ
REPORT_NN
for_PIN
the_DT
year_NN
to_PIN
31st_CD
December_NN
2002_CD
The_DT
Summary_NN
remuneration_NOMZ
report_NN
sets_VPRT
out_PIN
the_DT
annual_JJ
remuneration_NOMZ
earned_VBN [WZPAST]
in_PIN
2002_CD
together_RB
with_PIN
any_QUAN
gains_NN
under_IN
long-term_JJ
incentive_NN
arrangements_NOMZ
._.
It_PIT
also_RB
describes_VPRT
the_DT
background_NN
to_TO
and_CC
outlines_VPRT
the_DT
Groups_NN
remuneration_VPRT
policy_NN
together_RB
with_PIN
the_DT
performance_NN
graph_NN
as_IN
required_VBN [SUAV]
by_PIN
schedule_NN
7A_NN
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
The_DT
Directors_NN
Remuneration_NOMZ
report_NN
Regulations_NOMZ
2002_CD
,_,
schedule_NN
7A_NN
._.
Annual_JJ
remuneration_NOMZ
2002_CD
2001_CD
Total_JJ
Total_JJ
Fees_NN
and_CC
Other_JJ
Annual_JJ
annual_JJ
annual_JJ
salary_NN
benefits_NN
bonus_NN
remuneration_NOMZ
remuneration_NOMZ
Directors_NN
of_PIN
GlaxoSmithKline_NN
000 000 000 000_CD
000_CD
Dr_NN
J_NN
P_NN
Garnier_NN
967_CD
132_CD
1,353_CD
2,452_CD
3,450_CD
Mr_NN
J_NN
D_NN
Coombe_NN
475 15 457 947_CD
1,326_CD
Executive_NN
Directors_NN
1,442_CD
147_CD
1,810_CD
3,399_CD
4,776_CD
Sir_NN
Richard_NN
Sykes_NN
154_CD
8_CD
162_CD
414_CD
Sir_NN
Christopher_NN
Hogg_NN
252_CD
252_CD
63_CD
Sir_NN
Roger_NN
Hurn_NN
121 121 135_CD
Sir_NN
Peter_NN
Walters_NN
51_CD
2_CD
53_CD
136_CD
Mr_NN
P_NN
A_NN
Allaire_NN
68_CD
68_CD
68_CD
Dr_NN
M_NN
Barzach_NN
100 100 102_CD
Mr_NN
D_NN
C_NN
Bonham_NN
5_CD
5_CD
29_CD
Sir_NN
Peter_NN
Job_NN
59_CD
59_CD
63_CD
Mr_NN
J_NN
H_NN
McArthur_NN
62_CD
62_CD
73_CD
Mr_NN
D_NN
F_NN
McHenry_NN
62_CD
62_CD
68_CD
Sir_NN
Ian_NN
Prosser_NN
59_CD
59_CD
63_CD
Dr_NN
R_NN
Schmitz_NN
69_CD
69_CD
70_CD
Dr_NN
L_NN
Shapiro_NN
62_CD
62_CD
68_CD
Mr_NN
J_NN
A_NN
Young_NN
29_CD
2_CD
31_CD
80_CD
Non-Executive_JJ
Directors_NN
1,148_CD
17_CD
1,165_CD
1,432_CD
Total_JJ
remuneration_NOMZ
2,590_CD
164_CD
1,810_CD
4,564_CD
6,208_CD
Sir_NN
Richard_NN
Sykes_NN
,_,
Sir_NN
Peter_NN
Walters_NN
and_PHC
Mr_NN
Young_NN
retired_VBD
from_PIN
the_DT
Board_NN
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
on_PIN
20th_JJ
May_POMD
2002_CD
._.
Following_VBG [PRESP]
their_TPP3
retirement_NOMZ
they_TPP3
received_VBD
the_DT
value_NN
of_PIN
their_TPP3
shares_NN
and_PHC
ADSs_NN
as_IN
awarded_VBN
under_IN
the_DT
Non-Executive_NN
Directors_NN
share_VPRT
arrangements_NOMZ
and_CC
equivalent_JJ
SmithKline_NN
Beecham_NN
arrangements_NOMZ
._.
As_IN
at_PIN
20th_JJ
May_POMD
2002_CD
they_TPP3
had_VBD [PEAS]
been_VBN [PASS]
awarded_VBN
shares_NN
and_PHC
ADSs_NN
with_PIN
a_DT
total_JJ
value_NN
at_PIN
the_DT
date_NN
of_PIN
award_NN
,_,
as_IN
indicated_VBN [PRIV]
:_:
Sir_NN
Richard_NN
Sykes_NN
135,530_CD
:_:
Sir_NN
Peter_NN
Walters_NN
249,876_CD
:_:
Mr_NN
Young_NN
187,034_CD
._.
On_PIN
20th_JJ
May_POMD
2002_CD
the_DT
value_NN
of_PIN
the_DT
shares_NN
and_PHC
ADSs_NN
paid_VBN [WZPAST]
to_PIN
them_TPP3
was_VBD
:_:
Sir_NN
Richard_NN
Sykes_NN
122,860_CD
:_:
Sir_NN
Peter_NN
Walters_NN
241,468_CD
:_:
Mr_NN
Young_NN
174,354_CD
._.
The_DT
change_NN
in_PIN
value_NN
is_VPRT [BEMA]
attributable_PRED
to_PIN
dividends_NN
re-invested_JJ
and_CC
the_DT
change_NN
in_PIN
share_NN
price_NN
between_PIN
the_DT
dates_NN
of_PIN
award_NN
and_CC
20th_JJ
May_POMD
2002_CD
._.
Mr_NN
Young_NN
has_VPRT [PEAS]
elected_VBN
to_TO
receive_VB
the_DT
value_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
in_PIN
three_CD
equal_JJ
annual_JJ
instalments_NOMZ
and_CC
,_,
accordingly_RB
,_,
received_VBD
58,118_CD
in_PIN
2002_CD
._.
Following_VBG
Sir_NN
Richard_NN
Sykes_NN
retirement_NOMZ
from_PIN
the_DT
Board_NN
,_,
and_ANDC
in_PIN
recognition_NOMZ
of_PIN
his_TPP3
services_NN
to_PIN
the_DT
Company_NN
,_,
the_DT
Board_NN
decided_VBD [SUAV] [PRIV]
to_TO
make_VB
an_DT
augmentation_NOMZ
payment_NOMZ
to_PIN
the_DT
pension_NN
plan_NN
of_PIN
300,000_CD
in_PIN
respect_NN
of_PIN
Sir_NN
Richard_NN
._.
It_PIT
was_VBD [SPAU] [PASS]
also_RB
agreed_VBN [SUAV] [PUBV]
that_THVC
for_PIN
a_DT
period_NN
of_PIN
two_CD
years_NN
from_PIN
1st_CD
June_NN
2002_CD
Sir_NN
Richard_NN
be_VB [PASS]
appointed_VBN
Senior_JJ
Advisor_NN
to_PIN
the_DT
company_NN
,_,
at_PIN
a_DT
salary_NN
of_PIN
49,000_CD
per_PIN
annum_NN
and_CC
he_TPP3
received_VBD
28,583_CD
in_PIN
respect_NN
of_PIN
the_DT
period_NN
from_PIN
1st_CD
June_NN
2002_CD
to_PIN
31st_CD
December_NN
2002_CD
in_CONJ
addition_NULL
to_PIN
the_DT
fees_NN
and_PHC
salary_NN
above_PLACE
._.
Mr_NN
Bonham_NN
resigned_VBD
as_IN
a_DT
Non-Executive_JJ
Director_NN
on_PIN
21st_CD
May_POMD
2001_CD
._.
During_PIN
2002_CD
Mr_NN
Bonham_NN
received_VBD
5,000_CD
in_PIN
respect_NN
of_PIN
2001_CD
and_CC
the_DT
value_NN
of_PIN
his_TPP3
shares_NN
,_,
as_RB
at_PIN
21st_CD
May_POMD
2001_CD
,_,
as_IN
allocated_VBN
under_IN
the_DT
Non-Executive_NN
Directors_NN
share_VPRT
arrangements_NOMZ
._.
As_IN
at_PIN
21st_CD
May_POMD
2001_CD
he_TPP3
had_VBD [PEAS]
been_VBN [PASS]
awarded_VBN
shares_NN
valued_VBN [WZPAST]
at_PIN
4,539_CD
at_PIN
the_DT
date_NN
of_PIN
award_NN
._.
On_PIN
21st_CD
May_POMD
2001_CD
these_DEMO
shares_NN
were_VBD [BEMA]
worth_PRED
4,860_CD
._.
The_DT
change_NN
in_PIN
value_NN
is_VPRT [BEMA]
attributable_PRED
to_PIN
dividends_NN
re-invested_JJ
and_CC
the_DT
change_NN
in_PIN
share_NN
price_NN
between_PIN
the_DT
date_NN
of_PIN
award_NN
and_CC
21st_JJ
May_POMD
2001_CD
._.
As_IN
set_VBN
out_PIN
on_PIN
page_NN
27_CD
,_,
Non-Executive_JJ
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
receive_VB
a_DT
significant_JJ
part_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
and_CC
may_POMD [SPAU]
also_RB
elect_VB
to_TO
invest_VB
part_NN
or_CC
all_QUAN
of_PIN
the_DT
balance_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
._.
The_DT
value_NN
of_PIN
these_DEMO
shares_NN
and_PHC
ADSs_NN
at_PIN
the_DT
dates_NN
of_PIN
award_NN
are_VPRT [PASS]
included_VBN
in_PIN
fees_NN
and_PHC
salary_NN
above_PLACE
._.
These_DEMO
shares_NN
and_PHC
ADSs_NN
are_VPRT [PASS]
not_XX0
paid_VBN
out_PIN
until_IN
the_DT
Directors_NN
retirement_NOMZ
from_PIN
the_DT
Board_NN
._.
In_CONJ
addition_NULL
to_PIN
annual_JJ
compensation_NOMZ
,_,
GlaxoSmithKline_NN
operates_VPRT
share-based_JJ
schemes_NN
to_TO
provide_VB
incentives_NN
to_PIN
Executive_NN
Directors_NN
to_TO
achieve_VB
longer-term_JJ
growth_NN
in_PIN
shareholder_NN
value_NN
._.
Gains_NN
under_IN
such_JJ
schemes_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
exercise_NN
or_CC
award_NN
,_,
but_CC
reflect_VPRT [PRIV] [THATD]
value_NN
earned_VBN
over_IN
a_DT
period_NN
of_PIN
years_NN
._.
The_DT
timing_NN
of_PIN
exercise_NN
is_VPRT [BEMA]
normally_RB
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Director_NN
._.
Realised_VBN [PRIV]
gains_NN
in_PIN
2002_CD
on_PIN
exercise_NN
of_PIN
options_NOMZ
were_VBD
:_:
share_NN
option_NOMZ
schemes_NN
nil_VPRT
2001_CD
2,408,992_CD
:_:
long-term_JJ
incentive_NN
plan_NN
293,370_CD
2001_CD
3,307,203_CD
._.
In_PIN
previous_JJ
years_NN
,_,
Dr_NN
Garniers_NN
fees_NN
and_PHC
salary_NN
included_VBD
GlaxoSmithKlines_NN
match_NN
on_PIN
compensation_NOMZ
that_DEMP
is_VPRT [PASS]
deferred_VBN
._.
For_PIN
2002_CD
this_DEMP
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
within_PIN
contributions_NOMZ
to_PIN
money_NN
purchase_NN
schemes_NN
._.
Dr_NN
Garniers_NN
fees_NN
and_PHC
salary_NN
for_PIN
2001_CD
have_VPRT [PEAS]
been_VBN [BYPA]
restated_VBN
by_PIN
58,419_CD
,_,
reflecting_VBG [PRIV]
GlaxoSmithKlines_NN
match_NN
in_PIN
2001_CD
,_,
in_PIN
order_NN
to_TO
provide_VB
consistent_JJ
presentation_NOMZ
._.
The_DT
accrued_VBN
annual_JJ
benefits_NN
under_IN
the_DT
defined_VBN
benefit_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
were_VBD
:_:
Dr_VB
J_NN
P_NN
Garnier_NN
929,193_CD
:_:
Mr_NN
J_NN
D_NN
Coombe_NN
290,834_CD
:_:
Sir_NN
Richard_NN
Sykes_NN
729,046_CD
._.
In_CONJ
addition_NULL
,_,
Dr_NN
J_NN
P_NN
Garnier_NN
is_VPRT [BEMA]
also_RB
a_DT
member_NN
of_PIN
a_DT
money_NN
purchase_NN
scheme_NN
into_PIN
which_WDT [PIRE]
contributions_NOMZ
of_PIN
92,800_CD
were_VBD [PASS]
paid_VBN
._.
None_INPR
of_PIN
the_DT
above_PLACE
Directors_NN
received_VBD
expenses_NN
during_PIN
the_DT
year_NN
requiring_VBG [SUAV] [WZPRES]
separate_JJ
disclosure_NN
as_IN
defined_VBN
by_PIN
schedule_NN
7A_NN
._.
SUMMARY_NN
REMUNERATION_NOMZ
REPORT_NN
continued_VBD
for_PIN
the_DT
year_NN
to_PIN
31st_CD
December_NN
2002_CD
The_DT
Remuneration_NOMZ
Committee_NN
The_NN
majority_NOMZ
of_PIN
these_DEMP
are_VPRT [BEMA]
US-based_JJ
companies_NN
which_WDT [WHSUB]
operate_VPRT
In_PIN
reviewing_VBG
governance_NN
arrangements_NOMZ
,_,
the_DT
Board_NN
decided_VBD [SUAV] [PRIV]
during_PIN
globally_RB
._.
These_DEMO
companies_NN
are_VPRT
competing_VBG
for_PIN
the_DT
same_JJ
talent_NN
and_CC
the_DT
year_NN
to_TO
separate_VB
the_DT
roles_NN
of_PIN
the_DT
former_JJ
Remuneration_NOMZ
and_CC
any_QUAN
perceived_VBN [PRIV]
shortfall_NN
in_PIN
GlaxoSmithKlines_NN
competitive_JJ
position_NOMZ
Nominations_NOMZ
R&N_NN
Committee_NN
in_PIN
order_NN
to_TO
give_VB
a_DT
separate_JJ
individual_NN
could_POMD
lead_VB
to_PIN
a_DT
loss_NN
of_PIN
key_JJ
talent_NN
to_PIN
competitor_NN
companies_NN
._.
Board_NN
focus_NN
to_PIN
both_DT
functions_NOMZ
._.
Accordingly_RB
,_,
a_DT
Remuneration_NOMZ
Committee_NN
,_,
with_PIN
terms_NN
of_PIN
reference_NN
revised_VBN
to_TO
take_VB
into_PIN
account_NN
GlaxoSmithKlines_NN
remuneration_VPRT
policy_NN
was_VBD [PASS]
set_VBN
out_PIN
at_PIN
the_DT
time_NN
latest_JJ
governance_NN
standards_NN
,_,
assumed_VBD [PRIV]
the_DT
remuneration_NOMZ
of_PIN
the_DT
merger_NN
,_,
endorsed_VBN [PASTP]
by_PIN
shareholders_NN
then_RB
,_,
and_ANDC
has_VPRT [PEAS]
made_VBN
responsibilities_NOMZ
of_PIN
the_DT
previous_JJ
R&N_NN
Committee_NN
in_PIN
October_NN
2002_CD
._.
a_DT
major_JJ
contribution_NOMZ
to_PIN
the_DT
success_NN
of_PIN
the_DT
merger_NN
._.
The_DT
members_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
are_VPRT [PASS]
set_VBN
out_PIN
on_PIN
page_NN
16_CD
._.
Remuneration_NOMZ
policy_NN
GlaxoSmithKlines_NN
remuneration_NOMZ
policy_NN
is_VPRT
to_TO
pay_VB
at_PIN
industry_NN
Remit_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
competitive_JJ
levels_NN
with_PIN
a_DT
heavy_JJ
emphasis_NN
on_PIN
pay_NN
for_PIN
performance_NN
The_DT
Remuneration_NOMZ
Committee_NN
considers_VPRT [PRIV]
and_CC
regularly_RB
reviews_NN
and_CC
at_PIN
risk_NN
remuneration_NOMZ
._.
The_DT
policy_NN
is_VPRT [PASS]
designed_VBN
to_TO
:_:
the_DT
Groups_NN
policy_NN
on_PIN
Executive_NN
remuneration_NOMZ
for_PIN
approval_NN
by_PIN
the_DT
Board_NN
and_CC
determines_VPRT [SUAV] [PRIV]
the_DT
individual_JJ
remuneration_NOMZ
packages_NN
focus_VB
on_PIN
long-term_JJ
sustained_VBN
success_NN
of_PIN
the_DT
members_NN
of_PIN
the_DT
CET_NN
._.
focus_NN
on_PIN
shareholder_NN
value_NN
through_PIN
a_DT
strong_JJ
emphasis_NN
on_PIN
share_NN
plans_NN
Towers_NN
Perrin_NN
,_,
a_DT
leading_JJ
firm_NN
of_PIN
remuneration_NOMZ
and_PHC
benefits_NN
set_VPRT
high_JJ
levels_NN
of_PIN
minimum_JJ
achievement_NOMZ
consultants_NN
,_,
advises_VPRT
the_DT
Remuneration_NOMZ
Committee_NN
with_PIN
regard_NN
ensure_VB [SUAV] [PRIV]
integrated_VBN
performance_NN
assessment_NOMZ
throughout_PIN
the_DT
to_PIN
the_DT
remuneration_NOMZ
of_PIN
senior_JJ
executive_JJ
management_NOMZ
and_CC
the_DT
management_NOMZ
team_NN
to_TO
deliver_VB
concerted_JJ
action_NOMZ
towards_PIN
success_NN
Non-Executive_NN
Directors_NN
._.
In_PIN
2003_CD
,_,
the_DT
Remuneration_NOMZ
Committee_NN
provide_VPRT
opportunities_NOMZ
to_TO
earn_VB
globally_RB
competitive_JJ
rewards_NN
,_,
engaged_VBD
Deloitte_NN
&_CC
Touche_NN
to_TO
conduct_VB
an_DT
additional_JJ
independent_JJ
but_CC
only_DWNT
if_COND
performance_NN
is_VPRT [PASS]
delivered_VBN
._.
review_NN
of_PIN
GlaxoSmithKlines_NN
current_JJ
remuneration_NOMZ
policy_NN
._.
GlaxoSmithKlines_NN
executive_JJ
remuneration_NOMZ
consists_VPRT
of_PIN
four_CD
Background_NN
components_NN
:_:
salary_NN
,_,
performance_NN
bonus_NN
,_,
long-term_JJ
incentives_NN
GlaxoSmithKline_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
worlds_NN
leading_VBG [WZPRES]
research-based_JJ
and_CC
benefits_NN
._.
The_DT
relative_JJ
importance_NN
for_PIN
the_DT
Executive_NN
Directors_NN
pharmaceutical_JJ
and_CC
healthcare_NN
companies_NN
._.
As_IN
such_JJ
,_,
it_PIT
has_VPRT
to_PIN
of_PIN
the_DT
fixed_VBN
and_CC
variable_JJ
elements_NOMZ
of_PIN
pay_NN
is_VPRT [PASS]
illustrated_VBN
in_PIN
the_DT
be_VB [BEMA]
global_PRED
in_PIN
outlook_NN
and_PHC
operations_NOMZ
._.
The_DT
Group_NN
employs_VPRT
over_IN
table_NN
below_PLACE
:_:
100,000_CD
people_NN
in_PIN
over_IN
100_CD
countries_NN
._.
Over_IN
90_CD
per_PIN
cent_NN
of_PIN
Fixed_NN
Performance-related_JJ
its_PIT
sales_NN
are_VPRT [PASS]
generated_VBN
outside_PLACE
the_DT
UK_NN
._.
Short-term_JJ
incentives_NN
Long-term_JJ
incentives_NN
Base_NN
pay_NN
Performance_NN
bonus_NN
Share_NN
option_NOMZ
Performance_NN
The_NN
USA_NN
is_VPRT [BEMA]
the_DT
largest_JJ
pharmaceutical_JJ
market_NN
in_PIN
the_DT
world_NN
plan_NN
share_NN
plan_NN
and_CC
is_VPRT [BEMA]
fundamental_PRED
to_PIN
GlaxoSmithKlines_NN
success_NN
and_PHC
profitability_NOMZ
._.
Measures_NN
More_EMPH
than_PIN
50_CD
per_PIN
cent_NN
of_PIN
GlaxoSmithKlines_NN
pharmaceutical_JJ
Operating_GER
financial_JJ
EPS_NN
growth_NN
of_PIN
9_CD
TSR_NN
vs_NN
FTSE_NN
100_CD
sales_NN
are_VPRT [BEMA]
in_PIN
the_DT
USA_NN
._.
The_DT
CEO_NN
is_VPRT [PASS]
based_VBN
there_RB
,_,
along_IN
with_PIN
another_DT
measures_NN
percentage_NN
points_NN
EPS_NN
growth_NN
of_PIN
9_CD
eight_CD
of_PIN
the_DT
thirteen_VBN
person_NN
CET_NN
._.
greater_JJ
than_PIN
Retail_NN
percentage_NN
points_NN
Performance_NN
against_PIN
Price_NN
Index_NN
RPI_NN
greater_JJ
than_PIN
RPI_NN
individual_JJ
objectives_NN
over_IN
3_CD
years_NN
over_IN
3_CD
years_NN
The_DT
pharmaceutical_JJ
industry_NN
is_VPRT [BEMA]
international_PRED
,_,
highly_AMP
specialised_VBN
and_PHC
is_VPRT [BYPA]
characterised_VBN
by_PIN
a_DT
handful_NN
of_PIN
global_JJ
companies_NN
which_WDT [WHOBJ]
15-25_CD
%_NN
75-85_CD
%_NN
compete_VPRT
as_IN
intensely_AMP
for_PIN
talent_NN
as_IN
they_TPP3
do_VPRT [PROD]
for_PIN
business_NOMZ
._.
The_DT
industrys_NN
top_JJ
managers_NN
and_PHC
scientists_NN
are_VPRT [BEMA]
very_AMP
much_QUAN
in_PIN
To_TO
provide_VB
appropriate_JJ
incentives_NN
for_PIN
exceptional_JJ
performance_NN
,_,
the_DT
demand_NN
,_,
widely_RB
known_VBN [PRIV]
in_PIN
the_DT
industry_NN
and_CC
are_VPRT
internationally_RB
Committees_NN
policy_NN
is_VPRT
to_TO
provide_VB
market_NN
referenced_VBD
opportunities_NOMZ
and_CC
corporately_JJ
mobile_JJ
._.
The_DT
way_NN
all_QUAN
managers_NN
and_PHC
scientists_NN
beyond_IN
this_DEMO
for_PIN
truly_RB
outstanding_JJ
performance_NN
._.
However_CONJ
,_,
the_DT
in_PIN
GlaxoSmithKline_NN
are_VPRT [PASS]
rewarded_VBN
and_PHC
developed_VBN
therefore_CONJ
has_VPRT
Committee_NN
is_VPRT [BEMA]
aware_PRED
that_THAC
current_JJ
levels_NN
of_PIN
long-term_JJ
incentives_NN
to_TO
be_VB [BEMA]
industry-competitive_PRED
._.
It_PIT
is_VPRT [BEMA]
crucial_PRED
to_PIN
their_TPP3
retention_NOMZ
and_CC
do_VB
not_XX0
deliver_VB
this_DEMO
policy_NN
._.
Independent_JJ
market_NN
data_NN
demonstrate_VPRT [PRIV]
effectiveness_NOMZ
._.
Key_NN
market_NN
data_NN
with_PIN
regard_NN
to_TO
remuneration_VB
that_DEMO
GlaxoSmithKlines_NN
top_JJ
management_NOMZ
remuneration_NOMZ
is_VPRT [BEMA]
currently_RB
for_PIN
senior_JJ
management_NOMZ
,_,
science_NN
based_VBN
positions_NOMZ
and_PHC
sales_NN
uncompetitive_JJ
with_PIN
regard_NN
to_PIN
long-term_JJ
incentives_NN
._.
As_CONJ
a_NULL
result_NULL
is_VPRT [BYPA]
provided_VBN
by_PIN
a_DT
survey_NN
which_WDT [WHSUB]
covers_VPRT
the_DT
following_JJ
group_NN
of_PIN
their_TPP3
total_JJ
remuneration_NOMZ
opportunity_NOMZ
for_PIN
2002_CD
was_VBD
well_RB
below_PLACE
global_JJ
pharmaceutical_JJ
companies_NN
the_DT
competitor_NN
panel_NN
:_:
the_DT
industry_NN
median_NN
._.
Abbott_NN
Laboratories_NN
US_FPP1
Novartis_NN
Switzerland_NN
The_NN
Remuneration_NOMZ
Committee_NN
will_PRMD
continue_VB
to_TO
monitor_VB
closely_RB
AstraZeneca_NN
UK_NN
Pfizer_NN
US_FPP1
the_DT
quantum_NN
and_PHC
trend_NN
of_PIN
our_FPP1
competitors_NN
awards_NN
and_CC
will_PRMD
consider_VB [PRIV]
Aventis_NN
France_NN
Pharmacia_NN
US_FPP1
what_WDT
should_NEMD
be_VB [PASS]
done_VBN [PROD]
in_PIN
the_DT
best_JJ
interests_NN
of_PIN
the_DT
company_NN
and_PHC
Bristol-Myers_NN
Squibb_NN
US_FPP1
Roche_NN
Switzerland_NN
its_PIT
shareholders_NN
._.
Eli_NN
Lilly_NN
US_FPP1
Schering-Plough_NN
US_FPP1
Johnson_NN
&_CC
Johnson_NN
US_FPP1
Wyeth_NN
US_FPP1
The_NN
vesting_GER
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
Executive_NN
Directors_NN
is_VPRT [BEMA]
subject_JJ
Merck_NN
US_FPP1
to_PIN
the_DT
performance_NN
condition_NOMZ
that_DEMO
business_NOMZ
performance_NN
earnings_GER
per_PIN
share_NN
EPS_NN
growth_NN
,_,
excluding_VBG
currency_NN
and_CC
exceptional_JJ
items_NN
,_,
should_NEMD
be_VB [BEMA]
at_PIN
least_JJ
nine_CD
percentage_NN
points_NN
more_EMPH
than_PIN
the_DT
increase_NN
in_PIN
the_DT
UK_NN
Retail_NN
Price_NN
Index_NN
over_IN
any_QUAN
three_CD
year_NN
measurement_NOMZ
period_NN
._.
ANNUAL_JJ
REVIEW_NN
2002_CD
26_CD
|_NN
27_CD
SUMMARY_NN
REMUNERATION_NOMZ
REPORT_NN
continued_VBD
SHAREHOLDER_NN
INFORMATION_NOMZ
for_PIN
the_DT
year_NN
to_PIN
31st_CD
December_NN
2002_CD
Vesting_GER
of_PIN
awards_NN
granted_VBN [SUAV]
under_IN
the_DT
performance_NN
share_NN
plan_NN
are_VPRT [BEMA]
Ordinary_JJ
shares_NN
subject_JJ
to_PIN
two_CD
performance_NN
conditions_NOMZ
each_QUAN
relating_VBG
to_PIN
half_DT
of_PIN
the_DT
The_DT
companys_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
._.
awards_NN
,_,
business_NOMZ
performance_NN
EPS_NN
growth_NN
as_IN
for_PIN
share_NN
options_NOMZ
and_CC
Total_JJ
Shareholder_NN
Return_NN
TSR_NN
whereby_OSUB
GlaxoSmithKlines_NN
TSR_NN
Registrar_NN
is_VPRT [PASS]
compared_VBN
to_PIN
the_DT
TSR_NN
of_PIN
companies_NN
in_PIN
the_DT
UK_NN
FTSE_NN
100_CD
Index_NN
The_DT
companys_NN
share_VPRT
register_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
Lloyds_NN
TSB_NN
Registrars_NN
,_,
over_IN
the_DT
same_JJ
period_NN
._.
Even_RB
if_COND
these_DEMO
performance_NN
conditions_NOMZ
are_VPRT [PASS]
met_VBN
,_,
who_WP
also_RB
provide_VPRT
the_DT
following_JJ
services_NN
:_:
vesting_GER
of_PIN
these_DEMO
awards_NN
made_VBD
to_PIN
the_DT
CET_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
approval_NN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
._.
These_DEMO
conditions_NOMZ
were_VBD [PASS]
selected_VBN
at_PIN
GlaxoSmithKline_NN
Investment_NOMZ
Plan_NN
enables_VPRT
shareholders_NN
to_PIN
the_DT
time_NN
of_PIN
the_DT
merger_NN
and_PHC
aim_NN
to_TO
achieve_VB
a_DT
balance_NN
between_PIN
the_DT
reinvest_VPRT
quarterly_JJ
dividends_NN
and_CC
or_CC
make_VB
monthly_JJ
investments_NOMZ
in_PIN
expectations_NOMZ
of_PIN
UK_NN
institutional_JJ
investors_NN
and_CC
global_JJ
market_NN
practice_NN
._.
the_DT
company_NN
's_POS
ordinary_JJ
shares_NN
using_VBG [WZPRES]
a_DT
special_JJ
dealing_GER
arrangement_NOMZ
._.
Executive_NN
Directors_NN
are_VPRT [PASS]
employed_VBN
under_IN
service_NN
contracts_NN
in_PIN
which_WDT [PIRE]
GlaxoSmithKline_NN
Individual_NN
Savings_GER
Account_NN
is_VPRT [BEMA]
a_DT
the_DT
employing_VBG
company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
give_VB
24_CD
calendar_NN
months_NN
tax-efficient_JJ
way_NN
to_TO
invest_VB
in_PIN
the_DT
companys_NN
ordinary_JJ
shares_NN
._.
notice_NN
of_PIN
termination_NOMZ
and_CC
the_DT
Executive_NN
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
give_VB
12_CD
calendar_NN
months_NN
notice_VPRT [PRIV]
._.
Dr_NN
JP_NN
Garniers_NN
service_NN
agreement_NOMZ
GlaxoSmithKline_NN
Corporate_NN
Sponsored_NN
Nominee_NN
provides_VPRT
expires_VPRT
on_PIN
31st_CD
October_NN
2007_CD
and_CC
Mr_NN
Coombes_NN
expires_VPRT
on_PIN
a_DT
facility_NOMZ
for_PIN
shareholders_NN
to_TO
hold_VB [PRIV]
shares_NN
without_PIN
the_DT
need_NN
31st_CD
March_NN
2005_CD
._.
The_DT
compensation_NOMZ
to_TO
be_VB [PASS]
paid_VBN
in_PIN
the_DT
event_NN
for_PIN
share_NN
certificates_NN
._.
Shareholders_NN
details_NN
will_PRMD
not_XX0
be_VB [PASS]
held_VBN [PRIV]
of_PIN
termination_NOMZ
includes_VPRT
salary_NN
,_,
incentives_NN
and_PHC
pensions_NN
._.
on_PIN
the_DT
main_JJ
share_NN
register_NN
,_,
and_ANDC
so_RB
will_PRMD
remain_VB
confidential_JJ
._.
Non-Executive_JJ
Directors_NN
of_PIN
GlaxoSmithKline_NN
do_VPRT
not_XX0
have_VB
service_NN
Shareview_NN
service_NN
provides_VPRT
shareholders_NN
with_PIN
information_NOMZ
contracts_NN
but_CC
instead_CONJ
have_VPRT
letters_NN
of_PIN
appointment_NOMZ
._.
To_TO
enhance_VB
on_PIN
their_TPP3
investment_NOMZ
in_PIN
the_DT
company_NN
._.
Shareholders_NN
may_POMD
register_VB
the_DT
link_NN
between_PIN
Directors_NN
and_PHC
shareholders_NN
,_,
GlaxoSmithKline_NN
for_PIN
this_DEMO
service_NN
at_PIN
www_NN
._.
co._FW
uk_FW
requires_VPRT [SUAV]
Non-Executive_NN
Directors_NN
to_TO
receive_VB
a_DT
significant_JJ
part_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
allocated_VBN [WZPAST]
to_PIN
a_DT
share_NN
account_NN
and_PHC
Share_NN
dealing_VBG [WZPRES]
facility_NOMZ
offers_VPRT
the_DT
opportunity_NOMZ
to_TO
invest_VB
part_NN
or_CC
all_QUAN
of_PIN
the_DT
balance_NN
of_PIN
fees_NN
NatWest_NN
Stockbrokers_NN
Limited_JJ
offers_VPRT
a_DT
share_NN
dealing_VBG [WZPRES]
service_NN
on_PIN
in_PIN
a_DT
share_NN
account_NN
._.
These_DEMO
shares_NN
are_VPRT [PASS]
not_XX0
paid_VBN
out_PIN
until_IN
the_DT
Directors_NN
behalf_NN
of_PIN
the_DT
company_NN
to_PIN
shareholders_NN
wishing_VBG [WZPRES]
to_TO
buy_VB
or_CC
sell_VB
retirement_NOMZ
from_PIN
the_DT
Board_NN
,_,
or_CC
at_PIN
a_DT
later_TIME
date_NN
,_,
on_PIN
the_DT
basis_NN
of_PIN
the_DT
companys_NN
shares_NN
._.
dividends_NN
being_VBG [WZPRES] [PASS]
reinvested_VBN
in_PIN
the_DT
interim_NN
._.
Share_NN
price_NN
information_NOMZ
Performance_NN
graph_NN
Share_NN
price_NN
information_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
the_DT
companys_NN
website_VPRT
at_PIN
The_DT
new_JJ
regulations_NOMZ
covering_VBG [WZPRES]
Directors_NN
remuneration_NOMZ
require_VPRT [SUAV]
that_THVC
www_NN
._.
Information_NOMZ
made_VBD
available_JJ
on_PIN
the_DT
website_NN
does_VPRT
not_XX0
a_DT
graph_NN
be_VB [PASS]
presented_VBN
showing_VBG [PRIV]
the_DT
companys_NN
total_JJ
shareholder_NN
return_NN
constitute_VPRT
part_NN
of_PIN
this_DEMO
Annual_JJ
Review_NN
._.
Information_NOMZ
is_VPRT [BEMA]
also_RB
available_PRED
on_PIN
TSR_NN
against_PIN
the_DT
TSR_NN
performance_NN
of_PIN
a_DT
broad_JJ
equity_NOMZ
market_NN
index_NN
._.
Ceefax_NN
,_,
Teletext_NN
,_,
and_ANDC
from_PIN
FT_NN
Cityline_NN
by_PIN
calling_VBG
0906 003 5694_CD
or_CC
The_DT
following_JJ
graph_NN
shows_VPRT [PRIV]
GlaxoSmithKlines_NN
TSR_NN
performance_NN
0906 843 5694_CD
calls_VPRT
charged_VBN
at_PIN
60p_CD
a_DT
minute_NN
plus_PIN
VAT_NN
at_PIN
all_QUAN
times_NN
._.
against_PIN
the_DT
FTSE_NN
100_CD
which_WDT
has_VPRT [PEAS]
been_VBN [PASS]
chosen_VBN
because_CAUS
it_PIT
is_VPRT [BEMA]
the_DT
principal_JJ
index_NN
in_PIN
which_WDT [PIRE]
the_DT
companys_NN
shares_NN
are_VPRT [PASS]
quoted_VBN
and_CC
American_JJ
Depositary_NN
Shares_NN
against_PIN
the_DT
competition_NOMZ
panel_NN
set_VBN [WZPAST]
out_PIN
on_PIN
page_NN
26_CD
which_WDT
indicates_VPRT [PRIV]
The_DT
companys_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
GlaxoSmithKlines_NN
relative_JJ
performance_NN
against_PIN
its_PIT
peers_NN
._.
in_PIN
the_DT
form_NN
of_PIN
American_JJ
Depositary_NN
Shares_NN
ADSs_NN
and_CC
these_DEMP
are_VPRT [BYPA]
evidenced_VBN
by_PIN
American_JJ
Depositary_NN
Receipts_NN
ADRs_NN
,_,
each_QUAN
one_CD
of_PIN
which_WDT [PIRE]
represents_VPRT
two_CD
ordinary_JJ
shares_NN
._.
100_CD
ADR_NN
program_NN
administrator_NN
90_CD
The_DT
ADR_NN
program_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
The_DT
Bank_NN
of_PIN
New_NN
York_NN
as_IN
80_CD
well_RB
as_IN
Global_JJ
BuyDIRECT_NN
,_,
a_DT
direct_JJ
ADS_NN
purchase_NN
sale_NN
and_PHC
dividend_NN
reinvestment_NOMZ
plan_NN
for_PIN
ADR_NN
holders_NN
._.
70_CD
60_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
2003_CD
31_CD
12_CD
00_CD
31_CD
12_CD
01_CD
31_CD
12_CD
02_CD
The_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
at_PIN
the_DT
Queen_NN
Elizabeth_NN
II_NN
GSK_NN
Total_NN
Return_NN
Index_NN
GSK_NN
Pharma_NN
Peers_NN
Return_NN
Index_NN
FTSE_NN
100_CD
Total_JJ
Return_NN
Index_NN
Conference_NN
Centre_NN
,_,
Broad_NN
Sanctuary_NN
,_,
Westminster_NN
,_,
London_NN
SW1P_NN
3EE_NN
Notes_NN
on_PIN
19th_JJ
May_POMD
2003_CD
._.
The_DT
TSR_NN
graph_NN
above_PLACE
starts_NN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
first_JJ
accounting_GER
year_NN
following_VBG [WZPRES]
the_DT
formation_NOMZ
of_PIN
GlaxoSmithKline_NN
and_CC
uses_VPRT
,_,
as_IN
a_DT
base_NN
,_,
the_DT
share_NN
SmithKline_NN
Beecham_NN
plc_NN
Floating_VBG [WZPRES]
Rate_NN
Unsecured_JJ
price_NN
on_PIN
31st_CD
December_NN
2000_CD
._.
Calculations_NOMZ
for_PIN
the_DT
graph_NN
are_VPRT [PASS]
based_VBN
on_PIN
spot_NN
Loan_NN
Stock_NN
1990_CD
2010_CD
prices_NN
at_PIN
the_DT
beginning_GER
and_PHC
end_NN
of_PIN
each_QUAN
year_NN
as_IN
required_VBN [SUAV]
by_PIN
the_DT
Directors_NN
The_DT
loan_NN
stock_NN
is_VPRT [PASS]
not_XX0
listed_VBN
on_PIN
any_QUAN
exchange_NN
but_CC
holders_NN
may_POMD
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
,_,
whereas_OSUB
GlaxoSmithKlines_NN
performance_NN
conditions_NOMZ
use_VPRT
average_JJ
prices_NN
over_IN
a_DT
period_NN
of_PIN
a_DT
year_NN
._.
require_VB [SUAV]
SmithKline_NN
Beecham_NN
plc_NN
to_TO
redeem_VB
their_TPP3
loan_NN
stock_NN
at_PIN
par_NN
,_,
Therefore_CONJ
the_DT
above_PLACE
graph_NN
should_NEMD
not_XX0
be_VB [PASS]
taken_VBN
as_IN
an_DT
indication_NOMZ
of_PIN
the_DT
likely_JJ
i._NN
e._FW
1_CD
for_PIN
every_QUAN
1_CD
of_PIN
loan_NN
stock_NN
held_VBN [PRIV]
,_,
on_PIN
the_DT
first_JJ
business_NOMZ
day_NN
of_PIN
vesting_GER
of_PIN
awards_NN
granted_VBN [SUAV]
under_IN
GlaxoSmithKlines_NN
Performance_NN
Share_NN
Plan_NN
._.
March_NN
,_,
June_NN
,_,
September_NN
and_PHC
December_NN
._.
Holders_NN
wishing_VBG [WZPRES]
to_TO
redeem_VB
The_DT
average_JJ
price_NN
method_NN
was_VBD [PASS]
selected_VBN
because_CAUS
it_PIT
smoothes_VPRT
out_PIN
volatility_NOMZ
and_CC
reduces_VPRT
the_DT
impact_NN
of_PIN
any_QUAN
particularly_RB
large_JJ
temporary_JJ
price_NN
movements_NOMZ
all_QUAN
or_CC
part_NN
of_PIN
their_TPP3
loan_NN
stock_NN
should_NEMD
complete_VB
the_DT
notice_NN
on_PIN
the_DT
back_NN
at_PIN
either_CC
the_DT
beginning_GER
or_CC
end_NN
of_PIN
the_DT
performance_NN
period_NN
._.
of_PIN
their_TPP3
loan_NN
stock_NN
certificate_NN
and_CC
return_VB
it_PIT
to_PIN
the_DT
registrar_NN
,_,
to_TO
arrive_VB
2_CD
._.
Past_JJ
performance_NN
should_NEMD
not_XX0
be_VB [PASS]
taken_VBN
as_IN
a_DT
guide_NN
to_PIN
future_JJ
performance_NN
._.
at_PIN
least_JJ
30_CD
days_NN
before_IN
the_DT
relevant_JJ
redemption_NOMZ
date_NN
._.
SHAREHOLDER_NN
INFORMATION_NOMZ
continued_VBD
Financial_JJ
reporting_GER
Market_NN
capitalization_NOMZ
The_DT
market_NN
capitalization_NOMZ
of_PIN
GlaxoSmithKline_NN
at_PIN
31st_CD
December_NN
2002_CD
Financial_NN
reporting_VBG [PUBV] [WZPRES]
calendar_NN
2003_CD
was_VBD [BEMA]
72_CD
billion_CD
._.
At_PIN
that_DEMO
date_NN
GlaxoSmithKline_NN
was_VBD [BEMA]
the_DT
third_JJ
largest_JJ
company_NN
by_PIN
market_NN
capitalization_NOMZ
in_PIN
the_DT
FTSE_NN
index_NN
._.
Announcement_NOMZ
of_PIN
1st_CD
Quarter_NN
Results_NN
30th_JJ
April_NN
2003_CD
Announcement_NOMZ
of_PIN
2nd_CD
Quarter_NN
Results_NN
23rd_JJ
July_NN
2003_CD
Dividends_NN
Announcement_NOMZ
of_PIN
3rd_CD
Quarter_NN
Results_NN
22nd_JJ
October_NN
2003_CD
GlaxoSmithKline_NN
pays_VPRT
dividends_NN
quarterly_RB
._.
At_PIN
present_JJ
it_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
Preliminary_JJ
Announcement_NOMZ
of_PIN
Annual_JJ
Results_NN
12th_JJ
February_NN
2004_CD
that_DEMO
there_EX
will_PRMD
be_VB
a_DT
level_NN
dividend_NN
for_PIN
each_QUAN
of_PIN
the_DT
first_JJ
three_CD
quarters_NN
,_,
Publication_NOMZ
of_PIN
Annual_JJ
Report_NN
Review_NN
March_NN
2004_CD
with_PIN
a_DT
higher_JJ
dividend_NN
in_PIN
the_DT
fourth_JJ
quarter_NN
._.
Each_QUAN
quarters_NN
dividend_NN
is_VPRT [PASS]
announced_VBN [PUBV]
at_PIN
the_DT
time_NN
of_PIN
the_DT
quarterly_JJ
Results_NN
Announcement_NOMZ
._.
Results_NN
Announcements_NOMZ
Results_NN
Announcements_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
LSE_NN
,_,
The_NN
Board_NN
has_VPRT [PEAS]
declared_VBN [PUBV]
dividends_NN
for_PIN
2002_CD
as_IN
follows_VPRT
:_:
and_ANDC
made_VBN
available_JJ
on_PIN
the_DT
LSE_NN
news_NN
service_NN
,_,
and_ANDC
at_PIN
the_DT
same_JJ
time_NN
,_,
or_CC
2002_CD
2001_CD
Dividends_NN
per_PIN
share_NN
pence_NN
pence_NN
shortly_TIME
afterwards_TIME
,_,
are_VPRT [PASS]
issued_VBN
to_PIN
the_DT
media_NN
,_,
are_VPRT [PASS]
made_VBN
available_JJ
on_PIN
the_DT
companys_NN
website_VPRT
and_PHC
are_VPRT [PASS]
filed_VBN
in_PIN
the_DT
USA_NN
with_PIN
the_DT
Securities_NOMZ
and_PHC
First_NN
interim_JJ
paid_VBN
4th_JJ
July_NN
2002_CD
9_CD
9_CD
Exchange_NN
Commission_NN
and_CC
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
Second_JJ
interim_JJ
paid_VBN
3rd_CD
October_NN
2002_CD
9_CD
9_CD
Third_NN
interim_JJ
paid_VBN
3rd_CD
January_NN
2003_CD
9_CD
9_CD
Fourth_JJ
interim_JJ
payable_JJ
17th_JJ
April_NN
2003_CD
13_CD
12_CD
Financial_JJ
reports_NN
The_DT
company_NN
publishes_VPRT
an_DT
Annual_JJ
Report_NN
and_CC
,_,
for_PIN
the_DT
investor_NN
Total_JJ
40_CD
39_CD
not_XX0
needing_VBG
the_DT
full_JJ
detail_NN
of_PIN
the_DT
Report_NN
,_,
an_DT
Annual_JJ
Review_NN
._.
These_DEMP
are_VPRT [BEMA]
available_PRED
from_PIN
the_DT
date_NN
of_PIN
publication_NOMZ
on_PIN
the_DT
GlaxoSmithKline_NN
website_NN
._.
The_DT
Annual_JJ
Review_NN
is_VPRT [PASS]
sent_VBN
to_PIN
all_QUAN
shareholders_NN
on_PIN
the_DT
date_NN
Dividends_NN
ADSs_NN
of_PIN
publication_NOMZ
._.
Shareholders_NN
may_POMD [SPAU]
also_RB
elect_VB
to_TO
receive_VB
the_DT
Report_NN
As_IN
a_DT
guide_NN
to_PIN
holders_NN
of_PIN
ADRs_NN
,_,
the_DT
tables_NN
below_PLACE
set_VBN
out_PIN
the_DT
dividends_NN
by_PIN
writing_VBG [PUBV]
to_PIN
the_DT
Companys_NN
registrars_NN
._.
Alternatively_CONJ
shareholders_NN
paid_VBD
per_PIN
ADS_NN
in_PIN
US_FPP1
dollars_NN
in_PIN
the_DT
last_JJ
five_CD
years_NN
._.
The_DT
dividends_NN
are_VPRT
may_POMD
elect_VB
to_TO
receive_VB
notification_NOMZ
by_PIN
email_NN
of_PIN
the_DT
publication_NOMZ
of_PIN
adjusted_VBN
for_PIN
UK_NN
tax_NN
credit_NN
less_RB
withholding_VBG
tax_NN
,_,
where_RB
applicable_JJ
,_,
financial_JJ
reports_NN
by_PIN
registering_VBG
on_PIN
www_NN
._.
Copies_NN
and_CC
are_VPRT [PASS]
translated_VBN
into_PIN
US_FPP1
dollars_NN
at_PIN
applicable_JJ
exchange_NN
rates_NN
._.
of_PIN
previous_JJ
financial_JJ
reports_NN
are_VPRT [BEMA]
available_PRED
on_PIN
the_DT
companys_NN
website_VPRT
._.
Printed_NN
copies_NN
can_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
companys_NN
registrar_NN
in_PIN
the_DT
Since_OSUB
6th_JJ
April_NN
1999_CD
,_,
claims_VPRT [PUBV]
for_PIN
refunds_NN
of_PIN
tax_NN
credits_NN
on_PIN
dividends_NN
UK_NN
and_CC
from_PIN
the_DT
companys_NN
Customer_NN
Response_NN
Center_NN
in_PIN
the_DT
USA_NN
._.
from_PIN
the_DT
UK_NN
tax_NN
authorities_NOMZ
are_VPRT [BEMA]
of_PIN
negligible_JJ
benefit_NN
to_PIN
US_FPP1
shareholders_NN
._.
Year_NN
GSK_NN
$_$
GW_CD
$_$
SB_CD
$_$
Publications_NOMZ
2002_CD
1.24_CD
This_DEMO
year_NN
GlaxoSmithKline_NN
has_VPRT [SPAU] [PEAS]
again_TIME
produced_VBN
a_DT
separate_JJ
report_NN
2001_CD
1.11_CD
covering_VBG
the_DT
Groups_NN
contribution_NOMZ
to_PIN
society_NN
._.
The_DT
2002_CD
Corporate_JJ
2000_CD
1.10_CD
0.87_CD
and_CC
Social_NN
Responsibility_NOMZ
Report_NN
covers_VPRT
the_DT
issues_NN
that_TSUB
are_VPRT [BEMA]
of_PIN
primary_JJ
1999_CD
1.14_CD
0.86_CD
interest_NN
to_PIN
stakeholders_NN
,_,
including_VBG [PRESP]
the_DT
contribution_NOMZ
to_PIN
society_NN
,_,
business_NOMZ
1998_CD
1.19_CD
0.81_CD
ethics_NN
and_PHC
integrity_NOMZ
,_,
access_NN
to_PIN
medicines_NN
,_,
R&D_NN
,_,
community_NOMZ
investment_NOMZ
,_,
the_DT
environment_NOMZ
and_PHC
health_NN
and_PHC
safety_NN
._.
The_DT
report_NN
is_VPRT [BEMA]
available_PRED
from_PIN
Dividends_NN
paid_VBD
to_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
ADR_NN
the_DT
Secretariat_NN
at_PIN
the_DT
companys_NN
head_VPRT
office_NN
and_CC
the_DT
website_NN
at_PIN
holders_NN
are_VPRT [PASS]
expressed_VBN
as_IN
dividends_NN
per_PIN
GlaxoSmithKline_NN
ADS_NN
._.
Dividend_NN
calendar_NN
Share_NN
price_NN
2002_CD
2001_CD
Fourth_JJ
quarter_NN
2002_CD
Share_NN
price_NN
Ex-dividend_NN
date_NN
19th_JJ
February_NN
2003_CD
At_PIN
1st_CD
January_NN
17.23_CD
18.90_CD
Record_NN
date_NN
21st_CD
February_NN
2003_CD
High_NN
during_PIN
the_DT
year_NN
17.80_CD
20.32_CD
Payable_JJ
17th_JJ
April_NN
2003_CD
Low_NN
during_PIN
the_DT
year_NN
10.57_CD
16.26_CD
At_PIN
31st_CD
December_NN
11.92_CD
17.23_CD
First_JJ
quarter_NN
2003_CD
Decrease_NN
over_IN
year_NN
31_CD
%_NN
9_CD
%_NN
Ex-dividend_NN
date_NN
7th_JJ
May_POMD
2003_CD
Record_NN
date_NN
9th_CD
May_POMD
2003_CD
The_DT
table_NN
sets_VPRT
out_PIN
the_DT
middle_JJ
market_NN
closing_GER
prices_NN
derived_VBN [WZPAST]
from_PIN
Payable_JJ
3rd_CD
July_NN
2003_CD
the_DT
LSE_NN
Daily_NN
Official_NN
List_NN
._.
The_DT
companys_NN
share_VPRT
price_NN
declined_VBD
by_PIN
31_CD
per_PIN
cent_NN
in_PIN
2002_CD
from_PIN
a_DT
price_NN
of_PIN
17.23_CD
at_PIN
1st_CD
January_NN
2002_CD
Second_JJ
quarter_NN
2003_CD
to_PIN
11.92_CD
at_PIN
31st_CD
December_NN
2002_CD
._.
This_DEMP
compares_VPRT
with_PIN
a_DT
decrease_NN
Ex-dividend_NN
date_NN
30th_JJ
July_NN
2003_CD
in_PIN
the_DT
FTSE_NN
100_CD
index_NN
of_PIN
24_CD
per_PIN
cent_NN
during_PIN
the_DT
year_NN
._.
In_PIN
the_DT
two_CD
years_NN
Record_NN
date_NN
1st_CD
August_NN
2003_CD
since_OSUB
the_DT
merger_NN
,_,
the_DT
share_NN
price_NN
has_VPRT [PEAS]
declined_VBN
by_PIN
37_CD
per_PIN
cent_NN
from_PIN
Payable_JJ
2nd_JJ
October_NN
2003_CD
18.90_CD
at_PIN
1st_CD
January_NN
2001_CD
which_WDT
is_VPRT [BEMA]
in_PIN
line_NN
with_PIN
a_DT
similar_JJ
decrease_NN
Third_JJ
quarter_NN
2003_CD
in_PIN
the_DT
FTSE_NN
100_CD
index_NN
over_IN
the_DT
same_JJ
period_NN
._.
Ex-dividend_NN
date_NN
29th_JJ
October_NN
2003_CD
Record_NN
date_NN
31st_CD
October_NN
2003_CD
Payable_JJ
6th_JJ
January_NN
2004_CD
ANNUAL_NN
REVIEW_NN
2002_CD
28_CD
|_NN
29_CD
Internet_NN
United_NN
Kingdom_NN
United_NN
States_NN
of_PIN
America_NN
Information_NOMZ
for_PIN
investors_NN
and_CC
about_IN
the_DT
Investor_NN
relations_NOMZ
Investor_NN
relations_NOMZ
company_NN
is_VPRT [BEMA]
available_PRED
on_PIN
GlaxoSmithKlines_NN
980_CD
Great_NN
West_NN
Road_NN
One_CD
Franklin_NN
Plaza_NN
corporate_JJ
website_NN
at_PIN
www_NN
._.
com_NN
Brentford_NN
PO_NN
Box_NN
7929_CD
Middlesex_NN
TW8_NN
9GS_NN
Philadelphia_NN
Head_NN
Office_NN
and_PHC
Registered_NN
Office_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5557 5558_CD
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Fax_NN
:_:
44_CD
0_CD
20 8047 7807_CD
Tel_NN
:_:
1_CD
215 751 7003_CD
outside_PLACE
the_DT
USA_NN
GlaxoSmithKline_NN
plc_NN
Fax_NN
:_:
1_CD
215 751 3233 980_CD
Great_NN
West_NN
Road_NN
Registrar_NN
Brentford_NN
Lloyds_NN
TSB_NN
Registrars_NN
ADR_NN
program_NN
administrator_NN
Middlesex_NN
TW8_NN
9GS_NN
The_NN
Causeway_NN
The_NN
Bank_NN
of_PIN
New_NN
York_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5000_CD
Worthing_GER
Shareholder_NN
Relations_NOMZ
West_NN
Sussex_NN
BN99_NN
6DA_NN
PO_NN
Box_NN
11258_CD
www_NN
._.
co._FW
uk_FW
Church_NN
Street_NN
Station_NOMZ
New_NN
York_NN
NY_NN
10286-1258_CD
General_NN
enquiries_NN
,_,
Annual_JJ
Report_NN
www_NN
._.
com_NN
orderline_NN
and_CC
Corporate_JJ
Nominee_NN
service_NN
Tel_NN
:_:
1_CD
877 353 1154_CD
toll_NN
free_JJ
Tel_NN
:_:
0870 600 3991_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
1_CD
610 312 5315_CD
outside_PLACE
the_DT
USA_NN
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
outside_PLACE
the_DT
UK_NN
Customer_NN
Response_NN
Center_NN
Shareholder_NN
Investment_NOMZ
Plans_NN
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Dividend_NN
Re-investment_JJ
queries_NN
Tel_NN
:_:
0870 241 3018_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
44_CD
0_CD
1903 604 516_CD
outside_PLACE
the_DT
UK_NN
Monthly_JJ
Savings_GER
Plan_NN
queries_VPRT
Tel_NN
:_:
0870 606 0268_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
44_CD
0_CD
131 527 3746_CD
outside_PLACE
the_DT
UK_NN
ISA_NN
enquiries_VPRT
Tel_NN
:_:
0870 242 4244_CD
inside_PLACE
the_DT
UK_NN
Tel_NN
:_:
44_CD
0_CD
1903 604 594_CD
outside_PLACE
the_DT
UK_NN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
corporate_JJ
PEPs_NN
The_DT
Share_NN
Centre_NN
Limited_NN
Oxford_NN
House_NN
Oxford_NN
Road_NN
Aylesbury_NN
Produced_NN
by_PIN
Corporate_NN
Communications_NOMZ
,_,
Bucks_NN
HP21_NN
8SZ_NN
GlaxoSmithKline_NN
plc._NN
._.
Tel_NN
:_:
44_CD
0_CD
1296 414 144_CD
Design_NN
consultancy_NN
by_PIN
salterbaxter_NN
._.
Corporate_JJ
share_NN
dealing_VBG [WZPRES]
facility_NOMZ
Printed_NN
in_PIN
the_DT
UK_NN
by_PIN
Waddies_NN
._.
The_DT
paper_NN
used_VBN
NatWest_NN
Stockbrokers_NN
in_PIN
the_DT
production_NOMZ
of_PIN
this_DEMO
document_NOMZ
is_VPRT [PASS]
made_VBN
from_PIN
pulps_NN
harvested_VBN [WZPAST]
from_PIN
sustainable_JJ
forests_NN
,_,
also_RB
Corporate_NN
&_CC
Employee_NN
Service_NN
using_VBG [WZPRES]
sawmill_NN
residues_NN
and_PHC
forest_NN
thinnings_GER
._.
55_CD
Mansell_NN
Street_NN
It_PIT
is_VPRT [BEMA]
elemental_JJ
chlorine-free_NN
._.
London_NN
E1_NN
8AN_NN
Product_NN
names_NN
throughout_PIN
this_DEMO
publication_NOMZ
are_VPRT
Tel_NN
:_:
0870 600 3080_CD
inside_PLACE
the_DT
UK_NN
indicated_VBD [PRIV]
in_PIN
italics_NN
and_CC
are_VPRT
trade_NN
marks_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
,_,
its_PIT
subsidiaries_NN
or_CC
associated_VBN
Tel_NN
:_:
44_CD
0_CD
20 7895 5923_CD
outside_PLACE
the_DT
UK_NN
companies_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
Levitra_NN
a_DT
trade_NN
Email_NN
:_:
contactces@natwest_JJ
._.
com_NN
quoting_VBG [WZPRES]
GSK_NN
mark_NN
of_PIN
Bayer_NN
AG_NN
and_PHC
Nicoderm_NN
,_,
a_DT
trade_NN
mark_NN
of_PIN
Aventis_NN
SA_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
is_VPRT [PASS]
used_VBN
under_IN
licence_NN
Shareholders_NN
Service_NN
by_PIN
the_DT
Group_NN
._.
ANNUAL_JJ
REVIEW_NN
ANNUAL_NN
REPORT_NN
CORPORATE_JJ
AND_PHC
SOCIAL_JJ
A_DT
review_NN
of_PIN
major_JJ
The_DT
full_JJ
Financial_NN
RESPONSIBILITY_NOMZ
REPORT_NN
communication_NOMZ
statements_NOMZ
for_PIN
the_DT
A_NN
review_NN
of_PIN
our_FPP1
themes_NN
for_PIN
2002_CD
year_NN
ended_VBD
31st_CD
commitment_NOMZ
to_PIN
society_NN
and_CC
an_DT
abridged_JJ
December_NN
2002_CD
._.
and_ANDC
the_DT
environment_NOMZ
._.
version_NN
of_PIN
the_DT
financial_JJ
results_NN
._.
